Medical Oncology   

Questions discussed in this category



Would you consider omitting radiation in a elderly woman with ER-positive early stage breast cancer who was placed on 4 months of letrozole prior to l...

Patient has a second relapse post alloHCT for high risk APML

Prior guidance was mostly derived in the era of len maintenance +/- adding a PI for high-risk patients. Do you avoid live vaccines?

Would portal hypertensive gastropathy or colopathy sway you away from using it?

Will you now uniformly start with nivo/ipi > chemotherapy? If so, would you ever reintroduce another checkpoint monotherapy down the line? Or do yo...

Are there differences in management for those with stimulant use (e.g., methamphetamine, cocaine)?

What other pathologic features may you use to guide therapy decisions (e.g., mitoses/grade or NGS)? If you decide on adjuvant therapy, what regimen do...

As the cost of NGS decreases over time, is there still a need for more focused/targeted panels such as JAK2, CALR, and MPL? Are other genes important ...

Given interim analysis of PEACE V-STORM; also institutional data from SHARP consortium of using 25 Gy/5 fx for pelvic lymphatics. Can we extrapolate?

MSI stable, NGS without targetable mutation. Would you do FOLFIRI or FOLFIRINOX  followed by radiation to the lymph node? Would surgery be an opt...

RTOG 0848 presented at ASCO 2024 in abstract form: Abrams et al., Journal of Clinical Oncology 2024 What pathologic factors if any would you use to m...

Some medical oncologists tend to hold anticoagulation in patients who develop brain metastases for fear of causing intracranial hemorrhage. Is there a...

If the majority of lesions are PSMA positive lesions, do you proceed with Lutetium, and if so, how do you treat or consider therapy to the PSMA negati...

Would you omit treatment for stage IIIA melanoma with negative ctDNA, or add treatment for stage IIA with positive ctDNA?

Oral contrast adds time (2 hours before scan) for both the patient and the facility. Some institutions feel indicated for all outpatients, while other...

Does your approach depend on the patient’s response or PD-L1 level? Are there any studies supporting immunotherapy’s use beyond 2 years?

Do you routinely use PET/CT during treatment, such as after cycle 2, to evaluate for response? How would nivolumab treatment affect PET/CT interpretat...

If a patient develops central serous retinopathy on a MEK inhibitor despite dose reductions, is it ok to switch to a different BRAF/MEK combination?

If ADT acts as a systemic treatment, we would have expected to see a benefit with an RP just like with radiation. Yet, this is not the case. What are ...

There is conflicting data on whether the "surprise question" performs adequately enough.  Do you use this or other screening tools alone, or in c...

Do you need to have the non-contrast study when ordering the CT C/A/P with contrast, and what does the non-contrasted show that requires it in additio...

The primary nivo/ipi arm was q3 wks x4c, whereas the post-chemo crossover arm used q6 wks until progression. Is one schedule clearly more effective or...

Is there any data comparing Nivo/Ipi Vs Pembro or Dostarlimab? Can this be extrapolated from the CM-8HW Nivo/Ipi vs Nivo arm?

I had two prostate cancer patients recently take ivermectin against medical advice. Both of them had their PSA drop by 2-3 ng/ml. Are you seeing this ...

If a patient has clinical or biochemical progression while on either of these radiopharmaceuticals, would you stop the treatment or continue?

What is the harm of waiting for another recurrence after a second GTR to delay the toxicity of radiation and chemotherapy? The patient is a woman <...

The controlled trial below demonstrated improvement in dysphagia among Parkinson's patients. Might this have greater potential for benefit than modifi...

Do you use chemoRT-->cape,  gem/cis or gem/cis/durva? And do you include just perihilar or also small Intrahepatic Cholangiocarcinomas as well...

More specifically, the patient had a single, positive, 3 cm inguinal LN (no ECE, negative margins) removed at the time of APR. If offering RT, would y...

Is your management still guided primarily by risk stratification, or does the triple-negative status impact your decision-making about aspirin or cyto...

Would you consider holding, deferring, or skipping treatment? For hepatitis, how would determine if toxicity was immunotherapy vs chemotherapy relate...

This is rare but I've seen it twice last year! One with melanoma on nivolumab and one with lung cancer on pembrolizumab (both cases in deep remission)...

RADICALS-HD trial (ESMO 2022) demonstrated metastasis free survival benefit with 24 months compared to 6 months of ADT.

For instance, how would you manage a patient with both EGFR L858R and EGFR A647T mutations? Additionally, does the presence of brain metastasis influe...

What is your evaluation approach for RAI response? What cumulative dose do you use in practice for deciding a patient is RAI refractory?

Would your management change given that this recurrent lesion is over 10 cm and the patient previously achieved complete response on immunotherapy 5 y...

How do prior chemotherapy, site of disease, and pathological staging inform your decision? How about molecular markers (PD-L1, ctDNA)?

The 4 cm cuff recurrence occurred 3 years after definitive treatment with hysterectomy and vaginal cuff brachytherapy to 21 Gy. The recurrence had a c...

For example, if a patient with intermediate risk prostate cancer has a high risk Decipher score (10 year risk of metastasis with standard therapy of &...

Is there a subgroup of patients who benefited significantly from a specific protocol?

Are there data from trial patients who recurred, especially regarding what treatments they received?

According to NCCN guidelines, extraskeletal osteosarcomas should be treated as soft tissue sarcomas, which further expands the list of treatment optio...

AL amyloid biopsy proven on renal biopsy. Normal SPEP and FLC, bone marrow biopsy with 10-15% plasma cells.

E.g. would it prompt you to offer adjuvant RT in Masaoka IIA? Does the histology have a different prognosis?

Are there other settings where MRI is used for nerve assessment and radiation planning such as for certain definitive RT cases?

Given the POLARIX study data presented at ASH 2021 and subsequent longer term follow up, will this replace R-CHOP as the standard of care therapy in y...

And, for additional information, what are the differences in 5 year survival and disease specific survival for stage I NSCLC between lobectomy vs SBRT...

Would you recommend oncologic resection? Would you do neoadjuvant chemo and/or radiation (concurrent or sequential)? Pre-op radiation volumes would be...

The CROWN, ALTA, and ALEX trials showed improved efficacy with lorlatinib/brigatinib/alectinib vs crizotinib. How do you choose your first line therap...

Are there atypical ALK fusion partners that indicate sensitivity to ALK inhibitors? 

Are there any protocols in place? Aside from telling patients to use ice packs or bags or immerse hands/feet in ice water baths from 15" before to 15"...

There are some data indicating the 240 mg daily dose may offer similar (though not statistically equivalent) oncologic outcomes with reduced symptoms ...

Would you give pembrolizumab with chemotherapy or just chemotherapy? The patient had a history of mantle radiation several years ago.

Controlled extracranial disease on trastuzumab+pertuzumab for 2 years. Treatment options include switching systemic rx (T-Dxd, tucatinib) or WBRT. Not...

Patient presented with distant nodal disease and solitary liver metastasis and had normalization of CA19-9 from 22,827 at diagnosis, no evidence of di...

Do you consider supportive transfusions, and if so, have you been successful with keeping patients on hospice while receiving transfusions? Do you us...

No history of thrombosis and without other high risk features. Not on phlebotomies. Would you continue aspirin? Do you consider adding LMWH peripartu...

How do you distinguish whether toxicity is related to the immunotherapy vs the radiation vs both? Are you seeing higher rates of these due to the comb...

The patient is a female in her 40s. No mucosal changes were evidenced on clinical exam. Chemo-RT is recommended by GynOnc at an academic center. ...

While RET rearrangements certainly provide strong rationale for targeted therapy, is a point mutation such as this considered actionable? Mutation was...

Margin is less than 1 mm. Would the grade of the tumor affect your decision? Would any other factors go into your decision?

Would you continue ibrutinib even if they are placed on anti-platelet therapy such as clopidogrel or ticagrelor? When do you switch to an altern...

Does your institution prefer use of temporary placement each cycle of a PICC line for 5 days outpatient or long-dwell IV? Do your patients require ser...

What is the current data regarding acquired resistance mutations for ALK?  Should third generation TKIs such as lorlatinib be reserved for late...

Have you treated such cases with systemic therapies? If so, which ones (e.g., cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, or targeted age...

Patient with iron deficiency anemia from heavy bleeding from advanced uterine cancer. No evidence of hemolysis by smear or CBC profile. Could such an...

The approval for vorasidenib was granted for low-grade astrocytomas, but under certain conditions, it can also be recommended for, for example, anapla...

Is there objective evidence demonstrating a benefit of consolidative durvalumab or prophylactic cranial irradiation in patients with stage I small cel...

This particular patient previously progressed on platinum and is currently on lurbinectedin for >18 months. She had CR on PET. Now presents with a ...

What is your preferred sequencing of available therapies for a patient who remains fit for several lines of treatment?

Given the data from both INTERLACE and KEYNOTE-A18, how would you design a clinical trial to best answer the question on optimal management of locally...

Are there scenarios where one would rely on dual agent immunotherapy alone? Or would one generally err on the side of utilizing some form of metastasi...

Assume no epidural/cord compromise. Is kypho/vertebroplasty, radiation therapy, or conservative management (brace, antiresorptive therapy) the superio...

If a patient with a positive node just above the common iliac bifurcation, and will be treated with chemoradiation --> pembrolizumab according to A...

Is there a target IgG level to aim for? What should hematologists be aware of in monitoring these patients?

In particular, in the modern era of multi-parametric prostate MRI and PSMA-PET, certain findings such as EPE, SVI, or pelvic lymphadenopathy may be no...

Which regimen is preferred in second line for these patients? What is the efficacy of TDXd vs tucatinib in CNS metastases?    

Considering DB-12 study's exclusion of patients with leptomeningeal metastases, can T-DXd still be integrated into treatment plans for these patients?...

The patient is treatment naïve and asymptomatic. She also has disease in the body (bone and liver metastases). 

She had disease progression on palbociclib and letrozole. She also has a PIK3CA mutation however, did not tolerate alpelisib due to Grade 3 hyperglyce...

Neither GLOW nor SPOTLIGHT showed a statistically significant improvement in PFS/OS for non-Asian subgroups. It is reasonable to suspect that any PFS/...

Anatomically, the primary tumor is in the duodenum but extends into the gastric pylorus. Would Zolbetuximab be reasonable to offer with FOLFOX, rather...

What factors do you consider in choosing between BV-CHP/BV-CHEP vs DA-EPOCH/CHOEP with or without mogamulizumab?

Do you routinely check EKGs or echocardiograms? Or do you decide only if the patient is at risk for QTc prolongation or other symptoms?

Does the precise location of duodenal cancer even matter given that treatment would be 5-FU/platinum-based? Also, with the knowledge of the impact of ...

If a stage I colon cancer had positive ctDNA after surgery, what treatment, if any, would you recommend and for how long?

Estimating blood loss from hemoptysis is not always reliable. The bleeding may be due to the PE itself. Is anticoagulation with any degree of hemoptys...

What is the preferred dose, fractionation, and role of concurrent chemo? 

With first line approvals in both FOLFOX/Nivo and FOLFOX/zolbetuximab, how are you sequencing treatment if both CPS/Claudin markers are adequate to tr...

Do you prefer upfront cisplatin/etoposide for 2 cycles, then 50 Gy with ENI, then resection, or induction chemo followed by definitive chemoradiation?...

Solid tumor patients, other hematologic malignancies, patients with autoimmune diseases on immunosuppressive therapy? Do you consider workup if they a...

Are there specific AR Pathway inhibitors that can be crushed and used through feeding tube or would you just avoid ARPIs in such patients?

What if there is continued thrombocytopenia despite reaching complete remission (with incomplete marrow recovery)?

Which patients specifically benefit from both mpMRI and PET-PSMA?

Previously untreated, stage IV GE junction adenocarcinoma with overexpression of HER2 (3+ via IHC) as well as Claudin 18.2. What is the best approach,...

Patient has bilateral common, internal, and external iliac and femoral DVT from obstruction by a large uterine mass that is likely malignant and is pl...

In this recently published phase 3 randomized controlled trial, neoadjuvant nab-paclitaxel/trastuzumab/pertuzumab x6 cycles appear to compare favorabl...

The patient has a recurrence of the disease despite tapering prednisone and cyclosporine. Bone marrow exams x2 without MDS. Testing for all other caus...

Given the results of RADICALS-HD and RADICALS-RT trials, it seems as though there was no benefit to adding ST-ADT to RT, but a DFMS benefit for LT-ADT...

Is there a minimum time of waiting that is necessary between the completion of cancer treatment and liver transplantation?

E.g., patients with small CNS mets without vasogenic edema or symptoms. Epidural disease without epidural spinal cord compression or asymptomatic low-...

For either patients in general or for patients who will receive regimens with well-described toxicities such as irinotecan/UGT1A1. If so, do you requ...

Efficacy and cardiovascular safety appear similar per the PATCH trial updated at ESMO 2024. How would you counsel patients who decline LHRH agonists?

Bone marrow biopsy showed absent stainable iron. JAK2+ PV can sometimes present with reactive thrombocytosis if very iron deficient. Do you restore ir...

Is there any data on the efficacy of T-Dxd after progression on sacituzumab govitecan? Does your approach differ by hormone receptor status now that ...

Triplet v. Quadruplet? What regimen?  How would this change for a patient with high risk cytogenetics?

What would be the indications and what considerations are there from the first course of treatment?

The patient is an elderly female with a good KPS who presented with a cT2N1 triple-negative breast cancer. The patient refused chemotherapy and immun...

When using hypofractionated RT (i.e., 67.5 Gy in 15 fractions), can chemotherapy be delivered concurrently?  Options for systemic therapy in NCC...

Given that ER-negative patients were not enrolled to the DB06 trial, can results be extrapolated to this population?

Is there a role for immunotherapy, anti-angiogenesis, or TKIs? Can you use immune checkpoint inhibitors in combination with lenvatinib? 

Or do you generally prefer warfarin/non-DOAC agents? Do you consider trialing DOACs and testing anti-Xa DOAC levels to assess for absorption?

(For instance, TCx4 instead of ddAC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemother...

If a patient presents with de novo oligometastatic (i.e., meeting STAMPEDE low met burden criteria) prostate cancer with no prior history of primary t...

USPTF and CMS guidelines differ in age criteria, and NCCN guidelines do not have an upper age limit.

For example, per the IMROZ trial methodology, Isatuximab dosing does not change to monthly dosing until >18 cycles which can impact patient QoL and...

Or can we omit it in older patients given efficacy of these regimens? Is transplant-eligibility still an important distinction up front given options ...

What are your volumes and dose/fractionation for external beam boost in lieu of tandem and ovoid or tandem and ring implant?

How do you decide to trial a patient off treatment? When do you consider spacing therapy and at what frequency?

Do you think it works better if incorporated as early as possible in the patient's course, or is it better to "save it" for future recurrences after u...

Specifically, headaches thought not to be related to increased ICP.

How do you decide between ureteral stent and percutaneous nephrostomy for decompression?

For some patients, it may be overburdensome to make an extra trip to an ophthalmologist every other cycle. They may live far away from an ophthalmolog...

Are there any circumstances where use of T-DXd would supercede the use of CDK4/6 inhibitors or other non-chemotherapeutic options (PIK3CA etc?)

Both ALK and MSI-high status were noted on a liquid biopsy since there was not enough tissue available for molecular testing. Some reports suggest lo...

If they have been on IV heparin for 3 days, for example, would you subtract those days from the recommended loading dose time?

One particular circumstance involved detecting a ROS1 fusion upon the metastatic recurrence.  Is this pneumonitis risk seen with osimertinib alon...

With low #s of patients on the durvalumab PACIFIC trial with EGFR mutated disease, and LAURA trial design of osimertinib until progression, should we ...

If a patient is considered high risk for surgery, with another primary cancer (HCC) and has an incidental renal finding that is highly suspicious for ...

Guidelines do not provide strong guidance on who will benefit from temozolomide vs PCV or when to consider re-challenging with temozolomide.

Can you explain when would you consider light chain amyloidosis work up with fat pad biopsy?

Data from Massard et al., PMID 20181575 used an abbreviated 3-day course of EP with completion of EP and bleomycin at day 15. Should this approac...

For example, if MRI revealed prostate-confined disease but PSMA had moderate avidity in the bilateral seminal vesicles, would you obtain further biops...

Do you avoid using these agents only in patients with history of medullary thyroid cancer or pancreatic cancer? Are there other cancer risks we should...

PUMP-2 trial combined FUDR via HAIP with gemcitabine and cisplatin, no immunotherapy was on the protocol. 

Bone marrow biopsy does not meet criteria for MDS and no other identifiable cause of the cytopenias.

I have seen targeted therapies used (and studied) more often in the recurrent setting. However, there may also be some rationale for trying BRAF/MEK E...

If so, how long do you continue medication and when do you discontinue? Does treatment with surgical resection versus radiation alone change your mana...

In non-FGFR mutated patients, would you use cisplatin/gemcitabine or sacituzimab govitecan at this point?

For example, a large iliac or sacral plasmacytoma causing symptoms. Both medical oncologists and radiation oncologists get nervous about RT-related cy...

For example: eyeball test, simplified frailty assessment (Facon et al.), IMWG frailty score, ECOG only?

Would you change your radiation therapy treatment dose or volume if you needed to treat a chloroma? If a patient had a separate cancer (e.g., skin can...

Two recent studies show the benefit of up-front abiraterone for metastatic castration-sensitive prostate cancer, although these studies used control a...

These mutations were not eligible in the LAURA trial. Afatinib has a more durable PFS than osimertinib in these patients. How would you choose be...

Do next generation sequencing results influence diagnostic and therapeutic decisions for patients with MDS?

Does the interval of monitoring change if given with a concomitant immune checkpoint inhibitor?

How do factors such as the stability of the bleed, tumor histology, and patient condition influence your decision?

Ampullary carcinoma is not in the NCCN guidelines. Please address not only the role for therapy but the optimal regimen (i.e. Gem based, vs mFOLFIRINO...

Since the benefit of neoadjuvant chemotherapy is well-defined in muscle-invasive bladder cancer, is it reasonable to consider this in upper-tract tumo...

Would you consider the addition of carboplatin/paclitaxel + dostarlimab to radiation as opposed to radiation alone?

Patient with pT2 N2a (6/9 LN+, 5 with macromets, 1 with focal ENE) ER/PR+, Her2- s/p mastectomy.  Is there compelling reason to start PMRT prior...

Would you consider this stage IVA (spread to adjacent organ) or IVB (spread to distant organ)? For instance, would the presence of direct lumbar verte...

Since ECHELON-1 trial showed an improvement in PFS (but not OS), are there any situations where you would replace bleomycin with brentuximab...

Post-operative surgical course was complicated by anastomotic leak, septic shock, candidemia, wound infections, PE & DVT. Now recovering well.

Would you recommend concurrent chemoradiation or targeted therapy with lorlatinib?

Do you discuss the risk of sickle cell crises with G-CSF? What about for patients with sickle cell trait?

What would be your approach to a patient who went straight to surgery due to HR+ biopsy, but found to be triple negative on surgical pathology? 

Do you find that starting with chemoradiation increases the risk of complete obstruction secondary to transient tumor inflammation, or do you favor st...

Specifically, after chemo and RT to 36.0 Gy/15 fx with stable to slight progression of disease at 6 months, what (if any) regimen of reirradiation wou...

Are there characteristics which could help identify whether a follicular lymphoma might behave more indolently vs aggressively and inform treatment se...

Would you hypofractionate or be more conservative at 2 Gy per fraction? Would your management be affected knowing the patient is on hydroxyurea?

Given the FDA approvals for PARP inhibitors and combinations in mCRPC, when do you obtain NGS for mCRPC? Do you have a preferred assay?

Chemotherapy is associated with acquiring C diff colitis. Does immunotherapy share that same risk and necessitate ruling out infection prior to anti-d...

Would you treat with curative intent (neoadjuvant chemotherapy, surgery, and radiation to include the sternum)?

Would you be willing to treat an elderly patient on blood thinners who has PSMA+ PET, elevated PSA, and multiple urologists have deemed biopsy too ris...

At the time of initial diagnosis, there was no clear CNS involvement. When it became clinically apparent disease was refractory to EPOCH, there was CS...

Would you treat as cholangiocarcinoma with a gemcitabine/platinum regimen or would you use a more HCC regimen like atezo/bev or durva/trem?

Does a certain level of free light chain ratio reassure you against the possibility of AL amyloid? Is there a certain level that makes you more concer...

Would you reduce dose prior to adding supplemental oxygen? 

NCCN states that all operable NSCLC patients should be evaluated for pre-op therapy with strong consideration of nivolumab + chemotherapy for those wi...

Some consider T4N3 Stage IIIC to be a borderline case. None of these patients were included in either PACIFIC or KEYNOTE-024 for example. Would y...

PFS curves appear similar between the AKT-altered vs overall study population in the trial publication. Is there any additional information available ...

Do you only offer it for patients with a documented IgG < 400? Do you check the IgG at all, or are you doing primary prophylaxis?

Do the IMROZ and BENEFIT trials inform choice? In IMROZ, the high-risk population received only revlimid/dexamethasone maintenance. Should they have g...

Are there specific patients where you're more apt to continue versus holding IO while continuing TKI?

Do you pursue screening beyond age-appropriate malignancy screening, especially in younger patients? For how long do you continue to monitor beyond th...

The Mayo Clinic protocol recommends initial fields -1.5 Gy BID initially to 45 Gy followed by a Brachytherapy boost. If HDR /LDR is not available, wha...

What is your most and least preferred? In case of cancer in remission and in case of non-remission?

With the advent of PSMA PET/CT, this is my study of choice for high risk prostate cancer. Are there scenarios where standard FDG PET is useful? For ex...

mOS was 53.7 in experimental v. 54.3 in control; however ORR 71.3% vs. 36.7%, and mPFS 23.9 mo vs. 7.2 mo (HR 0.47). Does the lack of OS benefit sway ...

The FDA package insert suggests 2.5 mg daily in these settings, while the PrE1003 study demonstrated that a higher dose is feasible. Many oncologists ...

There are some retrospective data that CPCs are associated with worsened outcomes after transplantation. Anecdotally, CPCs could be collected as part ...

For example, when would you recommend clinical exam for surveillance versus imaging with MRI, CT or PET? 

Would you consider it for a patient who had bulky thoracic disease, with limited extrathoracic disease at diagnosis and achieved a CR after induction ...

The patient has extensive disease, and requires palliative radiation to the scapular area (proximal to the brachial plexus) in a region overlapping wi...

Since free light chains are removed by dialysis and SPEP can also be impacted, is there a reliable way to monitor patients with ESRD and MM?

Long-term ADT is deleterious to multiple organ systems (bone/sexual/psychiatric) and increases the risk of MACE. What level 1 evidence do we have to c...

Specifically, on re-staging imaging, would the tumor regression be strictly defined by reduction in cranio-caudal direction only, or would other measu...

On the EMBARK trial (Freedland et al., PMID 37851874), 25% of men had a prostatectomy and the publication states, "Patients were excluded … if ...

No clear inciting etiology found. Would you consider dexamethasone +/- cytokine blockade (IL-1, IL-6, or IFN-g)? What do you think about the data for...

The patient has an asymptomatic metastasis in the left atrial appendage. Would you start off with immunotherapy then add radiation later, or visa ver...

Are there any recent publications or resources regarding which immunotherapy agents are contra-indicated with the use of RT or that outline interactio...

How aggressive should we be in bringing elevated plasma/urine 5HIAA to normal levels in patients whose symptoms are controlled? Before we have the res...

DLCO 65% that is of unclear etiology but not due to disease and no cardiac or pulmonary functional limitations.

Although grade 3 toxicity rates were low, ~10.5% experience some degree of ILD, are there strategies to reduce risk before treatment starts? Are ther...

Would prior RT (>30 years ago in this case) to the breast or ATM mutation alter your recommendations?

Assume thrombolytics are not indicated. Do you favor early DOAC transition after 24-48 hours of heparin gtt or do you favor LMWH for 10-14 days follow...

Given nationwide shortage in vinblastine, several of my patients under active therapy are facing delays in their therapies. Is it appropriate to subst...

And if so, which one? Does nodal status affect your decision? Is there any evidence for ctDNA in this space?

Would you continue it until progression of disease? Or would you switch immediately to next line systemic therapy?

How would you approach treatment with systemic therapy, surgery, and radiation if there is evidence of little treatment response, tumor growth, and ne...

Do you do additional workup for venous obstruction or any other different testing/evaluation?

Do social or economic factors (i.e., relative cost of acquiring LMWH, the patient being injection averse) affect your decision to use DOACs? Do you s...

What clinical factors do you take into consideration? Would you recommend chemo-immunotherapy regimens for a fit patient who relapses at 6 mos post-t...

As immune checkpoint inhibitors have expanded into the neoadjuvant breast cancer setting, severe and unexpected autoimmune toxicities may cause delays...

The NCCN lists concurrent chemoradiotherapy as a primary treatment option in these patients. If so, what total dose do you deliver to involved ly...

Given the results of DESTINY-Breast03, and T-DXd's labeled indication in second-line, what is now the role of TDM1 in the treatment armamentarium of H...

While ESOPEC excluded squamous cell carcinoma, the Japanese JCOG1109 NExT trial also showed superiority of fluoropyrimidine/platinum/taxane over chemo...

If triplet chemotherapy is likely too morbid, would you prefer neoadjuvant chemoradiation per CROSS in this setting?

Should testing for germline mutations -- eg. saliva sample -- occur before or after the completion of chemotherapy - or the timing does not matter?&nb...

Is there data supporting the idea that chemotherapy must be onboard prior to delivering radiation for maximal radiosensitization (particularly for hea...

STAMPEDE answer is yes, intuitively it seems there must be a line somewhere though. For patients staged only with PET that is widely M1, should a CT ...

Would treatment be palliative (i.e. for ureteral obstruction) or definitive? Is there a role for chemotherapy or hypofractionation/SBRT?

Current NCCN guidelines recommended not combining relugolix with these agents until more data is available.  Any drug interaction concerns or ot...

Since HR low-positive, HER2 neg tumors behave aggressively similar to TNBC, does the degree of HR positivity factor into your decision-making?

How do the results affect your recommendations for workup and management?

Are there other mutations/biomarkers in CLL which may specifically predict for response or resistance to pirtobrutinib?

How does the changing landscape of first-line treatment impact your decision making for second line therapy?

Would you use nivolumab or a taxane? Is the data from the ATTRACTION-3 trial with an all-Asian patient population applicable to practice to the US pop...

A female in her 60s who has been on afatinib for 6 years. Has been NED on CT, PET, and MRI for > 5 years. Had isolated T-spine mets (radiated) and ...

Assume the patient is a good surgical candidate, and the perforation happened prior to initiating any treatment. Is the stent enough reason to avoid c...

Do you consider "bridging" therapy prior to transplant, and if so, what are your thoughts on the intensity of the chemotherapy?  

When, if ever, do you utilize adjuvant RT or chemotherapy?

Do you increase the dosage of the TKI or switch to a different generation TKI? How does your answer differ for EGFR vs. ALK, and for discrete brain me...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

Given the limited # of patients with PALB2 mutation on the PROfound trial (de Bono et al., PMID 32343890) and the benefit primarily driven by Cohort A...

For example, do you favor using different induction chemotherapy (gemcitabine/cisplatin or TPF) for endemic vs non-endemic disease? Do you favor usin...

ESOPEC compared perioperative FLOT vs neoadjuvant chemoradiation per the CROSS trial, and showed superior OS with perioperative FLOT. What concerns do...

Given that LU002 has failed to meet its progression free survival benefit in results presented at ASCO, will you offer consolidative radiotherapy for ...

How do you decide between entrectinib or crizotinib? Since no head-to-head comparison, can real-world datasets (such as Doebele et al., Journal of Cli...

S/P neoadjuvant chemotherapy and followed by oncologic surgical resection but with positive margins.

In a patient with no evidence of bleeding, do you use a platelet cutoff? Do you utilize genomic testing (eg CALR, MPL, JAK2, etc.) to decide on cytore...

Ropeginterferon is now a preferred therapy for Polycythemia Vera (PV) as per a recent update to the NCCN guidelines.

Nivo 3 + Ipi 1 Q2W x3 then Nivo alone? Or Nivo 3 Q2W & Ipi 1 Q6W until POD or toxicity? Or other?

Are there factors which would make you more likely to use atezo/bev vs durva/treme vs TKI?

I've seen a handful of fatal radiation pneumonitis associated with rapid steroid tapers by the non-treating physicians. How do you recommend prescribi...

Would you consider administering Keytruda (pembrolizumab) concurrently with radiation therapy for the treatment of a patient with an ER-negative, PR-n...

Is there data on the long-term effects of abemaciclib on future fertility and pregnancy after its discontinuation? Does the patient's desire for futu...

Patient in their 60s with TP53 mutation by NGS, treated 12 years ago with FCR, then at first relapse 2 years ago started ibrutinib. Bone marrow biopsy...

Most would argue that gain(1q) in combination with another high-risk feature constitutes ultra-high-risk multiple myeloma, and most would argue (with ...

Such as those meeting the eligibility criteria for NRG HN002, <10 pack years, HPV+ T1-2N1-2b, T3N0-N2b

Given the recent update from the NAPOLI-3 trial presented at GI ASCO 2023, the two regimens appear to have similar OS.

Can you explain the expansion cohorts into larger trials and the current amendments to the the protocol?

The OS benefit with Zometa was seen only in patients with myeloma bone disease achieving less than or equal to a partial response. SRE risk reduction ...

Are there specific safety or efficacy benefits associated with prolonged infusion times in this population?

Are there specific patient factors for which you would more preferentially use this regimen?

Is there a role for loco-regional treatment in this scenario? If a young patient with ER/PR positive cT2N2M1 IDC presents with a single bone metastasi...

Patient has multiple adverse features on pathology, however, PSA just became detectable one year after surgery. SPPORT included patients with PSA>0...

KEYNOTE-564 required CrCl 30 or above. Not having a baseline/stable CrCl may make it difficult to diagnose or treat IO nephritis. 

For many clinical trials, a screening bone marrow biopsy is necessary to get a new baseline. Do you do the same in real-world practice?

Do you treat this similarly to IDH-Wildtype GBM with the STUPP regimen? Is there any role of less-intensive paradigms, such as 59.4 Gy/33 fx?

Previous questions have focused on the newly diagnosed setting and choice of bisphosphonate versus denosumab. IMWG guidelines do recommend resuming zo...

For a patient with high risk disease and a severe enough reaction that additional taxane-based therapy is contraindicated, do you consider alternate c...

If so, what dose-fractionation do you utilize? What other factors do you take into consideration?

Would you recommend aiming for the postmenopausal range as per the lab reference range or do you have a specific goal?

For example, if mass is ulcerated and cannot be excised with polypectomy? Would you ever consider radiation and chemotherapy?

If so, do you modify your external beam dose? 

Burnmeister data from 2012 showed a local control benefit for radiation therapy in selected patients, but that was without immunotherapy. Is adjuvant ...

Initial path was T1cN0, and recurrence shows 2/21 ALN  involved with ENE, what would you recommend for therapy?

Would you give neoadjuvant chemo or hormonal therapy or go with surgery first? What chemotherapy would you use? 

Or other therapy - e.g., tolvaptan? Free water restriction may hinder QOL. Salt tablets may raise levels more quickly but have risks of edema and hype...

Current NCCN guidelines do not include adjuvant chemotherapy for patients treated in this fashion; however, in the PROSPECT trial itself, an additiona...

Patient with stage IV ER+PR+Her2- breast cancer progressed after CDK4/6 inhibitor+AI and then on Elacestrant. Guardant 360 showed ESR1 mutation and PI...

What is the ferritin target that you would aim for? What would be your approach for a ferritin >500? When do you order an MRI liver for iron quanti...

Would you consider radiation following surgical resection of an intramedullary benign nerve sheath tumor with a small amount of residual tumor (9 mm) ...

Given pelvic RT is likely to induce ovarian dysfunction/menopause, would you consider systemic options?

This would apply to gynecologic and GI cancers as well. And as long as the patient's partner is within the recommend age of <45 yo

There was a recall on viscous lidocaine and many of our patients cannot find it. What would you recommend as alternatives?

Do you insist on ambulatory/home blood pressures to rule in/out white coat hypertension? Does your practice have a system to log patients' BPs to supp...

What does it add beyond a serum electrophoresis or light chain testing? Are there certain types of patients where monitoring immunoglobulins is parti...

And is there any role in utilizing FGFR2 inhibitors in first line setting? The PROOF trial utilizing Infigratinib in first line was stopped after the...

Only the mCRPC population was included in the Fizazi et al. study, but the FDA approval is for prevention of skeletal related events from any solid tu...

In MONALEESA-2, it appears ~22% of those in the ribcociclib group received a subsequent CDK4/6 inhibitor. What was the rationale and could this have i...

The patient was initially treated with Carboplatin/Paclitaxel and progressed after 1 year. She was switched to pembrolizumab and had significant progr...

Would you consider it for a patient with good PS but with limited metastatic disease? What dose fractionation would you prefer?

What criteria do you use to define steroid-refractory disease? Does your management different by organ system involved - GI vs skin vs other?

Given OlympiA trial with olaparib benefit for gBRCA+ patients?What are barriers that you foresee? In your practice who performs mutation testing and w...

Would you wait until bowel symptoms are controlled or ever pursue diversion before starting treatment?

Would you consider using repretinib as first line therapy given its novel mechanism of action versus other treatment options?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical prac...

Are there other measures, pharmocologic or adjunctive, that can be used or are under investigation to mitigate cardiotoxicity related to chemo- or rad...

My understanding is that if someone isn’t medically operable, the default is to offer systemic therapy palliatively because breast cancer is tho...

Patient developed atrial fibrillation on Ibrutinib, severe fatigue and intolerance to Zanubrutinib and a maculopapular rash (grade 2) on Acalabrutinib

If yes, would you go with Zidovudine monotherapy versus combining with interferon-alpha? And what would be the preferred dose and duration? 

The patient presented with a numb chin, more to the right of his face; an MRI did report mandibular nerve opacity, which is non-specific per neuro-rad...

How do you choose between RIC compared to MAC? Is there evidence for one over the other in an otherwise healthy, young patient? Do you include hypome...

Aside from addressing the underlying case, is there a role for phlebotomy in secondary polycythemia such as in COPD or post-renal transplant erythrocy...

Are there certain patient subgroups for whom you would use the IO+PARPi? Is there data from DUO-E regarding BRCA status and its potential impact on ...

NCCN says "consider autologous HCT" while retrospective data seems to support SCT in most histologies like AITL

Do you give first-line CDK 4/6 inhibitors with Tamoxifen or Aromatase Inhibitor (+/- GnRH analog)?

Have you changed your practice given BMT-CTN 1506/Morpho results? Would you utilize maintenance therapy in patients who achieve MRD- remission?

Are there any precautions or pre-medications that may permit this treatment in patients who are fit for therapy but have exhausted all other treatment...

If CCRT is pursued, would you move forward with durvalumab consolidation? Assume the patient with ECOG PS 0 and no co-morbidities. How might this chan...

Would you offer consolidative brain SRS, SRS + consolidative RT to the primary (e.g. lung), consolidative RT to the primary alone?

Do you continue atezo alone if responding or switch to an alternative therapy such as dual IO or TKI? What about if the patient were experiencing subt...

Should these patients have a different threshold for utilizing a CDK4/6 inhibitor in the front line metastatic or as part of adjuvant therapy, or SERD...

Transplant is not part of the trial but is the standard outside of the trial. A041501 is a phase III trial to evaluate the efficacy of the addition of...

From NCCN (Rectal MS-33): SBRT is a reasonable option for patients who cannot be resected or ablated. What is the role of SBRT versus microwave ablat...

For example, how do you address tendency to "over-order" these tests in patients with common aches/pains but no structural abnormalities on advanced i...

Please assume that IVIG is fine (as it is for many Jehovah's Witness patients, since IgG is often not considered a blood product per se).

The patient had a prior right-sided ER+ HER2-ve breast cancer, treated with neoadjuvant chemotherapy, MRM with ALND, and PMRT They recently developed...

If so, would you recommend adjuvant chemotherapy and PCI after?

How would it change your risk group or management? Does Decipher help further inform treatment?

Do you feel differently about using these in patients with a history of HR-negative breast cancer?

Many options for vasomotor symptoms of menopause do not work well for men on ADT. However, fezolinetant is a neurokinin B blocker, so theoretically, s...

If yes, would you apply this broadly or reserve the addition of IO to chemotherapy for patients with high-risk histologies (e.g., carcinosarcoma) or o...

Does your decision depend on MMR status? Would you use the same approach for neoadjuvant treatment?In light of relevant trials including RUBY, GY018, ...

DUO-E, GY-018, and RUBY included patients with stage III and IV endometrial cancer WITH measurable disease.Would your decision change based on the mis...

Are there patients for whom you would still reserve IO for salvage/recurrent setting (eg IO + lenvatinib)? Would you base this on MMR status or other ...

I have a pair of patients with MRI+ and biopsy+ disease who have staging PSMA PET/CT that do not show disease within the prostate (or anywhere else).&...

With the recent publication in IJROBP showing a greater than 50% response rate, have you started integrating this into your practice? 

At the time of count recovery or do you continue it throughout induction and consolidation?

Does the type of autoimmune disease (ex IBD, rheumatoid arthritis, interstitial lung disease) matter?

Given CPX-351 was given to elderly patients ages 60-75 with a lower dose (60 mg/m2) Daunorubicin, can one generalize from this study to younger adults...

Does reducing the rate of infusion, or adding Montelukast reduce chances of future reactions? 

For radiation oncologists, how do you ameliorate the risk for radiation-related injury to epicardial coronaries during treatment sessions?

When (if ever) would you consider immune checkpoint inhibitor up front? Would you be less inclined to offer triple drug therapy? (Some thought that ta...

Young healthy patient, ER/PR positive HER2 negative right breast cancer with a synchronous single site of oligometastatic disease in the right 4th rib...

This would be for the "locally advanced unresectable" indication. Consider an older patient who is not eligible for NAC nor TMT due to nodal disease a...

Would you transplant a patient over the age of 70 with newly diagnosed myeloma? Does the risk category impact your decision?

The patient was recently diagnosed with pre-B ALL and is on day 10 of CALGB 10403. He is expectedly neutropenic as he received daunorubicin and vincri...

Are there any chemotherapy regimens that can be used in elderly patients with poor PS who are not candidates for BEP?

Would you follow an algorithm such as the one proposed by Hall et al., PMID 29940062?How do you decide between intrathecal chemotherapy vs systemic th...

There are various formulations of intravenous iron; each with varying costs, test dose requirement, elemental dose, and number or time of infusions ne...

While follow up ultrasound is not usually recommended in provoked DVT, it often is done either for other reasons or by other physicians. Would this in...

How do you counsel patients and caregivers? Do you prescribe medications (''appetite stimulants'') with the goal to improve appetite even if they do n...

What would you recommend for a patient in their 60s with stage IB grade 1 endometrial cancer without LVSI? How would this differ for a patient with st...

E.g., for a patient with myeloma, s/p induction therapy, and high-dose chemotherapy, followed by autologous rescue with inappropriate antibody respons...

If baseline testosterone is at castrate levels (e.g. <50), would you consider patient to have castrate-resistant disease?

For example, a patient has had multiple dose reductions for neutropenia and required an admission for infection while on palbociclib. Would you switch...

For instance, do you factor availability of RNAseq, inclusion of normal blood controls, and QNS rates into your decision?

Especially as the study was done before the adoption of total neoadjuvant therapy

Would you prefer doxorubicin based chemotherapy or are alternative TKIs useful in this scenario?

Does the anagrelide shortage play a role in your decision-making? Do you avoid anagrelide in general?

How are you incorporating CONTACT-03 data presented at #ASCO2023 (Pal et al., PMID 37290461) into your practice? Would you consider immunotherapy re-c...

For example, do you think young patients might potentially benefit from the addition of cisplatin, knowing the average age in this study was 65.

The patient previously received endocrine therapy alone and in combination with CDK 4/6 inhibitor. She does not have any targetable mutations on NGS. ...

What data may support the routine escalation of endocrine therapy? Should HER2 therapy be prioritized instead?

Would you treat with 1st line ET + CDK4/6 inhibitor if the patient is only low or moderately ER positive? 

Would you only give three cycles with radiation, or are you adding two more cycles of FOLFOX afterwards?

Would you consider OFS this far out from diagnosis and treatment in a young patient with high grade IDC was treated during pregnancy with neoadjuvant ...

Does DOTATATE scan results/burden of disease change your preference?

Is the therapeutic purpose of the proteasome inhibitor to maximize total dosage per week or number of infusions per week?

Would you offer single agent immunotherapy or chemo-immunotherapy with gem/cis durva/pembro?

Assuming no symptoms of TB, should patients be treated for latent TB prior to starting TNF inhibitors or other immunosuppressive agents?

Work-up was performed for isolated anemia which resolved to >11 g/dl after the reversible cause was treated.

In a patient with metastatic cancer to the lumbar spine and epidural disease on CT who presents back pain and leg weakness: Is a whole spine MRI in...

The SWOG 1801 trial showed improved event-free survival (EFS) in patients receiving neoadjuvant pembrolizumab followed by 15 cycles of adjuvant pembro...

Example: in a patient with a non-resectable pelvic mass involving the vagina but without evidence of distant disease, would you favor pelvic RT (as on...

How do you reconcile the apparent benefit in all patients in this group as opposed to the differential effects in premenopausal HR+ node-negative pati...

Are you concerned about cases where radiation has to be started urgently before leukapheresis?

What type of adjuvant chemotherapy would you offer? Would clinically positive lymph nodes or residual disease at the time of surgery change your decis...

Do you recommend observation, APBI, whole breast or whole breast with low axilla treatment?

Would you consider doing this in patients with adverse features such as grade 3 or PR negative status? 

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

Following SRS to the brain lesions, is it safe to closely follow the patient for recurrence?

If there are light chain deposits on the kidney, is that conclusive of MGRS?

Very-low-risk stage IIIA disease includes non-ulcerated lesions, primary ≤2 mm thickness, SLN metastasis <1 mm. Per NCCN the toxicity of adjuvan...

How will you translate treatment recommendations from older studies to the new staging system?

As SCLC in never smokers is extremely rare, do you consider NGS testing, or do you modify treatment in any way?

Is this acute or long-term, and does it matter whether this is SBRT vs fractionated?

Galsky criteria are for metastatic disease, can they be relaxed in localized MIBC setting given curative intent of therapy? 

Would you approach with curative intent with locoregional treatment or systemic treatment alone?

What is the work up and what is the duration of anticoagulation if used?

Would you continue KEYNOTE-522 neoadjuvant therapy? The patient has a PMH of sarcoidosis with no stroke risk factors. No residual deficits. 

This question seems quite specific but happens quite often. Multi-drug chemotherapy runs the risk of profound cytopenias and infections, while bispeci...

Do you always avoid heparin/enoxaparin or rechallenge if antibodies are negative?

Specifically, asymptomatic subsegmental PE diagnosed within a month from planned bilateral mastectomy for breast cancer. 

Do all patients with brain metastases get started on anticonvulsants?  Do you decide based on extent of edema, tumor size, or something else?&nb...

The patient's current PET scan showed no systemic disease. Due to his age, there is a concern of whether the patient would tolerate dual immunotherapy...

Would you treat both at the same time? Does one need to be prioritized over the other? Does Xeloda have any efficacy against Merkel cell cancer? How...

MONARCHE added an amendment to their protocol to exclude inflammatory breast cancer so they technically would not qualify for the trial though it's ha...

If yes, how do you assess the tumor response and how frequently while on neoadjuvant chemoimmunotherapy?

Severe lymphopenia can develop during treatment and increase the risk of Candida/HSV superinfection, along with potential challenges for any procedure...

This case involves an impressive ‘high volume’ vaginal recurrence and patient was not originally planned for adjuvant therapy. Concerned t...

Would you offer as first line treatment mitomycin/5FU with radiation or single agent immunotherapy?

Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was ...

The left breast cancer is an ER-negative, PR-negative, HER2-negative cT2N0 invasive ductal carcinoma, while the left lung primary is a cT2N1 squamous ...

This has become standard practice at our institution for patients with a good performance status, with whole brain radiotherapy given after the comple...

Will the results of the recently published randomized comparison of proton beam therapy (PBT) vs. transarterial chemoembolization (TACE) change the wa...

Is deferring chemotherapy based on low oncotype acceptable in setting of recurrence?    Would you recommend using a different AI, Tam...

Consider treatment of stage IVB cervical cancer with systemic therapy and local pelvic radiation therapy as in Perkins et al., PMID 31810653.

Would you recommend using chemotherapy based on RxPonder regardless of Oncotype score in a premenopausal patient? Or would you hold chemotherapy since...

Would non-gastric GISTs, high mitotic rate, large size, and young age of patient affect your decision? Especially knowing that TKIs suppress cell grow...

How do you decide when to “pull the trigger” in these cases where the growth trajectory is slow?

Is there a potential role for concurrent radiation therapy? What if the tumor is BRAF mutated?

Is there any data to support the use of immune checkpoint inhibitors either preoperatively or even definitively, similar to rectal or gastric?

Is it necessary to delay the start of radiation therapy for males planning on sperm banking for fertility preservation?

Since there is no overlap between chemo regimens for these cancers, how would you sequence treatment? 

Such as in a patient with essential thrombocythemia with a CALR mutation, younger than age 60, no history of thrombosis, no bleeding or vasomotor symp...

How frequently and what type of testing/sample are you performing MRD assessment? Does your approach differ between transplant-eligible and transplan...

Is there any role for targeted therapy, or would you consider consolidation durvalumab for these patients? 

For a node positive, triple negative patient that underwent neoadjuvant chemotherapy followed by breast conservation with a complete pathologic respon...

Are you more inclined to use non cytotoxic regimens such as R2 or PI3K inhibitors?

What systemic therapy is most appropriate, how would you sequence, and what RT dose fractionation would you use?

Considering this is stage IV disease, do your recommendations for definitive or adjuvant treatment (after surgery) change?

What clinical or radiographic factors would lean you in either direction - ie. time since index diagnosis, distribution or appearance of lung and noda...

While I am encouraged by the results of the LUMINA trial with respect to identifying patients who are less likely to benefit from radiation therapy wh...

Assuming the patient had no prior radiation and has no evidence of metastatic disease, would you start with adjuvant radiotherapy or adjuvant systemic...

24 months ADT + abiraterone + definitive RT is indicated for cN1 disease but not for pN1 disease per NCCN. Can the data be extrapolated to this popula...

Notably, the patient presented with renal failure due to ureteral obstruction and hydronephrosis, receives hemodialysis, and has limited systemic opti...

Do you utilize rituximab or any other specific management strategies?

Which group of patients will benefit with observation versus adjuvant immunotherapy?

What XRT dose do you use? Does the location of the disease (e.g., mediastinum) affect your decision when taking toxicity into account? would you offer...

Garcia-Manero et al., PMID 32285126Given the convenience of oral therapy, would you depend on the patient's ability to safely comply with the schedule...

Would a negative NGS eliminate the possibility of MDS? Is bone marrow biopsy indicated in a patient with pancytopenia with a negative NGS panel?

Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion? 

If NGS was positive would you treat with HER2 directed therapy? How, if at all, would you incorporate T-DXd into this treatment paradigm?

For example, initial imaging shows numerous bilateral nodal mets extending into the low neck but after induction gem/cis, originally involved nodes ar...

Exploratory analysis of the MAGIC trial suggested perioperative chemotherapy was detrimental in this subset of patients. Has availability of IO altere...

Pretreatment PSA 25.3 with Gleason 4+3=7 and MRI suspicious for ECE. Eight months after pelvic nodal and prostate XRT to 79 Gy, PSA is 5.02 (down from...

And is it different when using pembrolizumab or a combination of ipilimumab/nivolumab?

Several patients with inability to access oral cyclophosphamide or lenalidomide, have attempted assistance and grants to no avail.

Is this an artifact of what agent prior clinical trials used or something to do with the mechanism of action (i.e., less mineralocorticoid effect of d...

MRI pelvis shows a 3.5 cm primary that appears infiltrative and without clear parametrial extension on MRI. Staging PET negative.  Is there any ...

Given recent retrospective study showing potential lack of benefit with bortezomib-based maintenance therapy (Bumma et al., PMID 37021929).High-risk a...

Which PI and at what dosing intervals? Dexamethasone or not? Emory has now published data with VRd consolidation as well as KPd consolidation, while ...

Does the patient's MMR status affect your opinions? What is/are your current preferred second-line regimen(s)? 

Such as the case in which a patient is unresponsive to steroids, IVIG, TPO-agonist, rituximab, splenectomy, and even fostamitinib.

Do you re-challenge them? If so, what pre-medications do you give? Do you dose reduce the cytarabine? Or do you switch another regimen?

Would you consider low dose indefinite anticoagulation in any scenario? Any difference in approach between hematological malignancy and solid tum...

In patients with no apparent skin involvement but lymph-node showing basal cell carcinoma with extracapsular extension. Would this warrant radiation o...

A recent NCBD analysis (Rusthoven et al., PMID 27325855) suggests that the addition of prostate RT significantly improves survival compared to AD...

Specifically if metastatic risk estimate approached the failure rate in control arm of STAMPEDE for high-risk non-metastatic disease (69% MFS at 6 yea...

Given the crossover that occurred in the various clinical trials and the potential for prolonged disease duration, how do you integrate OS, PFS, treat...

Do you use the same high risk factors as adenocarcinoma when deciding on adjuvant treatment for early stage disease?

In which scenarios would you consider a parp inhibitor as the first line treatment of choice? 

Patient initially achieved CR with VAC-IE with resolution of presumed lung mets and 100% necrosis in LLE primary tumor on BKA. Then was NED again afte...

Please specify how your institution is allocating resources now or will be soon.

Majority of patients on the seminal trial (Gross et al., PMID 36094839) had tumors isolated to head & neck, what was the rationale for this?

What role, if any, does molecular testing play in diagnosis and management in the absence of available clinical trials?

Do you base your decision on extent of residual disease?  Does the use of (neo)adjuvant immunotherapy have an impact on surgical site size or he...

If so, would you do bone marrow biopsy or send for NGS panel in blood to look for high risk mutations? NCCN lists this as the risk criteria. 

(Assuming they meet MonarchE criteria) For example, if the patient is in year 2, 3, 4, or 5 of adjuvant endocrine therapy versus 9 months out, would ...

Is there a role for KEYNOTE-522 since ER + metaplastic breast cancer have similar behavior to triple negative metaplastic breast cancer? 

What is your approach to try to persuade her that photons would be a better option?

IMPower110 data add further support to use of checkpoint monotherapy; however guidelines continue to support either I/O monotherapy vs chemo-immunothe...

Based on GI regimen or urothelial carcinoma regimens?

Are you waiting until drug availability or changing to a preferred non-cisplatin radiosensitizer? If you're utilizing an alternative to cisplatin, wha...

Would you biopsy lymph node to confirm recurrence/histology?  If confirmed, how do you decide between RT vs chemotherapy? If chemo - BEP x3 vs E...

Is there a minimum standard for which stations to sample? Does lymph node size affect your recommendations?

Received neoadjuvant ddAC/T followed by adjuvant capecitabine for residual disease and found to have metastatic pulmonary nodules within months of sur...

Assuming there is clear laboratory and/or imaging evidence of disease progression, and assuming FISH data is already available from a prior biopsy, do...

Do you use a q4 week or q12 week formulation? If you use both in your practice, what factors into your decision making for either one?

Are there any instances where you would prefer a biosimilar rather than the reference product? 

Patient with stable disease on maintenance therapy with lenalidomide and dexamethasone

If you do not use the PORTEC-3 regimen for p53 mutated IA endometrial cancer, what specific protocol or combination of chemotherapy and radiation ther...

> 30s, female with metastatic colon cancer. Presented with a headache. Metastatic hemorrhagic mets per MRI 10/2022. Had radiation. Kras mutated, Br...

Assume the patient is not a candidate for surgery. What dose would you use? Would you recommend a lower dose to not damage the patient's kidney functi...

Do you wait to monitor response to empiric corticosteroids before pursuing a kidney biopsy?

If the patient received <2 months of immunotherapy, would you continue immunotherapy alone or transition to enfortumab monotherapy or EV+Pembro?

The surgeons at our institution are asking for repeat markers but I am not aware of any data or guidelines to support this. 

How do you take into account pathologic factors like %clear cell histology, myometrial invasion, and LVSI?  

Given the published results of the PRODIGE 23 trial where FOLFORINOX was used neoadjuvantly with FOLFOX post-op

240-300 mg/m2 prior exposure. How would your management change in young fit/older individuals with comorbidities? Would you obtain interval TTE during...

What imaging modality do you use (conventional, PSMA PET, etc.)? When do you image (ex: a PSA threshold or PSADT)?

Lately I have seen patients with a concurrent gynecologic (requiring chemoRT), head and neck (requiring surgery), and early stage NSCLC (requiring SBR...

Are there scenarios in which you would proceed with checkpoint inhibitor for PDL1+ disease before having full molecular testing results?

Dose-escalation RT trials have had mixed results in the past for advanced rectal cancer, while in the early rectal stage there is a tendency towards a...

How do you weigh definitive chemoRT vs minimally invasive surgical approach with neoadjuvant chemo followed by transanal excision, in light of results...

Would sidedness matter? Do you use ctDNA assays to evaluate for acquired RAS mutations to guide this decision?

Would you give a trial of IST first or immediately refer for SCT if the patient has matched siblings?

CheckMate 511 trial showed reduced toxicity with flipped dosing of ipilimumab/ nivolumab (ipi 1 mg/kg and nivo 3 mg/kg instead of ipi 3 mg/kg and nivo...

Do you worry about their marrow reserve and response to neulasta in terms of lymphocytosis and decreased ANC response?

Would you advocate for a targeted gene approach or a fully comprehensive NGS panel?

Would your recommendation change in a patient having pain from disease and you wanted a quick response?

How do you decide between starting infliximab, MMF, or IVIG? If a patient presents in respiratory failure (nearing or requiring intubation), woul...

How do you "have the talk" in a way that is straightforward without emotionally crushing the patient?

Is your approach different than that to a primary essential tremor?

E.g. loss of PMS2 expression by IHC only but MSI stable by PCR.

What would you want community oncologists to know when following these patients? Are there any other special issues to follow especially in AYA?

E.g. in a patient with tenuous cardiac function, would starting treatment several weeks earlier potentially improve outcomes?

The patient has also acquired mutations in BCR-ABL, namely p.Met244Val, (c.730A>G); 3.7%, which may confer resistance, and p.Phe359Cys, (c.1076T>...

History of 4th ventricle choroid plexus papilloma s/p GTR, now with recurrent disease in the 4th ventricle and the left lateral ventricle (7 nodules i...

When would you use 5-fluorouracil instead of, or in addition to, cisplatin during chemoradiation? When, if ever, would you offer adjuvant hysterectomy...

There is evidence that parents do not adequately understand the purpose of phase I pediatric cancer trials (Cousino et al., PMID 23071225). 

Is radiation effective in this case and if so, what dose would you use? Is there potential for perforation?

For example, concerning throbocytopenia or neutropenia during anal cancer treatment with concurrent mitomycin/5FU, or other pelvic malignancies treate...

The results presented by Sudeep Gupta (from the Tata Memorial Breast Group at 2022 San Antonio Breast Cancer Symposium #GS5-01) showed no benefit (pCR...

Do you consider any neoadjuvant therapy or proceed to surgery followed by adjuvant chemotherapy and osimertinib? Does the type of mutation (ex a rare ...

If so, what platelet count threshold would you use? Would age impact your decision? Would you do a bone marrow to rule out primary MPD in adults if th...

What specific platforms do you use, individual biomarker/PD-L1 status vs NGS, tissue vs liquid or both? Must you wait for PD-L1 testing if mutation t...

Does your choice of agent differ, or are you more or less likely to offer maintenance than if the patient had multiple myeloma alone?

Ex. TP53, BRCA, T790M, or another? As of now, T790M mutation is one of the few de novo mutations found in treatment naïve patients that have been...

Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you c...

Specifically, would you consider either neoadjuvant or adjuvant immunotherapy in this setting, or only after recurrence?

This is a recently described entity with poor prognosis, so even with a CR after RCHOPx6 cycles, is your bias to push for ISRT due to EBV being poor p...

In your practice, what is the proportion of patients receiving neoadjuvant chemotherapy who are diagnosed with VTE? Does this differ from patients rec...

It is understood that the trial's experience was to keep on treatment indefinitely until progression or unacceptable toxicity. We are asking about rea...

How would your choice of therapy differ (if at all) for high vs low risk disease? Would the specific anti-platelet agents used influence your choice ...

Would your systemic therapy choice be more similar to treatment of ovarian carcinoma or soft tissue sarcoma?

Would you consider using an IO-based treatment or move on to TKI? Does the presence of sarcomatoid or rhabdoid features impact your approach?

Would you recommend standard definitive chemoradiation followed by adjuvant durvalumab? Would you treat pre- or post-systemic therapy volumes?

Are patients with long standing malignant central airway obstruction poor candidates for central airway stents? What is considered to be an acceptable...

Given the substantial risks associated with transporting an intubated and ventilated patient to Radiation Oncology, is there any evidence to support t...

Given that pembrolizumab/trastuzumab with chemotherapy is new SOC for metastatic disease, how would you approach those with recent fluoropyrimidine + ...

If the patient had PSC and baseline atrophy preventing brachytherapy boost (received SBRT boost instead), would this change your threshold for stentin...

For patients not on study, would you consider replacing missed doses of peg with a non-asparaginase based chemotherapy?

There are conflicting reports whether it contributes to renal insufficiency. If you do switch, what is your preferred TKI in this scenario?

Since both pregnancy and cancer are risk factors for VTE, is there data to guide when or if we should prophylactically anticoagulate? If so, what shou...

Are there specific patient populations in which you may feel comfortable with a patient selecting only one adjuvant therapy approach (tamoxifen vs RT)...

The patient was a >70-year-old with right-sided cT3N1M0, ypT0N0 TNBC s/p NAC pembro/taxol x 4 cycles followed by mastectomy w SLN (0/4); post-opera...

Patients with deficient mismatch repair (dMMR) and microsatellite instability high (MSI-H) harbor high tumor mutational burden which tends to have fav...

Margins are negative (closest 4mm), grade 2, 3 of 23 lymph nodes positive with no extranodal extension. What is your preferred chemotherapy approach a...

The patient presented with spinal cord compression, had subtotal resection and instrumentation with metallic hardware. Main concern is that post op su...

Is there a subset of patients for which you consider one regimen over the other (i.e. AC-THP v.TCHP)? If using an anthracycline regimen, do you u...

Would you consider empiric SRS if biopsy/resection is not feasible? When would you consider liquid biopsy?

With studies showing non inferiority to zoledronic acid q 3 months in support of bone metastatic disease, would you consider extrapolating this data a...

Patients with gastric cancer can acquire new targetable mutations on progression. This could aid in additional treatment options in this group which t...

The prior recommendations were between 6-12 months, but also were based on chemotherapy after surgery. 

Would you treat this as a locally advanced breast cancer and offer surgery, radiation, and systemic therapy? Does your management change depending on ...

Does your treatment approach differ from Waldenstrom's Macroglobulinemia? Does the presence/absence of a MYD88 L265P and/or CXCR4 mutation change you...

In a woman with high-grade, clinically node positive invasive ductal carcinoma who receives neoadjuvant chemotherapy and breast conserving surgery, wo...

Is there data on efficacy or toxicity when chemotherapy is added to Proton beam therapy for head and neck cancer like there is data to support adding ...

If tolerated through Cycle #1, how aggressively do you try to titrate the selinexor dose up toward 100mg weekly or 80mg twice-weekly? And does your a...

What other molecular tests do you routinely order on such tumors?

How do you generally think about sequencing treatment among available options? Would your choice be affected by a patient's eligibility for transplan...

According to the NCCN guidelines, there is a highly selected group of T4a glottic larynx patients that can undergo observation instead of postoperativ...

Encouraging aggressive PO intake in patients with swallowing dysfunction may place them at risk for aspiration pneumonia, especially risky if undergoi...

Do you have a certain immunoglobulin level which you would use to determine this?

NCCN discusses targeted therapies (Everolimus) but also Temodar / Xeloda combination.

If so, what dose-fractionation regimen do you utilize? What are your target volumes?

If a patient with endometrial stromal sarcoma managed with fulverstrant has a single oligoprogressive lung nodule, is there any contraindication to tr...

How is your approach different from or similar to those who undergo surgical menopause? 

Is there an optimal chemotherapy regimen that optimizes cure rates while minimizing side effects?

Would you obtain baseline PFT on all patients or only selected high risk patients? Would you repeat PFTs regularly or only if clinically symptomatic?&...

Given strong TDXd efficacy in these patients is there a role to use it earlier than 2nd line? How does prior Her2-directed and/or taxane therapy...

What is your preferred dose/fractionation following a previous course of radiotherapy?

No evidence of distant disease elsewhere. Surgical resection is not possible. Would you recommend metastasis direct therapy to the liver (i.e. SBRT or...

What parameters/goals/targets do you use?  Do you treat PV, ET, and MF differently?

While rare, these patients were excluded from all frontline CDK4/6 inhibitor trials. Is there any data on the efficacy of ribociclib in the CNS or abi...

Results with fulvestrant and letrozole backbone in MONALEESA and MONARCH trials seem comparable, but PALOMA data is somewhat mixed. How do these trial...

Subgroup analyses in MONALEESA-2 suggest more benefit in de novo treatment naive patients, which is in contrast to MONARCH-3 data presented at ESMO 20...

If so, how do you incorporate GCSF into treatment of these patients?

If so, what assay would you use in this population? Do we have data on TMB/PDL1 status of long-term survivors?

In light of recent trials showing no difference in outcomes with RT+cetuximab vs RT+IO, does this potentially lead us to use immunotherapy in cisplati...

Are you waiting for BCG to become available or are you using other bridging therapies such as pembrolizumab?

Do you include pembrolizumab with platinum-taxane + bevacizumab or reserve it as a second line option?

I.E., can a patient with a questionable 5 mm node (MRI T2N1) which is negative on pathology after short course radiation be staged T2N0 and receive no...

In light of CheckMate 816 and IMpower010 and FDA approval for neoadjuvant chemo-nivolumab and adjuvant chemo-atezolizumab, how do you decide which sys...

NGS without any actionable mutations and PD-L1 TPS 15%. Would you offer chemotherapy, radiation, or immunotherapy and, if so, in what order?

What is your preferred agent (DOAC, warfarin, enoxaparin), and is periprocedural bridging necessary?

What would you recommend within the first year after ATG and thereafter if still maintained on cyclosporine?

If considering systemic therapy, would you consider standard chemotherapy or use biomarker-directed therapy (e.g., imatinib if ckit+, larotrectinib/en...

Do you wait for radiographic progression? What is your preferred imaging modality for re-staging?

No actionable genetic alterations were identified for this patient. Would you consider FOLFOX + durva, or even single-agent durva?

Are there specific clinical factors, efficacy, or treatment tolerability issues that lead you to favor one agent over another? How do you compare or ...

How do you decide between downstaging chemotherapy or upfront concurrent chemoradiotherapy? Both are listed as NCCN options. 

How does your approach vary based on residual disease left at the time of surgery? Please specify your approach for the amount of residual disease at ...

For nodes just inferior to the celiac/SMA axis and no other distant metastatic disease? Stage is formally M1, but just barely. The patient is otherwis...

TOPAZ-1 trial allowed for up to 8 cycles of gem/cis. Were there differences in chemotherapy duration/# cycles between treatment groups? Does use of du...

For a patient, who has received SBRT & WBRT for CNS disease, is there a role of autoSCT and HD-chemo in this setting (no residual extra-CNS diseas...

No preop therapy; dMMR in poorly cohesive and mucinous carcinoma component, pMMR in tubular adenocarcinoma component

What contraindications or concerns do you have in this scenario beyond assessing the Child Pugh Score?

What VAF burden would be considered significant prognostically or for treatment decisions?

If a patient previously received taxane-based chemotherapy for the initial cancer, is additional chemotherapy recommended or can HER2-directed and hor...

Is the marginal advantage of AC/T in 1-3 node positive outweighed by toxicity such as risk of cardiotoxicity and leukemia, regardless of RS?

What would be your next treatment for a young adult patient with medulloblastoma refractory to repeat resection, craniospinal irradiation, and initial...

There have been reports of pembrolizumab leading to lichen planus (my understanding is lichen planus pathophysiology unclear, but potentially autoimmu...

Can you use 50 mg BID if intolerant to 150 mg and 100 mg dosing? Any tips for side effect management to help patients stay on full duration?

MonarchE shows statistically significant improvement in IDFS and DRFS, but the magnitude of absolute benefit is modest (3-year IDFS and DRFS rates = 5...

C diff infection ruled out and CT abdomen pelvis shows diffuse enterocolitis extending far beyond the bowel-sparing IMRT radiotherapy field. 

How much weight do you give to a hgb/hct threshold versus symptoms?

General recommendations on dose and management presuming unresectable. 

Would surgical margins, evidence of angiolymphatic spread, number of lymph nodes removed during surgery inform your decision? 

Would the checkpoint inhibitor still work if blocking only that portion of the inflammatory cascade as opposed to more global blockade with steroids?

Some payors prefer leuprolide acetate injectable suspension (eligard) for ovarian suppression. This is not the preparation that was used in SOFT/Text ...

What is the risk of pregnancy loss in absence of anticoagulation? What would you suggest if the patient had anticoagulation in prior pregnancies and r...

If the patient has had prior prostate radiation and is not a surgical candidate, would you treat with systemic therapy alone? What is the natural his...

Confirmed no urothelial carcinoma and muscle in specimen without involvement. 

Is there a difference in efficacy if dose is given later point during the course of therapy?

Would you avoid combination with TKI given possible higher risk of osteonecrosis of the jaw?

Are there agents (eg. bendamustine) or modalities to avoid? Does washout times prior to collection vary between modalities?

Based on this review (Melamed and Lee, PMID 31998289), patients with MS on several DMTs may be at higher risk for certain cancers. How does this play ...

In what situations would you use a neuroendocrine chemotherapy regimen over carboplatin+paclitaxel?

Majority of patients on MonarchE received neoadjuvant/adjuvant chemo.  Does the availability of abemaciclib impact your decision to offer chemo ...

How would you balance the OS benefit from TOPAZ-1 with the risks of immunotherapy in this or other high-risk populations?

Please specify your approach in elective and emergency surgical situations

Patient had estradiol level checked by her gynecologist due to recent irregular bleeding. Estradiol level was markedly elevated on initial testing (90...

Would you offer adjuvant atezolizumab, osimertinib, or neither? Both IMpower010 and ADAURA only had patients with EGFR exon 19 deletion or L858R mutat...

Patient is young. Bilirubin normalizes when tucatinib is held, but again increases to grade 2 when it is restarted. Evaluation for hemolysis was negat...

How do you sequence systemic treatment options for in patients with Child's Pugh B (or greater) in context of IMbrave150 and HIMALAYA? When do you in...

Is data sufficient to adopt this as the new standard of care? Can you comment on the reported regional and race-based variations in outcomes?  ...

Is there a role for using pembrolizumab alone in microsatellite stable endometrial cancer if patients are unable to tolerate lenvatinib?

E.g. a patient with monoclonal protein with mild light chain ratio elevation. Do we need to get a BM biopsy in all such patients?

Do you look into their stage/risk to decide? Since patients can experience bone loss after stopping denosumab, how do you plan to discontinue?

Do you proceed with chemotherapy alone, neoadjuvant chemoRT, or definitive chemoRT? How do you communicate treatment intent to the patient?

Are there specific clinical or social scenarios that would preclude the use of this treatment?

In the KEYNOTE-775 study, what was the proportion of patients who had a recurrence free interval ≥1 year from platinum-based cytotoxic chemotherapy...

Are there any planned trials to compare lenvatinib + pembrolizumab and platinum-based cytotoxic chemotherapy for advanced or recurrent endometrial can...

Does your approach to the number of cycles vary based on plan to include radiation therapy or presence of certain histopathologic features?

Anecdotally, I have seen more serious IRAEs in patients I'm treating with this regimen than anticipated. Is there higher risk with this drug combinati...

Do the results of the unplanned subset analysis of the PACIFIC trial showing no OS benefit in this population lean you away from consolidation?

Would you use gem/docetaxel, anthracycline-based regimens or targeted therapies?

Would a negative dotatate PET change management for a patient for whom you were planning to start SSAs?

For example, portion is seen above and below the mesorectal fascia. Do you feel comfortable treating as colon cancer with surgery upfront?

Would you extrapolate from the DESTINY-CRC01 study, even though RAS/RAF mutations were excluded?

In this case, the patient had received daratumumab/lenalidomide/dexamethasone as part of a cooperative group trial. Would you say that the patient had...

Is there concern for increased toxicity from erdafitinib following avelumab similar to osimertinib toxicity following pembrolizumab in NSCLC? Does FGF...

Are there certain patient or disease related factors that would lead you to incorporate lenvatinib + pembrolizumab earlier?

What steps should be taken when switching premenopausal women from tamoxifen to AI? In this case, the change is due to newly discovered endometrial th...

Does your answer change based on clinical or molecular risk factors, and if so how? Does your answer change if MRD status after induction is unknown?

Infection is not part of the criteria for starting treatment both in UpToDate and in NCCN guidelines. 

How do you determine whether to add intrathecal chemotherapy in patients with +CSF? Would your approach change for primary vs secondary CNS lymphoma?

Would you treat with ADT if no metastatic disease? Does absolute PSA (e.g. PSA<2) inform decision?

iPET2 and iPET4 showed Deauville 5 response. CT biopsy after 4 cycles was negative. Patient is currently scheduled for 2 additional cycles of ABVD.

For example, if the primary breast tumor was HER2 IHC 1+, but a metastatic site was HER2 IHC 0, would you still recommend using T-DXd? Will you chang...

If so, do you use it for all patients or only cisplatin doses >= 70 mg/m2? What dose of mannitol do you use?

Additional imaging of the potential lesions, biopsy or assume negative given normal PSMA PET/CT. 

Do you have a BMI threshold where you would convert to weight-based dosing over flat dosing? Are certain agents of more or less concern - PD-1, PD-L1,...

Ewing sarcoma of the right lung, status post bi-lobectomy and adjuvant VDC/IE, with recurrence 6 years in the right lung only. He has reached a cumula...

Patient with initially stage IIIC right sided colon cancer s/p resection found to have metastatic disease prior to starting adjuvant therapy. MSI-H an...

Is there evidence that T-DXd crosses the blood-brain barrier?

How do you assess if a patient may be a candidate for CAR-T cell therapy?

Prior studies have shown that there can be significant variation between grading pathologists as to which samples are defined as HER2 IHC +1 versus HE...

Patient is a post-menopausal woman with 4 lymph node mets that was strongly ER+/PR+, HER2-negative invasive ductal carcinoma with a high Ki-67 w...

Would you use a different endocrine therapy treatment? Would you use indicators other than Oncotype to guide the need for chemotherapy?

Do you routinely offer post-operative adjuvant radiation in addition to chemotherapy? Are the results of the recently published negative phase II...

When is this discussed? What are the common/less common toxicities you advise patients on? Are there best practices for coordination with referring on...

Given the results of ZUMA-7, TRANSFORM, and BELINDA - how does this inform your current practice? What are the currently approved indications for CAR-...

Or would you proceed with cabazitaxel or other therapy? Initial chemo-hormonal therapy was ADT + Docetaxel x6 cycles.Docetaxel rechallenge at time of ...

Do you find the ibPFS endpoint sufficient to change practice for any or all patients, or will you await OS or other data/trials?

Specifically, how do you consider T-DXd use in setting of other antibody-drug conjugates (e.g. sacituzumab vedotin)? Are there any special considerati...

- Dialysis catheter used for hemodialysis- RIJ thrombus in dialysis catheter was incidentally found- Patient asymptomatic with no prior history of VTE...

What factors do you use to decide between weekly low-dose carboplatin and paclitaxel combination vs cisplatin based doublet, and do you routinelt...

Do you prophylactically start all patients on B12, B-complex, and/or omega-3? If so, what dose? What about ice mittens and booties?

If a patient has a painful breast lesion in the setting of rapidly progressing systemic disease treated with weekly taxol (60 mg/m2), would you feel c...

Alternatively, is a biopsy of a metastatic bone lesion preferred in a patient who has already progressed on chemo and hormonal therapy and has bone-on...

Do you ever add prophylactic Keppra (levetiracetam) for glioblastoma patients without a seizure history based on data such as this study (nature.com) ...

Do you drop or adjust the temozolomide at any point, or rather continue to progression as long as temozolomide is well tolerated?

Did S1800a stratify by prior treatment response? Would you choose different 2L treatment for a patient who progresses rapidlly on pembro + platinum do...

Is there anything to differentiate the two agents? CNS penetration reportedly with adagrasib, FDA accelerated approval has been given with sotorasib.&...

For example, in a patient on steroids for CNS or spinal metastases - would you use IO-IO vs IO-TKI or TKI monotherapy?

If yes, would you directly add olaparib at progression on abiraterone vs waiting to use abi/olaparib at a later line of therapy?

Would you offer adjuvant radiation? (Dose? Target?) vs Salvage? Would you add ADT? Would you add abiraterone? Would the number of lymph nodes involv...

Do you have a preferred way to incorporate advanced androgen blockade vs chemo vs sip-T vs Lu-PSMA vs PARP vs other targeted agents?

- monarchE included <1% Stage IA and < 5% patients with no chemotherapy.Ex: 64 yo, ER/PR 95%, Ki67 20%, cT1c N0 but pT1c N1a at lumpectomy/SLN b...

For example, are you more likely to incorporate T-DXd earlier in sequence for 2+ vs 1+? Is there any justification to change our approach in HER2-zer...

What precautions can be taken to limit infestation of the department?   Do you implement a treatment delay and if so how do you decide when...

Does the safety profile impact your choice significantly? Does your first choice vary by disease histology?

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...

What would your approach be in a patient with a mid-esophageal squamous cell carcinoma treated with chemoradiation therapy followed by surgery, with P...

Secondary MF such as post-PV, for example. Do you apply the same prognostic scoring systems? 

My experience has been that patients can be neurologically devastated years out from WBRT. In Medical Oncology practice at my institution, we do not r...

Endocrine therapy is usually not indicated for DCIS s/p bilateral mastectomy, but would the fact that residual tissue (nipple-sparing) alter your deci...

We know the longer we expose patients to lenalidomide, the harder collection will be. Would you collect now or switch to an alternative regimen to ach...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...

Would you consider the BEACON regimen (i.e., encorafenib/binimetinib + cetuximab) in this setting?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...

Patient has ED unresponsive to cialis/viagra; would you recommend testosterone replacement therapy?

Which patients would you recommend active surveillance alone, a less morbid procedure such as enucleation, or a Whipple surgery? How does age influenc...

How does graft function play into your decision making? How do you utilize post allogeneic transplant chimerism in clinical practice? Do you obta...

In patients with prior perioperative immunotherapy with early relapse, would re-introduction of immunotherapy be reasonable with high TMB? 

Is there role for IVIG? Would you alter the dose or time course of steroid therapy?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

How does the presence of specific mutations affect your adjuvant treatment planning or patient counseling? Given POLE mutation status can currently o...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

If so, how many cycles would you give? Both the MAGIC and FLOT trials showed difficulty with administering adjuvant chemotherapy.

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice? ...

I recently saw a patient who had been treated with concurrent pembrolizumab-RT elsewhere. Is this an acceptable practice outside the setting of a clin...

How do you operationalize finding biomarker information in EHRs/testing portals, either for your own patients or if they have changed providers? If a...

Definitions for "high risk" differ by whether patients receive neoadjuvant chemo and across other contemporary studies. Does the change in AJCC stagin...

What if Medical Oncology wants to give more systemic therapy and further delay XRT start date?What should we be telling the Breast/Plastic surgeon/Med...

At what PSA would you become suspicious for biochemical recurrence and pursue restaging? Is there a threshold value? What imaging modality would you ...

NCCN states to consider adjuvant chemotherapy similar to muscle invasive bladder cancer in this scenario, but one would avert adjuvant chemotherapy in...

Would you give trastuzumab every 2 or 3 weeks, pembrolizumab every 3 or 6 weeks?

Would you use it for initial staging or at time of biochemical recurrence?

In the setting of no personal or family history and no other risk factors for thrombosis, is systemic anticoagulation warranted if local treatments (e...

Would you consider gem+Abraxane to avoid FOLFIRINOX toxicity in a small, node-negative tumor?

Would you consider definitive local therapy (surgery, radiation?) if she achieved a good response to initial systemic therapy?

Would you consider omitting treatment if small tumor and early stage? Or would you use tamoxifen?

Patient was initially ER positive, HER2 positive. Currently she is on letrozole. Recurrence is ER/PR negative and HER2 positive and developed almost 2...

Given data from metastatic breast cancer trials that show benefit with continuing trastuzumab despite progression.

If radiation, what type? EBRT or brachytherapy? Any other techniques you would recommend, such as rectal balloon? 

In patients who continue to have insomnia despite diphenhydramine, benzos, and trazodone, are there other evidence based treatments that are helpful?

Is there evidence or experience to support use of targeted therapy for KRAS G12C mutated NSCLC as first line in place of chemotherapy? 

The Intergroup 0162 trial did not demonstrate noninferiority, although OS difference only 5.1 vs. 5.8 yrs.  Would pattern of spread affect your d...

Residual GEJ mass and progression in local lymph nodes after carbo+taxol chemoRT without distant metastases.

What would you offer a premenopausal woman with clinical T2N1 ER positive breast cancer for adjuvant therapy after she achieves a pathologic complete ...

What do you do if LFTs are elevated after one dose of neoadjuvant TCHP (highest ALT >13 times upper limit of normal, normal bilirubin) with prior n...

I have a patient in her 60s with CHEK2 mutation, diagnosed with bilateral breast cancer. Lumpectomy showed b/l tumors <10mm both ER/PR+, HER2-, but...

Is it necessary to test CPS given the FDA approvals are not contingent on CPS %?  If you do test, do you check 28-8 (nivolumab), 22C3 (pembroliz...

Does a progressing kappa/lambda ratio > 100 at any point in time warrant treatment, or does one wait to treat patients in the setting of a slowly i...

Weekly (20 mg/m2 D1, D2) and q 3 wks (70 mg/m2 x 3c or 100 mg/m2 x 3c) regimens have all been listed as acceptable.  For reference, RTOG 97&...

Assuming no overlap with prior RT doses, would a history of necrosis cause you to hypofractionate rather than deliver single fraction SRS?

Should these cancers be treated like hormone positive breast cancer or triple negative breast cancer? She is pre menopausal with cT1c grade 2 disease...

The forest plot from CheckMate 274 did not show a benefit for such patients? How would you select between adjuvant chemotherapy and adjuvant nivoluma...

How are your teams effectively evaluating and counseling patients to ensure they are prepared for potential extended adjuvant treatment approaches? Is...

Does this change for PDL1 1-49% vs >50%? Will you be more likely to employ other checkpoint inhibitors before use of HER2 targeting therapy? Or sta...

VIP can be considered, but given complex psychosocial issues and limited community cancer treatment resources, this question is being asked. 

If said patient was known to be gBRCA mutated, would you use neoadjuvant chemotherapy to enable adjuvant olaparib for those that did not have a pCR? &...

Do you view CPS < 1% or 1-4% separately? Do you view the incremental benefit of adding immunotherapy still advantageous given relatively poor outco...

Do you go by FDA approval alone, or incorporate other data into your treatment decisions?  How do you view updated recent presentation of CM-649 ...

Would you use reduced dose chemoimmunotherapy, single agent chemotherapy, or single agent immunotherapy if the patient is unlikely to tolerate full do...

Would you consider boosting the nodes?  What dose?  Would this change your recommendation for length of ADT?  

Would you consider chemotherapy, androgen blockade or triple therapy (chemo and AR targeting)?

Ref: Geyer et al, Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and hi...

Patient has been on pembrolizumab and had two symptomatic soft tissue mass treated with radiation. 

How much of the benefit of adjuvant chemotherapy do you expect to be due to ovarian function suppression due to the chemotherapy?

What is the impact among patients and providers? Has your documentation been adjusted now that patients can readily review?

Is dose modification of docetaxel necessary with Gilbert's when giving TCHP?

NCCN guidelines state check at baseline and then as clinically indicated. Some other sources state, can check prior to each cycle of BEP?  What ...

Patient is young and reoccurrence is one year after initial diagnosis of T1cN0 ER/PR positive, HER2-negative breast cancer treated with mastectomy, bu...

With conflicting data from the EORTC RCT and the Sarcoma meta-analysis collaboration, what factors determine when you would offer adjuvant chemotherap...

In subset analyses of OlympiA there seems to be smaller magnitude of benefit among HR+ patients. In your opinion, should adjuvant olabarib be offered ...

Peripheral blood flow shows prominent NK cell population but marrow aspiration/bx shows normocellular marrow with trilineage hematopoiesis. 

What combination of fluoropyrimidine, PD-1 inhibitor, or trastuzumab do you use?

Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?

In the absence of a VTE would you consider prophylaxis after a surgical procedure? Often non-hematologists order this testing but we are consulted for...

Would you restart hormonal therapy in a patient with a new diagnosis of LCIS 2 years after they have completed 5 yrs of AI for stage 1A IDC in the oth...

Patient underwent mastectomy for DCIS in the setting of previous lumpectomy and adjuvant radiation for the invasive breast cancer. 

How would you modify therapy for a younger, fit patient versus an older, frail patient? Lesions in stomach, small intestine, colon resulting in bleed...

Does treatment with B-cell depletion and/or negative anti-spike antibody status despite COVID mRNA vaccination influence your decision?

NCCN lists PCV as category 1 (and now with analysis in Abstract 2002 from ASCO 2019 showing benefit in IDH mutated), and temozolomide as 2B, yet temoz...

HCG 850, AFP normal, LDH ~500 pre-orchiectomy.  If tumor thrombus, would you favor 4c of BEP? Would you try biopsy it? How common is IVC thrombu...

Are there contraindications to drugs like oxaliplatin or abraxane? Does chronicity or severity of the patient's underlying symptoms play a role in yo...

E.g. One NSCLC with N2 disease, and additional ipsilateral small nodule that is a biopsy-proven second primary. When do you consider SBRT to a nodule ...

Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you ma...

KEYNOTE 811 showed improved response rate with the addition of pembrolizumab, but very few patients in this study had low PDL1.

Given multidisciplinary discussion has occurred and SBRT has been agreed upon as local therapy, how do you approach the presence of moderate/significa...

Would you always offer an FGFR inhibitor as second line therapy in these patients instead of a second line chemotherapy regimen?

Should this be sent on initial biopsy or on surgical pathology? What if an initially high risk patient has good risk findings post-operatively?What ha...

Are you offering patients beta-emitters (Samarium-153 lexidronam, strontium-89) to any patients?

Is a 3 month delay too long in someone who had postoperative complications?

i.e. treatment-refractory PV, prior to progression to PMF or AML

Are there clinical features (post-op PSA, Decipher score, pN+, pT3, etc) that would inform your decision?

Assume normal cardiac function and no obvious co-morbidities. No anthracycline previously due to age alone. The patient’s BRCA status is unknown...

If an older patient is only fit enough for single agent fluoropyrimidine therapy, would you prefer to give this neoadjuvantly or adjuvantly?

Would you ever consider adjuvant chemotherapy rather than adjuvant immunotherapy after the publication of the CM-577 results? If so, in which pop...

For instance, the foci found were pN1mi (0.5 mm) deposit in 1st SNL (1/13 LN) and mpT1mi (8 foci). Would you consider single or dual anti-HER2 blockad...

Do you worry about false negatives on PET, CT, MRI if ADT is started before the scan? Scheduling scans can sometimes book 2-4 weeks out. 

Are the early results of CASSIOPEIA (Abst 8003) from ASCO 2019 practice changing? What about the GRIFFIN results in 2020?

Do you allow pre-RT treatment with the CDK 4/6i and hold during RT, vs. allow concurrent with breast/chest wall RT, vs. delay starting CDK 4/6i until ...

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?

If a patient is asymptomatic at presentation, how do you incorporate local treatment options (RT/surgery) and when?

Do you modify the aspirin dose based off the lenalidomide dose? Do you ever use higher dose aspirin in lieu of an anticoagulant? The NCCN guidelines s...

How does cirrhosis and/or underlying thrombophilia affect your decision?

Patient has already received neo/adjuvant treatment with AC, paclitaxel, capecitabine, docetaxel, and carboplatin.

Would you consider neoadjuvant or adjuvant treatment and if so, which therapies? Patient initially had pT2N0 disease and recurrent disease is also ER+...

Do you consider size > 2cm, visceral pleural invasion or vascular invasion as indications for cisplatin-based chemotherapy? 

Patient previously received neoadjuvant ddAC-T with residual disease at surgery, followed by adjuvant capecitabine which was completed 2 months prior ...

Pathology details: 75% high grade large cell neuroendocrine tumor of the cecum (20-30 mitoses per 10 hpf, Ki67 75%) and 25% adenocarcinoma. Patient ha...

For medical oncologists, would you offer a PD-1/L1 inhibitor? For other subspecialties, how would you counsel the oncologist regarding the risk of usi...

In high-risk, node-positive HR+ Her-2 neg breast cancer patients who received neoadjuvant chemotherapy with residual disease, would you give capecitab...

How do you manage low libido in women with breast cancer on endocrine therapy? Other than managing vaginal dryness/dyspareunia, if just a desire/libid...

Resected small bilateral tonsil SCC & base of tongue SCC. The patient received 6 cycles of BEP 30 years ago for testicular cancer, and suffers fr...

Conversion tables suggest starting the new drug with the next dose but do not seem to answer this question (i.e. if switching from rivaroxaban 20 mg d...

G1 neuropathy and G3 neutropenia were observed with cycle 12 FOLFOX + bev. Would you reintroduce oxali at a lower dose or switch to irinotecan+EGFRi ...

Has your practice changed based on the randomized, phase 3 study showing prophylactic gabapentin is not effective? Please share your thoughts and exp...

For example: shorten IMiD duration each cycle, add scheduled G-CSF, add antibacterial prophylaxis, etc.

Will degree of PD-L1 status impact your decision? Would you ever offer to stage IB patients as per study enrollment?  Do AJCC v8 staging guideli...

How would you manage endocrine therapy 7 years after the original ER+/PR+/HER2- IDC, while on adjuvant tamoxifen/OFS develops a contralateral ER+/PR+/...

If you had a patient with otherwise average risk stage 2 colon cancer but had signet ring or mucinous components to their pathology, would this sway y...

Of note - the tumor tissue biopsy NGS did not show KRAS or BRAF mutations. Microsatellite stable. Patient received first line FOLFOXIRI + Avastin .

For patients who have already undergone trimodality treatment, what time frame do you consider for adjuvant IO?

Do you observe, offer adjuvant pembrolizumab, or give a first-line metastatic regimen (IO/IO or IO/TKI)? Does your recommendation vary based on risk c...

Is there a certain time interval where you would feel comfortable to rechallenge with immunotherapy at recurrence (6m vs 1y vs 2y?) Does degree of PDL...

Are the experts convinced by DFS when the OS is immature?  How many in BSC arm went on to receive immunotherapy and was that adequate?

What would you do for a patient with a non-EGFR actionable mutation?IMpower010 included EGFR and ALK mutated NSCLC. Is there any concern in the use of...

In elderly patients (>70-75) with a good performance status, does the risk of neurocognitive decline outweigh the benefit of PCI?

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

Do you initially start with systemic therapy alone or do you proceed directly to chemo-radiation? 

Is there a role of EBRT to the prostate with extended fields to cover the retroperitoneal nodes plus ADT (definitive therapy) or would you treat as ca...

This involves the primary site responding but progression with new bone marrow involvement with resulting cytopenias.

In light of updated monarchE trial data, it seems a SLNB would help delineate adjuvant treatment options in this population. However, Choosing Wisely ...

Grade 2 DCIS, post mastectomy with negative margins, sentinel nodes negative

This is in the setting of a patient who is now on ruxolitinib with rising leukocytosis and thrombocytosis, but cannot be on aspirin due to recent blee...

If the patient cannot tolerate methotrexate or further chemotherapy, how effective is radiation therapy (e.g. WBRT) in rendering the patient disease-f...

PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to ...

For stroke-like migraine attacks after radiation therapy (SMART syndrome), does your management of these patient's change with recurrent episodes? How...

How do you weigh the various efficacy endpoints in the trials of novel combinations in ccRCC?  Are there specific clinical populations that you ...

Many of the patients on ASCENT trial were heavily pre-treated and require growth factors. With the day 1,8 treatment cycle, is there a way to minimize...

Do you worry about fluoropyrimidine resistance with concurrent chemoRT? Is there any role for neoadjuvant immunotherapy?

What is your approach to a patient who underwent surgery for what was thought to be a thymoma, but ended up being a pure seminoma? No disease elsewher...

After 3-4 cycles of RVD, would you automatically take the patient to transplant if he has achieved at least a partial response, or is there any benefi...

For example, for outpatients or resource-limited settings with a moderate probability 4-T score (but low clinical suspicion), would you ever consider ...

What clinical criteria would make you prefer TORS as the initial treatment approach?  

Are there other treatment variations by clinical subsets (eg tumor location, histology, stage II vs III, other biomarkers) seen in CM577 or other data...

BRCA mutant, ER/PR positive and HER2 positive T2N0M0 breast cancer diagnosed 5 years ago, treated with bilateral mastectomy, BSO, 1 year of adjuvant a...

CheckMate 577 only included patients with R0 resection.For R1 resections, guidelines suggest observation vs re-resection only.  

Would you offer indefinite anticoagulation if the event is unprovoked and the patient has low bleeding risk? 

How do you stage? Like nasopharynx or p16+ oropharynx? Do you treat it like npx ca with chemo xrt + adj chemo or like opx p16+ with definitive chemo ...

Please also discuss the type and duration of anticoagulation.

For patients with hormone negative breast cancer and HER2 positive only by copy number, do you give TDM1 for residual disease or capecitabine?

How are you thinking about sequencing therapies for these patients (IO vs chemo vs T-Dxd)? Are the data from DESTINY-Lung01 strong enough to warrant e...

Would you think differently about chemotherapy based on %teratoma or size of lymph nodes vs number of lymph nodes (eg. multiple small LN vs single 2-5...

Can patients be re-challenged after developing ILD? Is the toxicity seen with T-Dxd a potential barrier to use?  Do you feel the dosing used in...

Do you add on additional cycles of 5-FU/capecitabine to go beyond 3 months of treatment? Or would you stop at 3 months of therapy, dropping the oxalip...

What is your general rationale for selecting from available options?

If yes, do you recommend it be given concurrently with chemotherapy or sequentially? What is your target volume and dose?

Given seemingly improved efficacy in ASCENT patients who had less prior treatment, would you consider use after only one prior agent rather than two? ...

Are there specific patient cohorts in whom you will more preferentially use sacituzumab govitecan? Can data from ASCENT be applied to patients with C...

Would the etiology of HCC affect your decision, e.g. non-viral hepatitis since less benefit was shown for this group in IMbrave150?

Based on the SCORAD III trial, will you now be treating patients with spinal cord compression with single-fraction radiotherapy? Is there anyone ...

Or with other available IO/TKI combinations should this be strictly reserved for intermediate/high risk patients only?  If selecting IO/TKI, do ...

Would you use immunosuppression in patients several years after curative treatment for melanoma?

Also is there value in using voxelotor for the purpose of reducing hemolysis, and if so what parameters do you use to determine when to initiate voxel...

If any clinical benefit (ie. CR, PR or SD) would you consider switch maintenance avelumab, surveillance until progression, or an alternate regimen?

Molecular profiling revealed no targetable alterations, however tumor mutational burden was >10 mut/Mb.

Patient in mid-30s with no major medical history presented with isolated left neck swelling. Incisional biopsy w/ HTLV1/2 associated ATLL, Ki67 of >...

Do you select treatment based on toxicity profile since efficacy of regimens will likely never be directly compared? Are there QOL indices that can ...

Do you try to keep Hb> 10 or 12? Or somewhere in between? 

Patient has progression of liver metastases while on pembrolzumab/axitinib. ECOG PS 1 and limited comorbidities.

Is there a particular sequence you would adjust contributing antirejection or antimicrobial medications? Is the use of G-CSF appropriate and at what c...

To what degree do you factor in patient preference when choosing among available treatments? Are there features of each regimen that you emphasize in ...

What would be your radiation volumes/dose and choice of chemotherapy?

Can you expand on this by sharing exactly what this routine workup should include? What additional tests outside of evaluating for POEMS and amyloidos...

For example, does a higher recurrence score influence your choice of TC versus AC-T?  Or your choice to add ovarian suppression to a premenopausa...

 If blood counts are sustained, do you continue or delay?

Do you treat with radiation therapy and what dose do you use? What dose do you accept to the duodenum?

Hydroxyurea is demonstrated to reduce complications and improve long-term outcomes in severe genotypes HbSS and sickle beta0 thalassemia. What clinica...

Lymph node is 4.5cm with no reported ECE. Does the size of the LN or presence or absence of ECE affect your decision?

Given that prophylactic cranial irradiation (PCI) has been shown to decrease the incidence of symptomatic brain metastases in patients with extensive ...

Do you routinely recommend any dietary changes or is the evidence not convincing?

Should patients with moderate penetrance pathogenic variants be managed similar to BRCA patients and consider risk reducing contralateral mastectomy?&...

Provoked or unprovoked VTE: Do you use D-Dimer (or even repeat imaging to reassess residual clot) in any capacity to guide anticoagulation duration? E...

Genes such as ATM, CHEK2, PALB2, RAD51C/D, BRIP1 seem to show some potential increased risk of ovarian cancer. Should these patients under prophylacti...

What about a higher penetrance PV such as PALB2? See JCO OGR 8/2021 by @Mark E. Robson discussing management of non-BRCA pathogenic va...

Would you prioritize the head and neck cancer or treat the lung cancer first with SBRT to take care of it first? How about if there is mediastinal inv...

GS 4+4. PSA low (1-2). CT and bone scan negative for lymphadenopathy or metastatic disease.  Prostate MRI pending. 

In a scenario where patient's other clinical/familial risk does not sufficiently qualify them? See JCO OGR 8/2021 by @Mark E. Robson discussing manag...

The recommended concurrent chemotherapy regimens (cisplatin/paclitaxel and cisplatin/FU) in NCCN are based on BID fractionation of radiation as in RTO...

Have you used anticoagulants other than coumadin? Or is that the only appropriate agent given monitoring is based on PT/INR?

The patient initially received definitive therapy with AC-T and RT to the breast as well as RT to a solitary bone lesion. She has been on AI for the l...

Does this data change your preferred first line treatment regimens when considering other options such as mAb combos, cytotoxic chemotherapy?

Is the non-inferiority margin of 1.429 sufficient, how was this selected? Is the open label (rather than blinded) study design of any concern? Is th...

Can experts comment on fungal pneumonia risk with individual BTK inhibitors as seen in ELEVATE-RR and whether this impacts their management decisions?

Do you feel comfortable with BTK inhibitors in these patients? In ELEVATE-RR patients on a/c were excluded, and rate of atrial fibrillation in the ac...

Can the ipsilateral supraclavicular field and bilateral hilar nodes still be limited stage? 

How would non-regional adenopathy change management? What about poor surgical candidacy?

Do you ever recheck JAK2/CALR/MPL/BCR-ABL? Would you recommend a bone marrow biopsy? Is cytoreductive therapy indicated?

Is there a role for aspirin or hydroxyurea? Do you perform phlebotomy, and if so, what goals?

Would you recommend surgery first or neoadjuvant therapy such as concurrent cisplatin/RT or another regimen?

The patient has extensive liver metastases and a high bilirubin. She has not received any prior systemic therapy in the metastatic setting. 

In the case of subtle single lineage dysplasia with normal cytogenetics, do you routinely perform NGS testing for CHIP-type clonal mutations? Do you ...

How do you balance the risk of an EGFR flare while holding osimertinib vs the risk of pneumonitis when continuing?

Did you change your practice given the SRE results in the control arm of EORTC 1333 at ASCO 2021? When using bisphosphonates or denosumab, what dosin...

Would radical prostatectomy and PLND suffice or would a cystectomy be warranted (even in the absence of bladder involvement) as well? 

Are two negative pleurocentesis' adequate to conclude that the patient does not have metastatic disease? Do you routinely recommend VATS and pleural b...

Colleagues in surgery have raised concerns about post radiation effects in the pelvis with the ordering of short course RT->chemo ->surgery.

If no direct invasion into prostate from bladder or urethra, is there any role for systemic therapy?

Do your recommendations differ between those who receive ABVD and escalated BEACOPP? Do you recommend consultation with fertility specialists for all...

Is there any role for denosumab? How do you counsel patients regarding the benefit of bisphosphonates on breast cancer outcomes?

Patient had an initial tumor response to TCHP, but still had significant residual disease present, including positive lymph nodes and residual breast ...

While building a trusting patient-physician relationship, what therapies could be discussed that may be aligned with naturopathic medicine? (i.e. L-gl...

In a patient who would be otherwise fit for surgery +/- adjuvant RT, and the delay is caused by COVID-related OR staffing issues, what would be your a...

Does patient age effect your approach? Would you consider RPLND for any patients in light of the phase II SEMS trial presented at the 2021 ASCO GU Ca...

What determines duration of therapy in patients who achieve stable disease or no evidence of disease on imaging? Is there any role for radiation in t...

This question arises from a case of a patient with multifocal nodular melanoma with circumferential involvement of the perianal region.

The patient was started on chemoimmunotherapy 3 years ago. Recent scans show small treated brain metastases (s/p RT several years ago) and no disease ...

Would you get bone marrow biopsy periodically? Would your approach change based off specific age or platelet count?  

Do you prefer WBRT, IT chemo or targeted systemic therapy and what is your preference on the sequence of therapies?

Patient with T2N1 disease and isolated liver metastases. Axilla and liver completely responded to chemo + IO, but limited residual breast enhancement ...

Would there be any benefit to surgery in a healthy/good PS patient? There is so little data on pulmonary atypical carcinoid and radiation respons...

E.g. for a 7cm central NSCLC, would you offer 8 fx SBRT or ChemoRT? Patient is not a surgical candidate.

One example of this scenario would be a patient receiving consolidative durvalumab after chemoRT for stage III NSCLC who develops a new peripheral lun...

Would your treatment approach be similar for a patient with suboptimal performance status?

If yes would you delay initiation of antineoplastic therapy to allow time for the vaccine to start acting?

Has the recently published interim analysis of the CATNON trial altered your utilization of temozolomide?Does IDH status change your treatment approac...

Is this a reason to start hydrea? Would you give oral iron after adequate control on hydrea?

Do you consider the small, but statistically significant, improvement in OS to outweigh the side effects of treatment?

Does the answer change on proximity/distance from breast (i.e. what if pelvis or lower extremity?)

While there are many factors involving:- type (DVT vs PE, unprovoked vs provoked) and severity of venous thromboembolism (VTE) size- duration of antic...

Do prior treatments for mHSPC change your thinking on whether or not to use sipuleucel-T?

Although a small subset, do you generally move these patients directly on to chemotherapy +/- immunotherapy or does it depend on the specific mutation...

If all work-up including peripheral flow, bone marrow biopsy, PET-CT returns negative, what additional management (if any) would be recommended?

Does manipulation of blood products (leukoreduction, irradiated) affect your approach? There is growing evidence that routine premedication (at least ...

In particular, is there any data on the efficacy of Ipilimumab/Nivolumab?

Given that risk definitions are based on size, mitotic activity, location and not necessarily genetics/biology, would an otherwise low-risk GIST, who ...

What is the role for adjuvant versus neoadjuvant chemotherapy?

While this is a known risk factor for venous [Meijers et al NEJM 2000] and potentially arterial [Yang et al, Am J Clin Pathol 2006] thrombosis, it is ...

If a patient has a large femoral metastasis that cannot be resected, but is to be stabilized with ORIF which will push tumor into the distal end of th...

In reviewing the data, LDH does not upstage to intermediate risk but those patients tend to do worse. Would one treat this patient as intermediate ri...

Given that olaparib was given within 12 weeks of completion of standard adjuvant therapy on the trial, will you still offer it to patients outside tha...

Would this change with someone who has a history of thrombosis (e.g. DVT/PE, MI, CVA)? Would this change with someone who is more fit vs more frail?

Patient has been treated with carbo/etop/atezo, WBRT, and maintenance atezo. Currently on high-dose steroids. Would you consider hospice or trial chem...

Results of AHOD1331 are not yet known, but adults have started using Brentuximab upfront for high risk patients  

Patient with hepC and advanced cirrhosis with multiple liver mets, but may be able to tolerate oral TKI or PARP. Would you offer this or focus on hosp...

Such as patients who are frail, elderly, renally impaired? Would you consider sirolimus over cyclosporine or tacrolimus for safer nephrotoxicity prof...

How does age play a role in this decision?  If you do intensify therapy, how do you explain the negative results of CALGB/Alliance 50303?

If starting with entrectinib would you still try crizotinib, or move to lorlatinib or another novel TKI? Or change entirely to chemotherapy, immunothe...

How often do you monitor ADAMTS-13 levels off therapy?

For example, do we prefer one regimen over the other in patients with a bleeding history or who have relapsed after a lengthy remission?

Is there any role of radiation therapy for these patient for symptomatic relief? 

Performance status is excellent. Second surgical opinion has also confirmed need for amputation, as the recurrence is now breaching intra and extra ar...

Osteosarcoma conventional type of the distal right femur. cT1N0M0 G3 Stage IIA on MAP protocol completed NACT followed by surgery on radical resection...

The patient was diagnosed with Ewing’s Sarcoma at the age of 10 and completed 6 cycles of vincristine, ifosfamide, etoposide, adriamycin 75 mg/m...

How is this impacted by patient features, cytogenetics/disease biology, depth of response, or other factors? What would compel you to continue 3 drugs...

How do you factor in patient age, frailty, patients with underlying organ dysfunction, or other clinical features? Do you still consider CyBorD or R...

Is DFS benefit in KN-564 in ASCO2021 sufficient evidence to change practice?

History of CDH1 mutation and prophylactic gastrectomy in 2017 - no other primary site found beyond vagina at diagnosis. Vaginal tumor completely resp...

In patients who have completed all adjuvant therapy. Similar test to what is available for stage 2 and 3 colon cancer patients by Natera.

In your experience, do certain regimens have more cumulative toxicity, financial impact, or patient convenience factors?

Do you recommend therapeutic phlebotomy to a certain Hct goal? Any strong evidence for thromboembolic risk related to erythrocytosis or if this is mit...

Post-treatment PET/CT and MRI Pelvis at 3 months showed near resolution of iliac and inguinal lymphadenopathy but new avid retroperitoneal lymph nodes...

Would you consider afatinib? Afatinib has shown some activity in NRG1 fusion + patients but amplifications is unclear. 

How do you manage the initial event, including length of steroid taper and the role of pancreatic enzyme monitoring? What is your experience of subse...

Colloid is a rare histologic subtype and considered to have more favorable outcomes compared with usual ductal adenocarcinoma, but no dedicated prospe...

Patient is on fulvestrant+CDK 4/6 inhibitor and with NED for 5 years. In which cases would you consider stopping CDK 4/6 inhibitor? 

Given long term data from Keynote 052 for pembrolizumab presented at ASCO 2021. What factors impact your treatment decisions? For cis-ineligible PD-...

Previously received pelvic EBRT and intracavitary brachytherapy. IORT was administered to the node-positive side wall at the time of exenteration.

Initially treated with definitive chemoRT but recurred with distant mets. Completed 6 cycles carb/tax/bev with minimal toxicity. Excellent performance...

If given both options, which donor would one prefer: haploidentical related donor or 7/8 mismatched unrelated donor using post transplant cyclophospha...

NCCN guideline V4.2021 DLBCL page BCEL-3 states stage I-II, bulky >= 7.5cm should be treated with 6 cycles of RCHOP, but most bone lymphoma studies...

This patient had resection of the primary, requiring multiple resections to obtain an R0 resection, followed by adjuvant radiation to the primary. The...

Are there scenarios where you would use a higher dose of lenalidomide in a novel doublet or triplet (eg. relapse on lenalidomide maintenance)?

Given recent data in Blood (Moik et al, 2021), and the potentially overlapping risks with other clinical factors associated with NSCLC. Will you alte...

Is there any difference between anticoagulants in this clinical context (e.g. anti-Xa inhibitors vs warfarin vs LMWH)?

There are many delivery methods of cannabis, including smoking, ingesting it through food, or inhaling it. Is one method more effective than another?

Would you test for resistance mutations in this setting, using blood-based sample if no progression outside CNS?

<40y/o female w/ initial biopsy showing G3 IDC with 80% ER+, 90% PR+, and HER2 positive (IHC 2+; 1.6 HER2/CEP17 ratio and 6.3 HER2 copies/nucleus.)...

Would you radiate? Surgery? Chemo? Follow with short interval scans? How would size of adenopathy (e.g. <2cm vs larger) and time of recurrence (wi...

Would you plan straight pediatric dosing using 2500 Units/m2 or a cap of 3750 Units as used in some adult ALL regimens due to excess liver/pancreas to...

Patients can develop sensory and motor symptoms such as paresthesias, jaw/facial pain and stiffness, cramping and twitching, ptosis and vision changes...

Recurrence was 2cm and PET confirmed local. Excision with positive margins. Current plan for salvage whole pelvic RT and vaginal cuff brachytherapy +/...

s/p optimal debulking. If this was an early-stage cancer would it change your adjuvant therapy recommendations?

Would you consider induction: TPF vs cis/gem or would you proceed with chemoradiation with cis/RT and consider adjuvant cis/5FU?

If so, how do you sequence it? Would you consider before adjuvant radiation vs concurrent with adjuvant (chemo)radiation vs after adjuvant radiation? ...

Does having a concurrent consumptive process e.g. DIC change your management? 

Has the recent approval of atezolizumab/bevacizumab impacted your decision making? 

Are you routinely performing molecular sequencing? Would you modify your treatment approach in first or later lines based on PDL1 status?

Since desmoid tumors are associated with high estrogen states, is there an optimal contraception approach? Is there an optimal time for pregnancy? How...

When would you consider utilizing autologous SCT in those with a PR or SD? Is there a potential role for BCMA-directed CAR-T or bispecific therapy in...

Recurrence picked up incidentally on CT. No germ line mutations, somatic tumor testing of node resulted negative. PET confirmed isolated recurrence

Would you recommend radiation, systemic therapy alone, or chemoRT? What about if this recurrence occurred during or shortly after completion of adjuva...

Is there an age cutoff below which you would offer adjuvant chemotherapy regardless of Oncotype results? (Example: A 35 y/o woman with T2N0, ER+, sen...

This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are withi...

Does it differ in the curative vs palliative setting? Specifically thinking about adjuvant CAPOX in a patient with a BSA of 3. ~400 mg of oxaliplatin ...

Presuming that imaging does not show distant metastatic disease, what would you offer? What about if the patient were PD-L1 negative?

What non-pharmacological interventions do you recommend? Do you routinely prescribe prophylactic laxatives to patients initiating opioids? How do you ...

Would you use ALK inhibitors such as crizotinib based on recent phase II data? Are there any research efforts to combine ALK inhibitors with current ...

How do you distinguish this entity from other plasma cell disorders (eg. MGUS, MM, etc.)?   Review of literature suggests that most of these pa...

What clinicopathological features would need to be present for you to recommend adjuvant chemotherapy? Would you treat pT3 disease? Any specific histo...

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

Are there any subsets of patients that you're more inclined to offer maintenance?

Benefit of oxaliplatin in patients >70 years of age is not proven and only 5FU/capecitabine in a MSI-H tumor is of questionable efficacy. What woul...

What would your treatment approach be- surgery or chemoRT? What is your preferred chemo regimen? Is there a % threshold other than 100% (e.g. 95%) th...

Would you use a small cell regimen over a more traditional FOLFOX-esque approach?

Would you offer this patient chemotherapy? What are your thoughts about OFS plus AI and avoiding chemotherapy?

Do you aim to give a total of 26 doses or do you stop at one year from first dose no matter how many were given?

What regimens would you consider combining it with? Any specific combinations to avoid or special considerations?

Would you choose to incorporate HER2-targeting agents, chemotherapy, endocrine therapy, or a mix of these?

The GeparSixto, CALGB 40603, and more recently Prospero support doing it; however, it is not currently endorsed by NCCN and the latter Prospero s...

What is your preferred risk stratification model?  There does not appear to be a consensus among experts as to what cutoff in recurrence risk ju...

How do you decide between supportive care v. chemoimmunotherapy? Is there a threshold of disease burden that would push you towards recommending hospi...

Do you always treat with the full 21-day treatment course, or can defibrotide be stopped if certain criteria are met sooner?

Assuming the patient is a candidate for all anticoagulation options (no mechanical valve, antiphospholipid syndrome, patient-specific contraindication...

Is Ommaya placement with CNS-directed therapy preferred to intrathecal or cranial irradiation? How do you interweave this therapy with systemic therap...

Do you prefer a cHL chemotherapy backbone or PMBL chemotherapy backbone?

While thrombophilia testing is not routinely recommended prior to starting OCPs, how about after the development of a VTE?

Does your practice vary based on risk status (low vs high risk) or specific mutation status (BRCA+ vs HRD+) given PAOLA subset analyses? 

In the post-op setting, would you delay 1 week even if it took them out of the 6 weeks post-op window? Meaning the loading dose of erbitux was given d...

I am considering every 6 week pembrolizumab dosing in patients >70 years old in whom I want to reduce clinic visits for, especially in the context ...

What specific platforms for determining somatic BRCA and HRD status do you use for a patient who does not carry a germline BRCA mutation?

There was an abstract in European J of Cancer (Srinivasan R, 2014:50: S6, P8) showing a good response rate with Bevacizumab and Erlotinib. Would you u...

Would you use R-CHOP or a more intensive chemotherapy regimen?  Would you consolidate with radiation therapy after 3 cycles or use systemic thera...

While the CKD population is at high thrombotic and bleeding risk, would you consider anticoagulating a patient prophylactically if they had a history ...

Conversely: In a patient with N2 EGFR+ NSCLC receiving radiation, would you still consider use of osimertinib?

What tumor or patient characteristics lead you to consider the use of neoadjuvant hormonal therapy without chemotherapy?

Would you recommend the patient stop testosterone upon this new diagnosis? If the patient is not amenable to stopping, would you incorporate an AI in ...

Are there particular patient characteristics (e.g. age, ER%, Ki67, grade) that make you more likely to choose neoadjuvant endocrine therapy?

Is the short time to recurrence a reason to not consider definitive management with surgery/radiation? Should systemic therapy be added if pursuing d...

If so, do you avoid pegfilgrastim given that <12 days will lapse between its administration and the next cycle?

Based on available results from the IMMUNED trial, which evaluated the role of adjuvant nivolumab/ipilimumab or nivolumab monotherapy vs placebo in re...

Do features such as nodal involvement, Ki-67, degree of ER positivity, etc. change your management? Would you use any gene expression assays to help y...

Are there any data to support a specific TKI therapy for non-T790M exon 20 mutations/insertions?

How many cycles do you prefer before and after? How long do you tend to wait before starting radiation after initial chemo and after radiation to resu...

How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?

Specifically, for cT2N0M0 small cell bladder cancer without response to neoadjuvant cisplatin and etoposide on imaging, would you proceed with cystect...

Post-auricular cutaneous angiosarcoma, pT1 (19 mm) with negative margins. Unclear if there is any indication for systemic therapy, given early stage a...

Would you differentiate between patients with measurable disease vs NED?  Are there specific data to guide us?

What was the magnitude of benefit for patients with EGFRm NSCLC by stage?  Are you still considering adjuvant osimertinib for patients with earl...

Would you consider high-dose dexamethasone (deliberating adverse effects of antenatal steroids) or move to next-line therapies?

If so, how long do you wait after surgery prior to imaging to avoid post-operative findings?

Is MDS/AML risk increased with longer duration of therapy? Does your approach differ for patients who are BRCA+/HRD vs wild type/HRP?

Is adjuvant radiation and/or adjuvant chemotherapy indicated? 

The current NCCN guideline version 2.2021 is a little confusing. On page HODG-2,  the clinical staging/risk classification did not include ESR, b...

Ref: EINSTEIN-CHOICE and AMPLIFY-EXT Would you approach this differently in patients with inherited thrombophilias?

If advanced stage do you follow same guidelines as Scc? Do you use same Cth regimen? Role of total laryngectomy ? 

How do you assess the risk of complications from including bevacizumab vs the known benefits of including it with chemotherapy?

For patients who have progressed on first line checkpoint inhibitor (e.g. Nivo/Ipi) and second line TKI (e.g. Cabozantinib) 

Does your recommendation differ between autologous and allogeneic transplants? Does your recommendation differ in allogeneic transplant recipients wh...

For example, in cold agglutinin disease or AIHA, antibodies can be detected via DAT, but are often not observed on assays for monoclonal gammopathies.

Are you performing repeat molecular sequencing after progression on targeted therapy? If so, are you obtaining tissue biopsy vs liquid platform?

Is data available regarding the percentages of patients in each arm who underwent staging PET or the breakdown of CNS imaging modalities?

If patients do recur, do you perform these tests on the initial surgical specimen or on tissue from a fresh biopsy (or both?)

Would you offer refractory doses (40-50 Gy) to the RPnodes and send for splenectomy? Or would you offer refractory doses to both RP nodes and spleen?&...

What systemic therapy options are available for ESRD patients?

Would you consider an Oncotype or Mammaprint? Would your management change if the patient had 1-3 positive LNs on SLNBx (as opposed to ALND)?

The woman was on on a GnRH agonist + AI due to her premenopausal status at diagnosis and now wants to know if she continues to need the GnRH agonist.&...

During the Stimate recall, how are we performing DDAVP challenges for newly diagnosed hemophilia A or von Willebrand disease?

Are the rates of adjuvant chemotherapy used in ADAURA consistent with real-world practice?

Does your management change based on the type of end-organ involvement at the time of diagnosis? Are there any reports of CNS involvement with non-se...

I know many centers are exercising extra precautions in light of the new concerns with coronavirus. How are people explaining things to their patients...

For example, gastric GIST, < 5 mitoses/hpf and size > 5 cm but < 10 cm is intermediate by NIH criteria but low by NCCN/CAP criteria.  Th...

In low-risk patients (age < 40) or patients with very obvious causes of blood loss or iron deficiency (menorrhagia, pregnancy), do you routinely pe...

Specifically, are there strategies you use to 1) empower patients to participate in decision-making and 2) reassure patients who may be skeptical?

If post-op with clear margins would you prefer adjuvant RT or close observation with surgery for optimal reduction of local recurrence? This particula...

For patients with low risk, early stage, HR+/HER2- breast cancer who initiated endocrine therapy in order to delay their surgery due to the COVID 19 e...

Do you use specific tools or take into account certain factors when considering treatment options for older adults?

Assuming no clinical trial, no actionable mutation, and PD-L1 < 50%, do you consider the patient to be primary refractory to platinum and move to s...

This includes handling saliva, vomit, sweat, vaginal secretions, semen, urine, and stool. Are there recommendations for intimacy, sex, laundry, and&nb...

I know that many advocate using vaginal estrogen in this situation.  Most of the studies of vaginal estrogen in this situation have been small an...

Are there particular mutations (eg SF3B1) or syndromes (eg MDS/MPN overlaps such as MDS/MPN-RS-T) where you are more apt to using lenalidomide?

Would chemotherapy alone suffice? Repeat biopsy and EUS were negative for residual disease.

If so, what is your time threshold for when you'll start PCP prophylaxis--when you anticipate steroid courses greater than 1 week? 1 month? 3 months?&...

Knowing the differential effect seen with menopausal status in RxPONDER, would you avoid chemotherapy or still offer chemotherapy, given that only 15....

Would you recommend re-excision or proceed to adjuvant therapy if the tissue margin is negative? Pathologist states that tumor foci at margin was only...

Patient had a clinical T2N0 cancer at diagnosis, completed 6 cycles TCHP, and had 0.2mm residual disease with 80% cellularity, negative sentinel node.

Given recent approval of niraparib (Zejula) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or prima...

Do you have any experience with intra-pericardial chemotherapy administration, and if so, in what cases?

Patient is 34yo and G0 referred from surgical oncology. Laparoscopic specimens of myoma and what appeared to be adhesions were significant for maligna...

An otherwise healthy patient with spleen only diffuse large B cell lymphoma with mild spleenomegaly, Spleenectomy plus Rchop or Rchop plus RT? 

If standard of care BEP chemo, tandem transplant, and radiation to primary site have been done previously.

Referring to a high risk patient with cT3N1 disease and ypT2N0 disease following neoadjuvant chemotherapy.

For example, will you recommend a certain vaccination timing in relationship to their treatment? Any concerns for reduced immune response or risks of ...

Or the converse:  changing to IV formulation after starting on subcutaneous pertuzumab/trastuzumab?

Conversely, is there any situation where you would prefer the IV over the subcutaneous formulation?

Tolerated first line, however now with rising Beta-HCG, new mass in uterus, and pulmonary metastases.

ASCO 2016 guidelines specified that SLNB was not recommended for T3/T4 N0 patients but uptodate allows it.

For example, a patient on cytoreductive therapy and aspirin BID, but suffers an arterial event, or a patient who is already on therapeutic anticoagula...

Does your strategy differ if the patient is on maintenance PARP inhibitor, bevacizumab, both, or neither? 

Is there a distinction between these tumors and patients with breast cancer with neuroendocrine features?

Does tumor size impact your recommendation? High grade? Young patient age?

Would it affect your decision whether original primary tumor and treatment was hormone positive or negative?

Does the advent of more effective therapies like peptide receptor radioligand therapy (PRRT) and capecitabine and temozolomide (CAPTEM) dampen enthusi...

In a patient with a medical or personal indication to induce oligomenorrhea/amenorrhea, how would you manage OCP therapy if a patient develops a VTE d...

Would gross ENE or R1 resection trigger you to consider adding chemo? If so, do you use weekly cisplatin or cisplatin/etoposide?

2 populations of cells with 95% negative by FISH (ratio 1.07) and 5% positive by FISH (ratio 10)

What is the lowest level you have seen with uncomplicated or complicated crises?

Do you consider placing an Ommaya for IT chemo with methotrexate or cytarabine? Knowing that leptomeningeal carcinomatosis carries such...

Can results from emerging AML data be extrapolated to high risk MDS populations? Is there data to guide the choice of continuing the HMA in combinati...

Based on MINDACT update from 2020, a 5% difference in DMFS for patients 50 years or younger was noted, favoring treatment with chemotherapy (93.6%; 95...

For T2bN0 or T3N0 disease, you consider radiation alone, sequential radiation followed by chemotherapy, or concurrent chemoradiation?

What clinical scenario(s) do you find results to be the most beneficial?

Is there a role for neoadjuvant cisplatin-based chemotherapy? Do patients with sarcomatoid histology respond to checkpoint inhibitors?

What parameters do you use to decide to treat beyond progression? Is there any efficacy data from this specific study subgroup in IMbrave150?

Do you go straight to TMPRSS2 genetic testing or what other lab testing (e.g. hepcidin) could be helpful?

Bulky adenopathy compressed bilateral ureters, CrCl < 30, post stent placement, but renal function has plateaued

After initiation of anti-TB treatment and 3 negative AFB smears, would you initiate concurrent chemoRT? Would you give sequential RT then chemo to giv...

Does the recent CROWN trial affect your first line treatment decision? 

Options: 1) ddAC-T- surgery- adjuvant capecitabine if residual disease 2) weekly taxol/carbo x 12 followed by dd AC x 4 3) Keynote 522- pembro/taxo...

In light of the SIRveNIB trial results and now IMbrave150, what is the role of intra-arterial therapy now?

Do you prescribe creams (e.g., urea) to prevent HFS, or is their use generally more reactive? 

There are mixed recommendations about re-testing vs simply waiting for a quarantine period prior to resuming therapy. 

If there are a low-risk patients who can be monitored, how would you do so? If unprovoked, would you consider stopping anticoagulation?

NCCN recommends either ISRT with rituximab/chemotherapy or ISRT alone in this scenario.  What factors help your decision making?

How would your treatment change given pCR rates are reportedly much lower in triple positive patients?

Is there a preferred strategy of transfusional support versus reduced-dose anticoagulation during the duration of thrombocytopenia?

No primary thoracic mass identified. Knowing these often following an aggressive clinical course, would you consider concurrent chemo/RT, incorporate ...

No actionable mutation on NGS testing. What approved therapy do you prefer? Are there specific investigational agents currently in clinical trial...

Many patients have had prior chemotherapy exposure with newly diagnosed AML that may not have classic therapy-related cytogenetics.  How do you a...

Would you consider adjuvant chemotherapy, radiation therapy, hormone therapy, or surveillance?

Initial treatment with Taxane-Trastuzumab-Pertuzumab with then maintenance with the two anti-HER2 agents and and an aromatase inhibitor. Would you bio...

Following chemoradiation, would you consider maintenance durvaluamb as for NSCLC even given the SCLC component? 

Is there any data justifying the use of systemic therapy over localized therapy (e.g. radiation or surgery) in this situation prior to a progression e...

The patient has a history of pelvic radiation and progressed through first line carboplatin/taxol. She has had a partial response to pembro/lenvatinib...

If no testicular mass on exam or ultrasound - is there a role for orchiectomy? What chemotherapy regimen would you use and how many cycles?

Rituximab has entered the treatment algorithm in the first-line setting for the initial treatment of TTP. However, in remission, the role of adjuvant ...

In patients with symptomatic disease that observation would not be appropriate, what is your preferred treatment?

Which Radiation modality, if any, would be preferred? Typical chemotherapy does not work for SFT. In which circumstance would you use VEGF ( Temozolo...

Or would you consider IO agent be given only after progression on platinum + fluoropyrimidine?

For example, is there any data to suggest a benefit to starting with immunotherapy prior to TKI or the alternative?

Are you employing more or less primary chemoRT v. surgery for some cancers? Are you dose de-escalating? What are issues radiation oncologists should b...

Assuming patient received appropriate local therapy for brain metastases, which agent would you use?

Do you only give intrathecal chemotherapy or systemic therapy?

Is there any specific precautions or concerns to consider with TKI initiation if the patient has vasogenic edema?

What are the scenarios in which a rebiopsy is warranted for follicular lymphoma?

Would you modify the radiation dose or field in this setting? Would you pre-emptively dose reduce chemotherapy, or modify the dosing of ruxolitinib?

I have heard <20% MRD. What about proceeding if patient is hypoplastic after chemotherapy?

The patient went straight to gastrectomy for clinical T1 gastric adenocarcinoma, but post-op was up-graded to T4 disease.   Both ARTIST and Inte...

(assuming that the patient is int-poor risk, has measurable disease outside of the CNS, warrants treatment with appropriate PS)

Would you offer SBRT to both sites, SBRT to the primary and standard fractionation to the node due to proximity to the main bronchus/proximal lobar br...

Pre-menopausal women make progesterone and their menses are typically lighter on tamoxifen because it's a mild endometrial ER stimulant blocking their...

How has your practice been impacted by the ECOG 2108 (Khan et al. ASCO 2020 Abst LBA2)? Are there sites or distribution of disease that prompt you to ...

After optimizing symptoms and reversible factors, and attempting cognitive-behavioral interventions and exercise, do you recommend pharmacologic agent...

Does the absence of an OS benefit in the AG221-AML-005 presented at ASCO 2020 deter you from this strategy?

How do you decide on other chemo regimen? (Dosing, frequency, carboplatin based, non-platinum based etc.) Would you use Cetuximab? Altered fractiona...

What is the time window in which you would consider adding AR targeted therapy? Is there a time frame in which you would NOT consider introducing sin...

Given the changing landscape of treatment, some patients may have already received capecitabine previously.  Would this impact your treatment rec...

Does the reported positive endpoint in OS for Checkmate 743 change your practice?

Would you consider use of immunotherapy with checking PDL1? What chemotherapy agents would you consider along with mastectomy/radiation?

What do you do/say when a discussion of evidence-based information doesn't convince a patient that this is her best chance of cure? Some patients even...

The patient remains without evidence of systemic disease outside of the CNS on serial imaging. Would you continue treating with SRS as lesions appear,...

Would you consider an anthracycline based substitution vs changing to nab-paclitaxel or a combination with platinum agent?

In patients who are intolerant to hydroxyurea, anagrelide and interferon

Has anyone omitted post path fracture radiation of pelvis/long bone in favor of starting endocrine treatment first? Or would one omit RT and start a C...

Data suggest patients with D842V-mutated or KIT/PDGFRA WT GIST do not respond to imatinib, but NCCN guidelines does not take into consideration mutati...

Do you prefer surgery vs radiation? For surgical patients, do you offer neoadjuvant chemotherapy? If so what regimen? 

Is there an optimal strategy to minimize unnecesary steroid use?For example, pre-treatment dexamethasone or 3 day dexamethasone? Prednisone only conti...

Would it make a difference if the VTE diagnosis occurs during bevacizumab therapy or whether it preceded the cancer diagnosis?

Is it at neutrophil recovery, at documentation of CR on bone marrow biopsy, or is there a different point in time?

Topotecan, nivolumab/ipilimumab and others are listed within NCCN guidelines, and lurbinectedin was recently approved in this space. How do you decide...

Is there data and FDA approval for this indication? What about for nodal failure after radiation? 

The upfront plan is to use a definitive radiation dose of 66 Gy. My reading supports the use of 5FU + cisplatin but another doctor is recommending FOL...

She had had 4 prior biopsies. Would the fact that she received 2 months of neoadjuvant tamoxifen due to COVID change your approach?

Would you consider this refractory disease and go on to salvage regimen and auto-SCT, or is there a role for definitive XRT to the site of residual di...

The recent NELSON trial evaluates screening in a slightly different population than the USPSTF/NLST criteria. Which will you follow?

Since no data exists or is pending, and the two disease processes are similar, should we consider PARP inhibition in this setting? This is assumi...

While the KATHERINE trial for HER2+ used path staging, CREATE-X for TNBC with capecitabine used the Japanese Breast Cancer Society response criteria. ...

How do you balance risk of chemo after surgery with risk of progression of disease while waiting for healing after surgery before starting chemo?

Given the recent reclassification of gain(1q21) as a high risk cytogenetic abnormality, has this changed your practice in managing newly diagnosed pat...

Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?

TROG 99.03 showed nearly 20% improved PFS at 10 years with chemoimmunotherapy despite 31/75 patients assigned R-CVP vs 44/75 assigned CVP without ritu...

How would the sidedness of the tumor, BRAF, RAS,HER2 or MSI status affect your decision?

Is there evidence for daratumumab-based doublet regimens? Would your choice differ based on the patient's transplant eligibility?

< 4 lymph nodes involved, initial diagnosis was 11 years ago when she was treated with mastectomy and adjuvant tamoxifen for 5 years.

For example, for joing replacement surgery? Do you hold the revlimid for certain about of time before and after?

Would you consider still immunotherapy even if aggressive disease vs single agent chemotherapy?

Does the SYSUCC-001 trial presented at ASCO 2020 change your practice?

I care deeply about clinical trials but have always struggled on how to approach this topic. I would really appreciate tips from those of you who have...

This patient underwent mastectomy and ALND (10/28 positive lymph nodes). Immediately following axillary LN dissection (and prior to radiation) imaging...

Is there a preference for obinutuzumab over rituximab in early relapsed DLBCL, or in primary refractory disease?

An ASCO 2020 poster from the German Testicular Cancer Study Group found that 37% of CSIS seminoma and nonseminoma were miscatagorized resulting in ina...

Is there data to support every 3 week dosage v. weekly? https://ascopost.com/news/march-2022/postoperative-weekly-vs-every-3-week-cisplatin-i...

Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal ...

What advice do you give regarding dietary practices, feeding tubes / parenteral nutrition, and pharmacotherapy specifically for cachexia?

For a patient not on dialysis? Outside of single agent 5FU, all other standard chemotherapeutic options would be contraindicated for nephrotoxicity.&n...

Would your approach change based on the type of reaction (eg. Stevens-Johnson syndrome vs DRESS)? How would you address maintenance (if any) post-tra...

Patients oftentimes have cardiac co-morbidities with requirement for anti-coagulation making TKIs, including Bevacizumab, difficult to dose. Would the...

For instance, would you discontinue when there is resolution of adenopathy and normalization of counts? If so, do you overlap ibrutinib with other the...

Should treatment be based on current histology (rhabdomyosarcoma) or origin (germ cell)?

This has been a common practice in the community. Is there a benefit for certain patients?

What if the patient has a history of confirmed COVID-19 but has since recovered?

Discussion of treatment options for midline low-grade glioma causing life-altering symptoms in a pregnant patient to avoid teratogenicity.

At what age would you treat an early stage hodgkins lymphoma patient with ABVD + RT (adult treatment) vs OEPA x 2 or AV-PC x 3 (pediatric paradigm)?&n...

Patient previously received neoadjuvant carboplatin, anthracycline and taxane regimen and is BRCA negative.

Can it be prevented? How do you evaluate patients? What non-pharmacologic or pharmacologic interventions do you use for treatment?

When using short course RT, the NCCN guidelines currently recommend short course RT followed by chemotherapy, followed by surgery. Many surgeons are h...

Does the availability of first line checkpoint inhibitor therapy affect your treatment decision? 

How would this change if the patient had metastatic HR+,HER2- breast cancer and now has symptomatic pancytopenia secondary to BM involvement after TCH...

Do different modalities of imaging (PET vs MRI vs CT) help you to distinguish one etiology versus the others? What about other clinical characteristic...

Would you consider single agent IO such as Nivolumab, given data are not strong (Checkmate 459)?

Do you limit it to post-pubertal patients? Do you offer it only if they will proceed with bone marrow transplantation after CAR-T?

Would you treated with local therapies (RFA or SRS) and continue pembrolizumab or would you move to second line treatment?

There are conflicting reports of increased incidence of bleomycin-induced lung toxicity with G-CSF.

Do you worry about the ability to collect stem cells (at the time of progression to MM) if someone with SMM has been on prolonged lenalidomide?

Would you consider genomic assays before neoadjuvant chemotherapy? How would you modify your treatment given the COVID-19 pandemic?

Would you use dual agent chemotherapy such as FOLFIRI, combination of chemo with biologic- IRI/Cetux or all 3 drugs simultaneously? How would sidednes...

T1a - 2mm; N1 - 1 ipsilateral lymph node measured 6mm Oncotype says too small to test and NGS says too few cancer cells to determine status.

Upfront surgery vs neoadjuvant therapy? And if neoadjuvant therapy, which regimen? Patient has a good PS.

Obviously, patient and caregiver preferences are paramount. But, what factors do you consider? Does expanded hospice (e.g., Medicare Care Choices) inf...

Would you consider using recently approved agent for symptomatic / unresectable PN, Selumetinib prior to Systemic Chemotherapy in this setting?

A patient with stage 3 melanoma on adjuvant nivolumab needs radioactive iodine for papillary thyroid cancer.

Quite often we encounter cholestatic hyperbilirubinemia, wherein GI and IR do not believe ERCP with stents or PTC will alleviate jaundice. If the pati...

There are multiple regimens including IGEV and most recently reported results of BEGEV without preference on NCCN guidelines.

What are the risks of infection with COVID-19 if using immunotherapy?  

How do you prescribe a steroid taper? If it is grade 2, would you keep them on low dose prednisone while continuing? When do you feel comfortable re-c...

Are there specific mutations or co-mutations were you would consider use of this agent? 

Given the rarity of DLBCL with MYC/BCL2/BCL6 rearrangements, do you approach this disease differently than DLBCL with MYC/BCL2 or BCL6 rearrangement, ...

Aside from smoking cessation, what interventions have you found useful to manage patients with chronic symptomatic laryngeal edema? Steroids seem to b...

For example, would you consider switching to an outpatient regimen in lieu of AIM for metastatic soft tissue sarcoma?

Would you treat with typical small cell paradigms such as surgery followed by adjuvant platinum doublet +/- radiation vs definitive chemoradiation? Or...

Should staging and treatment decisions be made based on imaging alone?

Patient is a  67yo with a pT1 (2.5mm) pN1a merkel cell of the chest, 1 mm deep, widely clear margins, SLN with 1.5mm met, 11 additional axillary ...

Would the recommendation differ based on HR+ vs. TNBC vs HER2+ classification? Would you recommend against immediate breast reconstruction?

Given that majority of benefit is derived from the capecitabine, would this be an acceptable option to decrease patient contact with the healthcare sy...

Would you consider regorafenib based on the REGOBONE trial? Or would you consider other agents knowing that we do not have positive survival data with...

How would you approach a patient who is receiving chemoRT but has confirmed COVID-19 with minor symptoms, as breaking treatment for 2 weeks quarantine...

Personally, my practice is to guide patients directly to surgery or to do neoadjuvant chemotherapy rather than to do neoadjuvant endocrine therapy, bu...

For example, if you had a triple positive breast cancer found on breast biopsy and repeat ER/PR/HER2 testing at the time of surgical resection showed ...

The phase 2 trial of pembrolizumab in JCO 2019 showed efficacy, and I have patients preferring to avoid chemotherapy. 

What features are used to distinguish anaplastic multiple myeloma (AMM), and what other conditions should be considered in a differential diagnosis (e...

When a physical exam is important and telehealth is not a good option, should we be proactive and reschedule or should we continue to see them as sche...

Mitigating the spread of COVID-19 is of utmost priority now that containment measures have failed. Social distancing will help "flatten the curve" of ...

Would you forego neoadjuvant chemotherapy? Are you using growth factor support differently? Any changes to immunotherapy? Other considerations?

Many commercial testing assays report on EGFR gene amplification in addition to the known sensitizing mutations. Are there any data that this can be u...

Would you treat with chemotherapy (carboplatin/etoposide) vs anti-pd-1 monotherapy vs combination chemoimmunotherapy vs supportive care?

Is there specific workup you perform? Are there preventive measures? Once established, are there non-pharmacological and pharmacological treatments yo...

Would presence of features considered high risk in stage II sway your interpretation of the IDEA trial? 

ie, not a classic NTRK3-ETV6 fusion.The patient has progressed through CDk4/6 inhibitors and intolerant of alpelisib, and does not want chemotherapy.&...

She has no other site of disease progression and has been on an aromatase inhibitor (progressed in the CNS while on a study with adjuvant abemaciclib)...

The APT trial reported excellent DFS, OS and RFI for tumors <=3cm but few were smaller T2s (2-3 cm) and few were >70 years old.

For example, for a patient that has been through multiple disfiguring surgeries and radiation and wants to delay time to next resection.

Tumor 13 cm on back with retiform and kaposiform features; all margins negative except one abuts inked margin; atypical cells with 4 mitosis/HPF. Add...

With extensive use of NGS testing, it is commonplace to identify mutations that have no validated therapeutic intervention, but strong biologic signal...

Would you offer nodal dissection and/or additional adjuvant immunotherapy in addition to wide local excision?

This patient is interested in conceiving and therefore would like to wait to start the tamoxifen.

For example, if a patient had testosterone pellets injected, perhaps making endocrine therapy less efficacious, would that sway you to use chemo?

Being that this is a favorable histology would you use Oncotype Dx to help decide on neoadjuvant chemotherapy? Would you recommend neoadjuvant endocri...

In the absence of side effects, would you be inclined to continue beyond 10 years as chemoprevention? Would you factor an intermediate/high oncotype R...

How would you manage symptoms? How would you adjust the adjuvant regimen (dose reduce, omit paclitaxel etc)? What strategies would you consider for pr...

In your experience, what approach has been successful to bridge to surgery?

To me, the recent NEJM study is flawed in that the control arm did not have maintenance treatment while the experimental arm used maintenance Dar...

Would you recommend surgical resection if feasible? Or just monitor every 3-6 months as NCCN guidelines suggest? Would your management differ based o...

How would a much higher risk cancer affect decision making? How would you treat him? 

Data presented at the 2017 SABCS (abstract GS1-01) of the EBCTCG meta-analysis stating a benefit of dose-dense chemotherapy applies to ER positive and...

Would you proceed to autologous transplant, or switch to an alternate regimen (eg. daratumumab-based) first? Would the type or degree of organ involv...

How do you choose between single-agent or combination chemotherapy versus newer treatment strategies such as palbociclib?

Abstract 5014 at ASCO annual meeting 2019 showed superiority of PSMA-PET imaging over fluciclovine-PET imaging.  Are you utilizing these speciali...

Would your choice be affected by which high risk features the patient has (eg. double- or triple-hit status vs IPI score of 3-4)?

Keynote 407 recently published data on pembrolizumab +/- chemo for metastatic squamous cell lung cancer.  The confidence interval for the group w...

Specifically with reference to rural settings where the logistics of early in the week delivery may be more challenging.

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?

Especially if you don't have trials available at the moment. Would you try off-label erdafitinib (given recent data on bladder cancer) or 2nd line ge...

Up to six cycles of treatment were given in the ABC02 trial.  Do you offer other treatments if you don't continue gem/cis beyond 24 weeks?

Of note, CLASSIC (Noh; Lancet Onc 2014) nor ARTIST (Lee; JCO 2012) evaluated other histologic subtypes, is the approach to treatment any different tha...

Our medical oncology team wants to give a patient Vitamin B12 and Folate 1 week before chemo- do we need to push back the RT start date to start both ...

This question has come up most frequently with respect to the flu vaccine recently. Also, frequently this has been asked about the shingles vaccine an...

In light of the results of the ESPAC-4 trial, is combination gemcitabine plus capecitabine being considered over single agent gemcitabine for adjuvant...

For example, if a biopsy reads: lesion comprised of spindle cells arranged in a fascicular pattern, elongated, hyperchromatic nuclei, focally positive...

Would you recommend it for a mammographically occult primary or if the patient had dense breasts?  What if a high risk patient decides not to hav...

If so, for what platelet count threshold and do you have a preference as to which agent?

Once a tissue biopsy has confirmed light chain amyloid, what additional tests do you perform as part of a standard workup? In whom should treatment b...

Would you offer adjuvant chemotherapy to a post-menopausal woman with a BRCA2 mutation and a T2N0 ER positive breast cancer with an oncotype of 12?

There are multiple options that carry a category 2B recommendation in the NCCN guidelines. Does germinal B center type vs activated B-cell type play a...

Are there specific patient groups where you would choose one over the other? Are the cost differences significant enough to dissuade you from choosin...

In practice, does starting with chemoradiation followed by chemotherapy result in a significant delay in initiating chemotherapy or a patient's abilit...

How do you approach this given the limited # of patients this applies to?  Checkmate 017 and 057 only had 5-7% of patients still on nivolumab at ...

In the SPARTAN trial, median PSA at study entry was ~ 7. Does the MFS benefit extend to patients with low PSA(< 2 or < 1)?

Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be r...

It is included in favorable histologies on NCCN, but no mention of how to treat based off HER2 status.

In patients who have a mixed response or progression and are poor candidates for other systemic agents, would you consider consolidating the chest? Wo...

Would your recommendations change in the neoadjuvant versus adjuvant or metastatic setting?

In the absence of a frontline clinical trial, would you treat with carboplatin+pemetrexed+pembrolizumab or consider IMPOWER 150 or other?

Would the presence of peritoneal carcinomatosis change your treatment strategy? If Ki-67 <50%, would you avoid platinum based cytotoxics?

Are the other options of chemotherapy that can be used instead of platinum based doublets, including with paclitaxel? 

i.e. doxorubicin, ifosfamide + RT. Do you worry about decreased locoregional control or increased toxicities with the use of G-CSF in combination with...

Specifically, do you consider repeating maintenance therapy after second line therapy if a patient had already received 2 years of maintenance rituxim...

The German trial included patients with tumors up to 16cm from the anal verge, while the Swedish trial update found no local control benefit for tumor...

Would you consider first line treatment with somatostatin analog or Lu 177 dotatate? Is observation an option for asymptomatic patients?

Given the variable and sometimes indolent disease course of these patients, as well as the absence of a clear overall survival benefit in the PROMID&n...

-The data on induction for adult H&N ca has been mixed (excluded NPX) but recent data suggest a benefit for adult NPX. -Given that this is standa...

Would you still proceed to high-dose therapy and autologous SCT? Would you incorporate radiation pre- or post- transplant? Or offer additional salvag...

Do you re-challenge with nivolumab alone, change from nivo 1/ipi 3 to nivo 3/ipi 1 upon re-challenge, or stop immunotherapy altogether if grade 3?&nbs...

For instance, if the fluclicovine scan shows a few small avid nodes not only in the pelvis but extending to the paraaortic region, would you treat the...

Specifically, do you utilize 3 cycles of chemo with ISRT or 6 cycles? Do you use R-EPOCH or R-CHOP in these cases?

Knowing that benefit of contralateral mastectomy is lower in older women who has already manifested BRCA related cancer and 10-20 % mastectomy related...

For instance, do you ever start with dasatinib 50 mg daily?  Are there any titration schedules that you follow?

NCCN include active surveillance as an option in specific circumstances based on Rini et al. (Lancet Oncology 2016) however this set is not well defin...

Would you treat with chemoimmunotherapy based on IMvigor130 data presented at ESMO Congress 2019?

What would be the next line of treatment, PRRT, capecitabine and temozolomide or other?

Does the results of the tnAcity trial influence your decision in choosing a 1st line option?

In a patient with lung cancer with both NSCLC and SCLC components, would you offer carbo/pem/pembro or carbo/etoposide/atezolizumab? Or any other alte...

Is there a "best" way to approach treatment of the viral infection i.e concurrently with therapy, prior to therapy, delayed or post therapy? Does this...

If you do employ this strategy, are there a number of liver lesions (eg <4) or duration of response that guide your decision making?

Would you suspect progressive disease v. radiation necrosis vs optic neuritis due to immunotherapy. Eyes were within radiation field 8 months ago.&nbs...

Status post nasolacrimal stent with improvement.  Would you re-challenge or permanently discontinue docetaxel?

e.g. lymph node metastasis, presence of tumor involving the peritoneal surfaces and/or the abdominal wall. If so, which regimen would you offer?

NCCN recommends annual CT surveillance indefinitely after year 5, but I’m curious how many physicians continue and for how long?

Given the PFS benefit seen in the most recent ECOG-ACRIN, and the prior study of Rd showing an OS benefit, is your practice to put any high-risk SMM p...

e.g. mixed indolent/aggressive NHL, mixed NHL/HL? Is there a definitive way to discern composite from transformation? NCCN does not list recommendatio...

The NCCN guidelines regard  MET exon 14 skip mutation   as an emerging biomarker but no formal recommendation to start crizotinib. If high P...

Would you alter your SBRT dose? How long would you hold the VEGF inhibitor before and after? Does the primary matter (e.g. NSCLC vs. colorectal)?

Are there any biomarkers that would affect your decision for first line PD-1 therapy (including but not limited to STK11)? 

1st-line pembrolizumab is supposed to be used AFTER failure of appropriate targeted agents in this setting, but would you consider the reverse sequenc...

if so, are there specific cytogenetic, molecular, clinical, or hematologic factors that you take into consideration?

A number of phase 2 trials support various combinations (e.g. gem/ox, cape/cis, cape/ox, 5-FU based) -- how do you decide either between these regimen...

The NCCN seems to make its recommendation based on extrapolation from colon cancer, but those patients are not treated with pre-op chemoRT.

More generally, do absorption issues effect the efficacy of tamoxifen and/or aromatase inhibitors?

Specifically, how do you explain potential cognitive decline in a way that explains what changes they can expect in their daily lives?

How would you figure out how to treat someone with a prior localized HR+,HER2- breast cancer treated with adjuvant AC-T (5years ago) and a recent ipsi...

How would you handle high risk features (eg double hit) with the limitations of dialysis?

Patient initially was started on cetuximab due to renal insufficiency of unclear chronicity (uncontrolled hypertension) that significantly improved du...

For instance, not chronic autoimmune diseases (eg RA, IBD) that may relapse/remit but events like Guillan Barre syndrome that is not likely to recur b...

Would you consider an aggressive approach with RT and/or surgery to the bone lesion and treat the primary as locally advanced breast cancer?

Although platinum/5-FU was used in KEYNOTE-048, can an alternative like carbo/paclitaxel be given since it may be better tolerated?

i.e. gross disease on scans that is too diffuse to be removed completely and/or decreasing but not normal markers Do you pursue close surveillance, s...

Given not surgical candidate and within 1 year of chemoRT (recurrence within RT field), would you repeat chemoRT, RT alone, or systemic therapy alone?...

Is there an age limit you use to consider MAP? Would you consider using AIM instead?

How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?

How would you approach a post-menopausal woman who now wishes to start adjuvant endocrine therapy more than 3 years since surgery?  

Would you prefer first-line AI/CDK 4/6 inhibitor, or first-line AI followed by 2nd-line fulvestrant/CDK 4/6 inhibitor (either abemaciclib, once availa...

Would presence of TP53 mutation weigh in on the offer of radiation? Would there be any change expected on the chemo regimen?

Would you consider adding trastuzumab to cis/gem in the first line? If not, would you consider adding Her2 directed therapy to FOLFIRI or FOLFOX in th...

Do you continue with FOLFIRI for a period and then switch to olaparib (and if so, when do you make that switch) or do you switch directly after FOLFIR...

How about those with metastatic disease eager to maintain quality of life? Do you risk progression of disease if the TNF blocker is re-started?

Particularly if steroids are used for non-immunotherapy toxicities (COPD exacerbation, brain edema, autoimmune diseases to name a few) -- when do you ...

Specifically, would you consider utilizing sodium thiosulfate in adults based on the pediatric data from Brock et al. NEJM 2018?

Would you give 3 cycles of RCHOP followed by consolidative IFRT or 6 cycles of R-mini CHOP? Is there a role for 3 cycles of R-mini CHOP followed by IF...

Thrombosis was ruled out and no etiology was found.  Would you start ponatinib back at a lower dose, transition to omacetaxine or begin transplan...

If yes, would you still recommend dual HER2 directed therapy? After the TRYPHAENA trial, neoadjuvant therapy with dual HER2 directed therapy has beco...

How do you assess risk of tumor lysis syndrome, and is hydration sufficient or should hypouricemic agents be used as well?

What would be a safe dose for ifosfamide and how would you time with HD? Alternatively, would you recommend a different regimen? What about using neoa...

Given metastatic disease and not a trial candidate, how would you approach this scenario? How does an underlying diagnosis of NF1 affect your decision...

Given that DBA is associated with increased incidence of MDS, AML and other solid tumors, would this modify your treatment recommendations?

For early stage disease in a single breast, would you consider neoadjuvant chemotherapy or upfront surgical staging followed by adjuvant therapy? What...

Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/pa...

On occasion, patients with locally advanced gastric cancer are poor candidates for FLOT-like chemotherapy. Should such patients be taken to surgery up...

Do you tailor treatment to a goal response?  Do you refer to data illustrating improved prognosis if the patient develops a CR or PR?

Provided the sternal lesion was low volume and treated with curative intent and patient has been on tamoxifen for < 5 years, would you switch to AI...

UpToDate indicates that VIP is an alternative to BEP for men who are not candidates for bleomycin, and that one criteria for not being such a candidat...

Has the utility of BRAF in CRC expanded beyond guiding prognosis? Is there a role in non-metastatic CRC?

Patient characteristics would unarguably be a deciding factor, but outside of these how would you approach the situation?

Patient has small cell carcinoma of the bladder with extensive hepatic metastases. Would you extrapolate the approach from IMpower133?

PIK3CA and ESR1 mutations on NGS without other targets and who has progressed on CDK 4/6 & AI and several single agent chemotherapies.  Aside...

NCCN suggests to consider continuation of imatinib from some single/multi institution non-randomized trials for ~2 years, but does not suggest what fa...

With the recent finding of benefit of pembrolizumab and SBRT (PMID: 31294749), would you consider "adjuvant" pembrolizumab for PDL1 positive patients?...

Do you recommend or make any modifications in the PACIFIC regimen for patients > 75 years of age?

There is some data on TMZ and 5FU based regimens, but convincing evidence is lacking. How would you approach this situation?

Should cystectomy remain standard of care? (Recently debated in JAMA Oncology: http://jamanetwork.com/journals/jamaoncology/article-abstract/2520055...

Tamoxifen prophylaxis has not been studied in women <35 years old, but it would be reasonable to assume they would benefit.

In a patient with a prior response to ADT and progression on taxane and platinum chemotherapy, would you consider AR directed therapy?

I have seen some advocate for this in the community, although a Cochrane metanalysis did not find an advantage to giving the taxane earlier.

Some specific questions: Would you recommend repeat biopsy to confirm residual disease? How would your recommendations vary if the patient had pre...

In a patient with who had undergone neoadjuvant TCH-P, lumpectomy, and RT and is currently on AI, pertuzumab, and trastuzumab, how do you think about ...

Would you reserve TKI for after standard of care chemotherapy and immunotherapy or consider earlier line of treatment?

Do you await molecular and cytogenetic results prior to initiating therapy, or does age and function status primarily drive your choice?

NCCN does not list any preferences for the TKIs in their guidelines.

Neratinib was studied following adjuvant trastuzumab. Do you extrapolate that data to give neratinib to patients who have received adjuvant T-DM1 inst...

The ABC trials (Blum, JCO, 2017) used six cycles of TC. Is it because of the superiority seen with TC x four cycles versus standard AC x four cycles (...

I.e., Can day 2 Rituximab (RCHOP) or day 6 Rituximab (DA-EPOCH, Hyper CVAD) be given? Or should only Day 1 Rituximab be used with chemoimmunotherapy i...

In clinical practice, consolidation chemotherapy is sometimes used, though this was not implemented in the PACIFIC trial.Antonia et al., PMID 28885881...

Would you be more or less likely to use a cisplatin-containing regimen if a patient had previously responded to chemoradiation with concurrent cisplat...

Since some prior studies (eg. Eskelund et al. Blood 2017 130:1903-10.) have shown intensive chemoimmunotherapy does not overcome the ad...

Often patients are referred to medical oncology for adjuvant therapy for early stage breast cancer after BCS and just before starting radiation.

Per the ALSYMPCA study, they excluded patients with > 3cm lymphadenopathy. Patient is currently on enzalutamide and leuprolide and refuses docetaxe...

For instance, in borderline cases for neoadjuvant therapy (e.g. T2N1 disease), should both be obtained to increase accuracy?

Would this approach be different for a patient treated with tri-modality therapy (ie neoadjuvant chemoradiation followed by resection)?

Given the prior results of Keynote 189, how do you plan to utilize the data from Keynote 042 with pembrolizumab monotherapy?  

Or do you reserve in case of oligo-progression or progressive/symptomatic disease? 

Would you give chemotherapy concurrently with radiation? Would you change your radiation dose?

Does the STAMPEDE trial, showing a survival benefit with the addition of docetaxel to standard treatment, change the standard of care for high risk, n...

There is increased stroke risk after 65 years of age with bevacizumab. Does that stop you from using it?

Would you offer definitive management with radiation and ADT? Or systemic therapy alone such as with ADT+abiraterone?

She developed biopsy proven skin nodules while on paclitaxel. PDL-1 positive and BRCA negative. Would you consider atezolizumab with a different agent...

What are the major factors that impact your decision? If you opt for surgery, what factors impact your decision to offer RT preoperatively vs. postope...

KEYNOTE-062 showed deep durable responses are possible with upfront pembro, specifically in the CPS >10 subset, with OS advantage when compare...

ENZAMET and TITAN trials published at ASCO 2019 show benefit to both 2nd generation AR antagonists when compared to placebo but wondering how this wil...

She is otherwise asymptomatic and no LFT abnormalities. Would you switch to chemotherapy or offer different endocrine therapy?

Rate of pneumonitis was low in the PACIFIC trial but does it mirror the real world setting? We are seeing increased pneumonitis in our practice.

For example - Would you offer tandem transplantation in a young, fit patient in a CR after first transplant, but with MRD detectable?

Some ENTs advocate for a neck dissection as a way to avoid chemotherapy if there is a high chance there is no ECE. This is without removing the primar...

Would you proceed with induction chemotherapy (eg TPF or cis/gem) to downstage or neoadjuvant chemoRT? Would your approach be different if there is or...

Do you feel it is important to start durvalumab within 14 days of completing cCRT?  What real life challenges do you face in doing so and wh...

Have you seen RAI or lenvatinib be efficacious for locally advanced disease — allowing for better surgical outcomes?  Do you utilize EBRT?

FDA package insert lists posaconazole as strong cyp3A4 inhibitor and states to consider other therapies.

For those that do receive adjuvant therapy with stage II disease, we know magnitude of benefit to be lower.  If the decision is made to administe...

Medical inoperability is clearly defined, anatomical resectability is also pretty much clear (invasion of trachea/carina/esophagus, etc). But what abo...

Would you treat to the GEJ regardless of whether the positive node was identified in the upper portion of station 8? Do surgeons routinely dissect to ...

NCCN guidelines recommend adjuvant chemotherapy for patients with stage 2 or 3 R0 resected NSCLC including 4 cycles of platinum based chemotherapy, bu...

Do you follow invasive or DCIS guidelines? Would you consider re-excision in a patient with multifocal microinvasive carcinoma of the breast arising i...

Do you offer perioperative chemo with metastectomy with an isolated liver metastasis? The RENAISSANCE/AIO-FLOT5 trial (PMID:30448343) is seeking to an...

Why do the NCCN guidelines suggest using neoadjuvant therapy only for patients with T2 or greater tumors?

Should this be done at the time of recurrence or after failure of 1st line therapy for recurrence?

 If so, would you treat as node + BC with  anthracycline and taxane regimen or   non-anthracycline regimen (i.e  docetaxel and cyc...

With increasing utility of immunotherapy across cancer types, patients with history of solid organ transplants may face need for cancer IO. How do you...

Patient defers chemotherapy. She is currently on anastrozole/Herceptin and perjeta with a response but it is suboptimal. I would like to add a CDK 4/6...

Does presenting total white blood cell count affect your decision? Does myeloid subtype affect your decision? 

How would you treat metastatic, unresectable, solitary fibrous tumor in a patient with mild hemophilia A? Each anti-VEGF medication comes with a warni...

Do you consider specific pre-medications, an alternate checkpoint inhibitor, or abandon ICI altogether? 

Data was presented at ASCO in 2017 that abemaciclib has brain activity in HR positive breast cancer.

Retrospective studies (PMID: 29935305, PMID: 30125216) have shown a correlation between poorer outcome and baseline steroid use in patients treat...

If you are using a standard 30/10 fractionation, is there a benefit to keeping chemo on board for radio-sensitization?

Most guidelines recommended adjuvant chemotherapy if tumor size was >3cm at the time of TAILOR Rx and patients with tumors >5cm were not include...

How might your decision change if the patient had a suitable 10/10 donor? How about if the patient had a targetable molecular mutation such as IDH2?

The use of neoadjuvant CDK 4/6 inhibitors is not standard of care, but there are clinical trials looking at this question and patients who are chemoth...

AI+ CK4/6 inhibitor? Fulvestrant + CK4/6 inhibitor? AI + fulvestrant? AI + fulvestrant + CK4/6 inhibitor?

Are there any patient and/or pathologic features that would lend you to considering IL-2 over other approved I/O or TKI therapies?

Would you proceed with modified radical mastectomy followed by systemic therapy, or would you consider neoadjuvant therapy? Would biomarker status mat...

Does the presence of N1 disease push you towards offering chemotherapy or would you continue endocrine therapy based on the PR?

Retrospective data suggest clinically significant disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung canc...

Although the MMR vaccine is contraindicated in immunosuppressed patients on anticancer treatment according to CDC/ACIP and IDSA guidelines, data on sa...

First line pembrolizumab is only approved after progression on TKI - but would you ever offer chemo-immunotherapy prior to target therapy? 

Is the timing of progression (in relation to chemoradiation) a factor, and is there any role for repeat PD-L1 testing at the time of progression?

Arterial events have clear instructions to permanently discontinue on the FDA label.  Especially in HCC without many other treatment options, giv...

The FDA has approved the new dosing schedule of Nivolumab 480 mg every 4 weeks for multiple disease sites (melanoma, RCC, urothelial carcinoma, SCC of...

How does grade or performance status affect your treatment decisions?

Does anatomic location (eg retroperitoneal or thoracic) affect your treatment decision?

Do you have a time threshold for re-challenge with platinum?  Of note, Checkmate 141 defined platinum refractory as relapse within 6 months of pl...

For the first treatment day (during combined chemo/XRT courses), is it ok to give XRT first then send the patient for chemo or should the chemo be giv...

When 5FU is a backbone to so many regimens, when (if ever) do you consider re-challenging so as not to abandon an entire line of therapy?

The NCCN recommends either systemic therapy + brachytherapy or pelvic RT + brachy or brachy alone or observation. How do you decide among these option...

Would you consider adding atezolizumab to a cisplatin/irinotecan regimen, or cisplatin instead of carboplatin?

In obese patients, would it make sense to switch from a GnRH agonist to an antagonist based on the data from the recent JCO study of dagrelix vs. trip...

This is specifically in regards to metastatic colon cancer with good disease control of disease on FOLFOX and preserved hepatic function.  

NCCN recommendations seem to mention these patients as not candidates for preoperative systemic therapy if the invasive carcinoma extension cannot be ...

What would be the optimal sequence of surgery, radiation, and chemotherapy for this patient? This patient has an excellent performance status and...

Clinical T1c patients were included in the KATHERINE trial that often are treated with adjuvant paclitaxel and trastuzumab

Is there a point at which there may be no benefit? More than 3 months from breast surgery? 6 months? 1 year?

Would you maintain dose density of chemotherapy and use peg-filgrastim prior to delivery of the baby? Would you defer taxane and anti-HER2 therapy unt...

If so, what would be the regimen that you would consider and what factors would sway you for or against chemotherapy for such patients?

The ABC trials show a DFS advantage of anthracycline-based regimens. Would age alone procure you from using it in a patient?

This patient is a young lady with stage IV ER/PR positive, Her2 negative with oligometastatic  breast cancer undergoing a planned bilateral oophe...

Given the recent press release regarding the update on the phase 3 soft tissue sarcoma study of LARTRUVO (olaratumab) showing no benefit to the combin...

Given the recent results presented from the Griffin trial, would you choose a daratumumab-based regimen (eg. D-VRd) over other salvage options (V...

Can repeating Oncotype on a locoregional recurrence show a change in the biologic behavior of the cancer over time and guide treatment decisions?

In light of the data from ERA223 showing increased deaths and fractures with the combination of radium-223 and abiraterone compared to abiraterone alo...

The recurrence was 2 years after treatment with ddAC + T.  If you elect for systemic therapy after local therapy, what chemotherapy would you use...

IHC has been repeated and confirms triple negative disease. 

What features would make you more likely to recommend radiation therapy with chemotherapy?

No other site of metastatic disease. It is unclear if this situation should be managed as two separate primaries or metastatic disease.

Two new phase 2 studies this year with apatinib/oral etoposide (AEROC) and sorafenib/topotecan (TRIAS) were released, and NCCN also lists many single ...

One such patient progressed through trastuzumab/pertuzumab/letrozole and TDM1 alone.  How would you combine ER+ approaches (eg CDK 4/6 inhibitor ...

Do your recommendations differ if patients are pre or postmenopausal given the data?

There is no primary and no distant disease seen on restaging PET. RTOG 0236 shows significant regional failure rate. Some have reported salv...

Do you ever start radiation +/- 24-48 hrs from C1D1 for chemotherapy due to logistical barriers? Do you prefer chemotherapy to start at beginning of ...

Treatment for small cell/neuroendocrine prostate is extrapolated from data on small cell lung cancer. It now appears that Carboplatin + Etoposide + At...

For instance, in stage III, would you use chemotherapy in neoadjuvant or adjuvant setting?  What regimen would you use?

Do you recommend or withhold influenza and pneumonia vaccines while on treatment with checkpoint inhibitors?

Are you directed by symptoms, PSA changes or do you have a standard schedule regardless of those factors?

Would the site of disease relapse play a role in your decision (i.e. isolated lymph node recurrence versus failure at primary site of disease)?

Which appetite stimulants are the most effective? How do you respond to patients who request medical marijuana?

And how long? According to the ABCSG-16 Trial there was no difference in extending AI beyond 2 years after an initial 5 years.  

Has the recent data presented at ASH affected your choice of regimen? Would your choice differ between transplant-eligible and transplant-ineligible ...

Shanafelt et al. recently presented results from the phase III E1912 study at ASH 2018. Will you still utilize FCR as first-line or now use Ritux...

Since the randomized phase II data from Gomez et al presented at ASTRO 2018 showed a survival benefit, is there concern about randomizing patients to ...

Does the answer vary based on whether it is neo/adjuvant or metastatic setting?

Would MRD assessments affect your clinical decision making for MM patients outside of a clinical trial?

Is concurrent chemotherapy necessary for these patients?

One example is the original breast cancer ER high 90%, PR mod to high 40%, Her2 negative.  A liver metastasis diagnosed 2 years later showed ER l...

Does the lack of D2 dissection automatically necessitate adjuvant chemoradiation therapy (ie <5 LN obtained)? Would the presence of high risk facto...

What are your thoughts with the new KEYNOTE-522 regimen? Would you just use carbo/paclitaxel/pembro part of the regimen or give as much doxorubicin as...

I have seen favorable clinical trial reports on dasatinib for metastatic disease, but no data on possible adjuvant use.  NCCN guidelines suggest ...

Does papillary histology influence your decisions regarding surgery, chemo, radiation dose or nodal coverage?

For a patient with cT3-4N0 rectal cancer, does the dose of the previous RT affect your decision making (for example, 45 Gy to the pelvis with boo...

If there is no other evidence of metastatic disease, would you offer thoracic radiation? Either upfront with chemo or after initial system therapy if ...

OS benefit was limited to patients with endocrine sensitivity, defined as either a documented clinical benefit (CR, PR, or SD for ≥24 weeks) f...

Abstract LBA5_PR ‘Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCA): survival results from S...

Routinely? Only with oropharyngeal cancer etc.? Given that low expression of EGFR subset did better, do you believe there is a true benefit in cetuxim...

The NCCN guidelines suggest surgery can be considered for up to T3N2 NSCLC after a period of induction chemotherapy/chemo-radiation without progressio...

Specifically, what regimen would you choose in a patient with new renal failure but not requiring dialysis?

Is this recommended in a certain subset of patients (EGFR positive or 1 metastasis only)? Or should we await maturation of the MD Anderson/Colorado/On...

What factors influence your decision (patient/disease characteristics, additional agents added to induction chemotherapy, CR1 or later, etc)?

Currently, nivolumab is approved as a second line systemic therapy for patients with metastatic HCC with Child-Pugh (CP) A-B7 based on results fr...

How do you approach a decision to retry a previously failed therapy if patient does not wish to pursue a clinical trial? Does sidedness (left or right...

Does an age over 70 years, size, histology and hormone receptor status affect this decision? 

If a patient obtains a PR or less to front line cladribine, what factors help you chose between a second course of cladribine, an alternative pur...

Carbo/pemetrexed/pembrolizumab, carbo/pemtrexed without immunotherapy or second line immunotherapy (Nivo, Pem or atezolizumab)?

Patients with T3aN1a( stage IIIA per AJCC7) were excluded from nivolumab adjuvant trial. Would you consider nivolumab in these patients?

Do you offer chemotherapy upfront in all patients or only if borderline resectable/unresectable?  If you treat, what regimen do you use and how l...

Prospective International Randomized Phase II Study of Low-Dose Abiteraterone with Food versus Standard Dose Abiraterone In Castration-Resistant Prost...

The patient only had disease involving the right breast and axillary, cervical, and supraclavicular lymph nodes. She had complete response to with ddA...

Would you offer locoregional control alone, locoregional with adjuvant therapy, or active surveillance?

What would you consider in the first and second line settings with intact MMR/MSI?

Prior to the PACIFIC trial, patients were treated with definitive chemo/rads. With local recurrence <1yr after chemorads and definitive treatment f...

Would starting with chemotherapy be preferred in this situation and consider concurrent radiation, then switch over to Pembrolizumab once some control...

Checkpoint inhibitors have demonstrated durable responses in clinical trials, which was never seen with cytotoxic chemotherapy in the past. What are t...

When is it warranted to utilize targeted therapies for known mutations (eg. midostaurin or an alternative TKI for FLT3 mutations, ivosidenib for ...

Does the choice of initial induction regimen affect your decision for when to employ lenalidomide maintenance? Are there situations where you would c...

Are you routinely using letermovir as CMV prophylaxis in high-risk patients? Any special considerations with its use versus other antiviral agents? ...

There is a gray area in clinical decision making where the practice seems to be different for borderline size tumors such as a 7 mm T1b lesion with no...

If yes, what dosage and do you use it continuously or intermittently? Regarding provera, many patients with ER/PR (+) breast cancer worry about taking...

In a patient s/p orchiectomy and with pelvic lymphadenopathy, would you consider lymph node biopsy to confirm involvement by non-seminomatous germ cel...

Most of the studies have excluded non clear cell histologies. If you use a similar approach to clear cell, have you seen similar responses?

For which patients would you consider addition of apalutamide or enzalutamide? How do you decide between the 2 drugs?

The recent SPARTAN trial showed a remarkable improvement in metastasis free survival and many other secondary endpoints except the lack of significant...

There is no evidence of disease outside the lung on PET, and the patient is completely asymptomatic with negative EGFR, ALK, ROS1, and BRAF and a PD-L...

PD-L1 < 50% and no targetable mutations. Would you use carbo/pemetrexed/pembrolizumab or Nivolumab or pembrolizumab?

NCCN guidelines recommend both single agent Pembro and/or Ipi/Nivo as first line options. How would you choose between the two? In case of the latter,...

NCCN recommends to change therapy or maintain current therapy in this setting without further clarification. What thresholds would cause a change in t...

Not to decrease recurrence risk, but for chemoprevention of new ER-positive DCIS or invasive disease based on the Gail Model. If so, is there data to ...

Would you treat differently for de novo disease vs disease arising from large cell transformation of an indolent NHL?

Given the rarity of this in MF, is it still predictive of response to lenalidomide therapy?

For example, would a + vascular margin, extranodal extension of N1 disease, translobar disease, or high risk histologies (large cell neuroendocrine, s...

Does their candidacy for autologous HSCT affect your decision to use maintenance lenalidomide?

Would you repeat PET or is it adequate to change to CT surveillance? Although surveillance PET/CT is not recommended by NCCN guidelines, these are oft...

Would you treat with localized therapy with chemoradiation or SBRT or consider ROS-1 directed therapies? 

The FDA recently approved Braftovi (encorafenib) and Mektovi (binimetinib) in combination for unresectable or metastatic melanoma. When would they be ...

Would you use the same schedule as early stage NSCLC primary?

The current NCCN guidelines reserves radiation for patients who are not resectable after induction chemotherapy. Does it make sense to offer concurren...

What are the special considerations in the non-metastatic setting vs metastatic setting?

Lung primary is inaccessible for biopsy and metastatic sites are only 2 small bone lesions. In a non-smoker, a driver mutation is suspected but would ...

For example, would you consider this in a patient that would otherwise be eligible for adjuvant treatment (stage III or stage IV with oligometastatic ...

The patient is a pre-menopausal woman with low-grade, stage I IDC who initially could only tolerate 10 mg of tamoxifen for her first year of trea...

Young woman with Her2 positive disease involving her right breast, regional lymph nodes, and liver had a CR on PET after therapy with THP and now plan...

Would you switch chemotherapy regimens (i.e if the patient received FOLFOX/Avastin, change to FOLFIRI/Avastin)? Would you treat wuth immunotherapy per...

The NEJM 2015 paper by Tolaney et al only included 1.5% of patients with micrometastases.

Would your choice of treatment change if the same patient was T790M negative and osimertinib was given as a first-line therapy?

If a patient has ER/PR+ and Her2 positive disease in the primary tumor while axillary lymph node core biopsy is ER/PR+ Her-2 negative, do you man...

Do you prefer carboplatin-paclitaxel-bevacizumab, carboplatin-pemetrexed-pembrolizumab, or chemotherapy alone?

In a patient treated over 10 years ago with mastectomy and chemo now with recurrence in the ipislateral axilla, would you offer additional with chemot...

Which of the systemic options would you give concurrently with radiation therapy in the adjuvant setting? According to NCCN guidelines, high dose...

Would you consider repeating neoadjuvant chemo/RT? Does this, occurring in the context of Lynch Syndrome, change the treatment approach?

Does the more recent NEJ026 trial describing benefit from Bevacizumab plus Erlotinib over Erlotinib alone in patients with EGFR driver mutations ...

Certainly ovarian cancer will respond to carboplatin and paclitaxel and it sounds like a reasonable chemotherapy to give to a stage IV NSCLC, however ...

Specifically, this patient had a new left lacrimal gland metastatic lesion that developed four years from her initial diagnosis and is currently under...

Testicular ultrasound, CT, and tumor markers are without abnormalities outside of the mass.

There are now five PD-1/PDL-1 inhibitors approved for metastatic bladder CA, one (Atezolizumab) as first-line therapy in cisplatin-ineligible patients...

If there are 3 negative scans, do you continue annual screening?

Does the more recent data regarding the continued utility of brentuximab vedotin and the utility of PD-1 inhibitors factor in to your reasoning at all...

A recent phase III trial published in JCO describes the NVALT-11/DLCRG-02 study, evaluating PCI vs observation in patients with stage III NSCLC s/p co...

Is there any data to suggest delayed initiation of adjuvant treatment would be beneficial? Or would close surveillance be reasonable? Patient is asymp...

Would you do this for ER+ patients? According to the PERSEPHONE trial presented on ASCO 2018, in HER2+, non-metastatic breast cancer, 6 months Hercep...

Specifically, would carbo-taxol-bev-atezo (IMpower 150) be an attractive option given the activity of bev-atezo in sarcomatoid PDL1+ metastatic RCC (I...

What systemic therapy do you use? Do you incorporate any multi-modality therapies?

I have a patient who will be climbing to the base camp of Mount Everest. Does a climb to 15,000 feet increase her risk? Should she wear a compression ...

Could one make a case for addition of Rituxinab frontline to increase the chances of a complete remission and even maybe achieve MRD-negative status ?

Does it differ from the treatment of other relapsed peripheral T-cell lymphomas? Are there any clinical trials or case series focused on SPTCL? Is t...

Does presence of intraperitoneal spread and solitary extraperitoneal visceral metastasis affect management?

Would you give neoadjuvant chemotherapy in a patient with T1 N1 M0 ER/HER-2 positive cancer if they are candidates for upfront lumpectomy?

If there is no response to neoadjuvant AC -->T, would you offer additional adjuvant chemotherapy?

High enough risk to justify anthracycline+taxane chemotherapy followed by ovarian suppression + aromatase inhibition.

Would you initiate abiraterone or enzalutamide for the rising PSA or wait until the patient is symptomatic or has a new site of metastasis?

For the Impower 150 trial, is there data reported on PFS and OS for ABCP vs ACP (atezolizumab/bevacizumab/carboplatin/paclitaxel vs atezolizumab/carbo...

Or would you wait to start coincident with the start of cycle 2? If a shorter time from the start of any therapy to the end of radiation (SER) is sign...

Many times we encounter patients who do not have a tissue sample readily available or in whom obtaining such a sample would be hard. On a more molecul...

Can you comment based on the results of PRODIGE 24 from ASCO 2018?   http://abstracts.asco.org/214/AbstView_214_218335.html

Can SRS or whole brain radiotherapy be reserved for progression in these young, healthy patients?

In the context of the new staging systems and possible differences of HPV mediated vs smoking mediated oropharynx SCC, would you ever not recommend co...

Technically, you can have up to 55% of larger cells circulating and still be called CLL.

Can you extrapolate the data on Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma to patients on a...

The PERSEPHONE trial to be presented at ASCO suggests 6 months of Herceptin is non-inferior to 12 months in early Her2 postive disease.

In this study, doses of 2mg/kg Q3wks, 10mg/kg Q3wks and 10mg/kg Q2wks were used. What did the majority of these patients in CR receive? 

By the definition this would be M1 disease, but would definitive treatment be appropriate? Is there clear data that a single pleural nodule has no cha...

Do you start with 1250 mg/m2 BID and then dose reduce based on toxicities? Many studies across varied types of malignancies have shown good tolerabili...

Would you consider "aggressive" concurrent chemoradiation followed by SRS to the CNS lesion and possible consolidative immunotherpay (the PACIFIC...

How do you treat these patients if they progress after immune checkpoint inhibitors?

Would you consider MS an absolute contraindication to this treatment?

What is the optimal regimen for a pre-menopausal female with progression of ER+,PR+ and Her2 neu negative breast cancer while on tamoxifen for six mon...

Once you decide to begin treatment, any special precautions you would use for protein levels starting that high.

Pt previously treated with radical prostatectomy and adjuvant radiotherapy. If recommending therapy, what is the role of concurrent abiraterone + AD...

Would your recommendation change at all depending on time to relapse or original stage of melanoma?

Given the results of Keynote 189, is there any benefit of chemotherapy+pembrolizumab in specific subsets of patients in the first line setting?

The patient initially had a great response to THP for four months, but now with quite a bit of lung, pleural, and nodal involvement.

If the patient has large, bulky nodes would you consider starting after chemotherapy for cytoreduction? Or otherwise consider replanning mid-treatment...

Based on new FDA approval of nivolumab plus ipilimumab in the first-line setting for intermediate- and poor-risk disease, would you give the combinati...

Do you offer additional adjuvant chemotherapy, proceed to adjuvant endocrine therapy, or search for a suitable clinical trial?

Could observation and serial cystoscopy be a reasonable option or is surgery necessary? If recommending surgery, can a procedure less than a nephroure...

Intramammary lymph node involvement has been shown to have a poorer prognosis (Hogan, Surg Onc, 2010). Would Oncotype be useful in these patients...

Assuming that the involved area is too widespread for RT. Would you try single agent rituximab first? Or obinutuzumab? What if rituximab alone gave on...

CIC-DUX4 fusion sarcoma is a rare entity, the aggressiveness of which is comparable to Ewing's sarcoma. A major dilemma is whether to treat these pati...

The recent NEJM phase II trial http://www.nejm.org/doi/full/10.1056/NEJMoa1715519?query=featured_home looked at a small cohort of 24 patients and show...

Knowing that the analysis now is more detailed than it was 10 years ago. What about non-Ashkenazi Jewish breast cancer patients with suspic...

While we await the results of TailorX, what has been the experience in your practice? If the decision for adjuvant chemotherapy is made, do you f...

If staged so due to satellite lesion and negative nodes? How do you decide between adjuvant PD-1 inhibitor or BRAF/MEK inhibition in BRAF-mutated pati...

Assuming SRS to the resection cavity is advised, would you recommend early immunotherapy to improve outcomes/enhance a possible abscopal eff...

In the absence of clinical trial, is there are role for dose-escalating alectinib, or would you consider brigatinib or chemotherapy?

Patient does not qualify for breast cancer screening by annual MRI per criteria (IBIS lifetime risk<20%, no known genetic predisposition,...

the MZL was untreated in the past prior to transformation. Do these patients have a higher risk of recurrence post CR as opposed to patients with de ...

Originally received anthracycline and taxane based regimen.  Would you use carbo/paclitaxel or capecitabine or a different approach?

Do you follow treatment guidelines for indolent lymphoma or CLL? How do you get 17p testing on someone with only lymphadenopathy?

When would you favor delivering local therapy (e.g. SBRT) prior to systemic therapy?

5FU/mitomycin C or 5FU/cisplatin? Is there any benefit of cisplatin in terms of skin toxicity?  

Specifically, in patients that had progression or developed toxicity on ibrutinib? Idelalisib is very toxic and venetoclax a labor-intensive drug to g...

Even though Venetoclax is not FDA-approved yet, assuming you can get it off label? 1. Gemtuzumab: What dose/schedule and which HMA? 2. Venetoclax: W...

Would you consider referring the patient for HIPEC at some point in their treatment, possibly after giving adjuvant chemotherapy, especially if patien...

These patients have been largely excluded from these trials.  What if the infection is well controlled?

In a patient who underwent laparoscopy for endometriosis and was found to have a 1mm focus of neuroendocrine tumor, would you recommend further surger...

My practice had always been to transfuse for plts < 10, but the recent ASCO guideline change suggests  that in the post-autoSCT setting it is ...

Is there a difference among all the commercial genetic testing labs? Is there anything beyond CLIA- and CAP-certification that we should look for...

After mastectomy for the locally recurrent disease, would you consider "pseudo-adjuvant" chemotherapy for local recurrence per the CALOR trial? If so,...

What factors dictate choice of observation versus 6 months of adjuvant peri-operative chemoradiation plus chemotherapy especially if patient did not r...

Can you apply the ACOSOG Z0011 study to women who have HER2 positive disease?  

Assuming it is clinically indicated, would a checkpoint inhibitor be efficacious in a patient who has a concurrent autoimmune illness (PMR/TA) and is ...

If filgrastim, how many days would you give? Pegfilgrastim is often not covered by payers if given less than 14 days before chemotherapy.

Would you ever considering re-starting immunotherapy before completing the taper? According to the new guildelines on managing immunotherapy related ...

Do you refer all patients who are felt to be at high risk to a genetic counselor for testing or are you comfortable performing a MyRisk panel in your ...

The patient has no medical problems and no history of leukemia/MDS. Biopsy of the filum terminale and arachnoid confirmed a myeloid sarcoma and MRI sh...

Recent NEJM study showed an increased breast cancer relative risk in longer durations of hormonal contraceptive use that could last up to 5 years. Pre...

An article (BRCA mutation and outcome in BC. Ellen Copson, et al. Lancet Oncol. 2018) showed G3, BRCA+ breast cancer had poorer prognos...

If you treat pre-chemotherapy volumes, is there a benefit to induction chemotherapy even in bulky disease. If so, how do you define disease that ...

Pt has progressed on AI and Faslodex. Goal is radiation to axilla as a palliative intent and Capecitabine to control systemic disease. 

Data reported by Motzer et al Lancet 2015 demonstrated a statistically superior PFS benefit of lenvatinib monotherapy over everolimus alone. In partic...

What factors influence your decision (R1 v. R2 resection? T stage?) If sequential, do you typically prefer radiation before or after chemotherapy?

Subq has been shown to have lower risk of neuropathy. Is there any reason to use weekly IV still?

Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?

Obviously the details matter a lot, but are there guiding tenets one should follow beyond expressing condolences to the family?

If so, when? Are there certain ERBB2 mutations that would predict response to trastuzumab and/or neratinib? 

Following the dosage guidelines based on absolute neutrophil count may cause the patient to end up receiving lower doses.

Would you consider using CKD inhibitors upfront in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Hercepti...

Is the use of immunotherapy being considered, and if so, is the data extrapolated from treatment of mNSCLC and head and neck SCC?

This is in regards to the risk of secondary cancers after radiation therapy or cytotoxic chemotherapy (such as anthracyclines) in an immunosuppre...

Taking into account the overlap between treatment regimens for esophageal and gastric cancers, in what clinical context might you feel comfortable tre...

In a patient with multiple poor risk features including TP53 mutation, 1q amplification, stage III, and circulating plasma cells, would you consider a...

For a lesion that appears radiographically consistent with a high grade glioma, would you treat empirically if there is hesitancy to perform a high ri...

Assuming the patient was initially treated with surgical resection and adjuvant chemotherapy followed by radiation and appropriate endocrine therapy.

What do you do with low grade (grade 1/3) tumors? In other words, does high grade pathology over rules?

NCCN lists CRT as category 1 but also lists chemotherapy alone as an option.  Is this decision based on discussion between surgeon and oncologist...

In light of two phase III randomized trials showing duloxetine (S1202) and acupuncture (S1200) both improve AIMSS, which would you try first? Wou...

Would the exact Oncotype score guide your decision (ie closer 25-30 v. >30-35)? NCCN recommends Oncotype only for tumor size < 5mm but this case...

Recent evidence has been mixed, with no DFS or OS benefit in 1 trial (ASSURE, Haas et al, Lancet 2016) and DFS benefit in another (S-TRAC, Ravaud et a...

The abstract of the pooled meta-analysis is not definitive (JCO 35, 2017: suppl; abstr LBA1), and of the phase III trials (SCOT, TOSCA, Alliance/SWOG ...

If Oncotype is high risk, what regimen of adjuvant chemotherapy would you recommend?

Would you use a regimen with lower incidence of neurotoxicity such as CMF or a taxane-based regimen with a low threshold to dose-reduce?

Would you consider using ckd inhibitors in triple positive breast cancer previously treated with chemotherapy, endocrine therapy, and Herceptin? NCCN ...

How do you approach treating ER/PR positive/HER-2 positive metastatic breast cancer? Do you combine hormonal therapy / chemotherapy and HER-2 directed...

If a patient with stage II or III colon adenocarcinoma who presents to your clinic 12-16 weeks after surgical resection do you give adjuvant chemother...

Does HER2 or PD1/PDL1 positivity change first line treatment (i.e. preferential enrollment on clinical trials) or do such patients still receiving sta...

We often treat elderly women with lumpectomy and adjuvant hormonal therapy without radiation. I am concerned about how to proceed after the 5 year poi...

For example, how significant does the M protein have to increase for you to begin a conversation about new therapy?

Many women are distressed when asked to discontinue hormone replacement therapy or use intravaginal estrogen suppositories.

Can T790M mutation develop within this early time frame, or are these perhaps patients who may benefit from switch to chemotherapy?

Some patients request chemotherapy scheduling adjustments to avoid feeling ill on major holidays. Delaying chemotherapy by a few days isn't of particu...

Example case: Patient given neoadjuvant docetaxel + cyclophophamide achieves a partial response after 3 cycles of Taxotere + cyclophosphamide but is u...

Are results of BCIRG-006 trial applicable for patients with triple positive breast cancer or only for those with HER2+? 

Given the apparently stronger results from KEYNOTE 052 (pembrolizumab) compared to IMvigor 211 (atezolizumab), would you consider pembrolizumab for pa...

Or do you recommend treatment with systemic therapy alone, as this represents Stage IV disease?

Are you using ctDNA blood tests for targetable mutations at the time of diagnosis, at the time of disease progression, or not at all?

The GTX (gemcitabine, docetaxel, capecitabine) regimen is listed as a category 2B recommendation in the NCCN guidelines- when would this be ...

Specifically, to you lean towards elotuzumab or a daratumumab-based regimen?

How does this approach change with mediastinal lymph node involvement? What are the indications for definitive or adjuvant radiotherapy +/- chemothera...

The current treatment for bladder adenoCA is surgery. However in non-surgical candidates, RT is an option. Would you consider adding chemo ? Also woul...

Since immune check point inhibitors have been approved for GEJ and gastric cancer, would a distal esophogeal adenocarcinoma be considered GEJ or does ...

What is the best evidence for what dose to use? When would you give it in relation to the checkpoint inhibitors? Which metastatic sites do you choose ...

Would you consider subtotal gastrectomy vs medical therapy?

Tamoxifen prophylaxis is FDA-approved, but would you extrapolate from adjuvant/metatastic data for hormone receptor positive breast cancer in post-men...

If so, what chemotherapy regimen would you use? If not, what management options would you generally recommend?

In the absence of data demonstrating a clinical benefit for one strategy versus the other, what do you do in practice?  

Most oncologists are comfortable offering FOLFOX for 1st line metastatic adenocarcinoma. Would you be comfortable offering FOLFOX to met. squamous eso...

If a patient will receive a total of 4 cycles ABVD and has a CR by PET/CT after cycle 2, can RT be omitted to non-bulky sites to avoid toxicity?

Is there a change in approach over the past few years? Would there be a role for the 12-gene recurrence score?

How do you select between the available treatment options (gemcitabine, docetaxel, paclitaxel, nab-paclitaxel) in combination with platinum?  Up...

Is there data for switching from nivolumab/ipilimumab to pembrolizumab if a patient develops significant pneumonitis but also had a significant radiog...

NCCN puts "preferred" regimens but only category 1 is cisplatin and fluoropyrimidine. When would you use that regimen over FOLFOX?

If so, how do you manage counseling for someone with low health literacy?

Based on 2-3% MSH2 mutation and 1% MLH1 mutation rates in metastatic disease regardless of castration sensitivity, should we be looking for this earli...

If choosing systemic therapy, do you prefer bevacizumab with or without irinotecan? Have you used anti-PD1 agents (e.g. nivolumab) off label? 

When there is biopsy proven mediastinal disease, do you offer definitive chemoradiation and monitor, or do you try to prove the presence/absence ...

Has the recent FDA approval of dabrafenib/trametinib changed your practice?

Being that there is limited data on CNS penetration with either regimen, what would you prefer in a patient who already received whole brain RT?

If current systemic treatment is otherwise controlling the disease and is well-tolerated, is there value to locally aggressive therapy in an attempt t...

The FDA recently approved neratinib based on data from the ExteNET trial; however, benefit appears modest and the risk of toxicity is not low.

Do you offer neoadjuvant RT with resection and node dissection vs. definitive radiation?  How extensive does the nodal disease have to be for you...

Do you have a cutoff in terms of tumor size, number of LN, Oncotype score, etc that makes you choose lower vs higher intensity chemo?

In a patient who developed oligometastatic disease before completing adjuvant XELOX, what treatment(s) and duration of treatment would you recommend?

I have a few patients with kras braf mutation negative metastatic colon cancer treated with upfront FOLFOX- bev followed by 5FU-bev who had regression...

There is limited data that suggests steroidal AI exemestane could be of some benefit after nonsteroidal AI failure (Lonning PE et al. J Clin Oncol 200...

Specifically I am thinking if a PET scan shows complete response, would it be reasonable to stop bleomycin and continue AVD?

When PDL1 expression is negative, but IHC for mismatch repair expression is consistent with mismatch repair deficiency (MLH2, MSH2, and MSH6 expressed...

Would you approach this situation as synchronous primaries (eg. FIGO IA in both) or as a locally advanced endometrial cancer (FIGO IIIA)? What adjuva...

In patients with new bone pain and without any evidence of bone metastases receiving GnRH agonists, how do you manage pain symptoms?

I.e. either for treatment of high-risk disease or intolerance/contraindication to tamoxifen. Will you continue it for the full 5 year course?

Are the results of the STAMPEDE trial presented at ASCO 2017 practice changing?

Drug information indicates a patient may need 3-4 months off TKI. This seems like a long time off drug. Would a MMR of a certain duration make it less...

In a patient with isolated leptomeningeal disease (no systemic disease), would you still recommend systemic therapy?

Regorafenib has been approved for patients with advanced HCC post-sorafenib, but the benefits are slight and toxicity substantial.  Nivolumab has...

Specifically when given as a single agent. Any role for G-CSF?

PET/CT/bone marrow biopsy negative for evidence of distant disease. Following 4 cycles of combination chemotherapy with no evidence of progressive dis...

Have the results of LUX-Lung 7 changed your routine practice? Are there promising up-front clinical trials that these patients may benefit from?

Assume good compliance with oral therapy, equivalent access to either agent, no contraindictions to either therapy, and absence of any visceral crisis...

Do you reserve this approach for only women with triple negative breast cancer or all-comers?

Do you incoprate Ki67% or mitotic rate into your treatment decision, and is there any use for somatostatin based imaging such as octreoscan or gallium...

Can immune check point inhibitor be restarted if grade 4 hyperglycemia (with acidosis and insulin drip requirement) has resolved?

Given recent FDA accelerated approval of pembrolizumab for MSI-H tumors regardless of site of origin, does it make sense to apply MSI testing, in...

If biopsy of the lesion is consistent with GI origin adenocarcinoma and there are no other sites of disease, would wedge resection followed by adjuvan...

If not, what is your thyroid hormone withdrawal protocol?  If so, would you still treat a patient with possibly metastatic disease?  

Does your management differ if the hiccups are felt to be related to chemotherapy as opposed to the disease itself?

Given the non-specific nature of AFP and its elevation in various benign conditions, is there an AFP cutoff level or change over time for which you wo...

In a patient who already received 13 courses of radiation (with complete response), is there any other effective treatment?

Which patients do you consider to be chemotherapy-ineligible for the sake of this treatment decision? How strong does the contraindication need to be?

Should we be routinely sequencing ALK to select an ALK inhibitor with the appropriate efficacy, matched to resistance patterns?

Tumor involves stomach, liver, and lymph nodes. Pathology is suspicious for sarcomatoid carcinoma, possibly sarcomatoid cholangiocarcinoma.

What would you choose if there is no response to neoadjuvant AC-T? Taxol, THP, TCHP?

Do you prefer neoadjuvant chemotherapy or proceeding directly to surgery, followed by adjuvant therapy?

What clinical considerations factor into your decision to choose leuprolide vs goserelin vs triptorelin vs degarelix, etc?

Assuming cytotoxic chemotherapy is given, would you still then proceed with adjuvant endocrine therapy?  Would you switch agents or classes of en...

In LAP07's second randomization (capecitabine+54 Gy vs maintenance gemcitabine +/- erlotinib), 60% of unresectable pancreatic cancer patients who did ...

NCCN guidelines offer suggested schedules for interval imaging and laboratory studies, but also make it clear that the quality of evidence for these r...

What determines which you select first? How do concerns about cross-resistance factor in after progression on one of these agents?

To what extent do you worry about overlapping myelosuppression? Is there any advantage to overlapping therapy?

Is there a role for salvage LN dissection or salvage RT to the node? And is there a role for systemic therapy (ADT or chemotherapy) in addition? If yo...

Do you prefer this approach based on the FALCON trial showing improved PFS with frontline fulvestrant?

Do you extrapolate the results of OPTIMIZE-2 and CALGB 70604 showing that an every 12 week dosing of zolendronic acid is noninferior to ever...

Two retrospective studies from Stanford showed that patients who received ADT had an increased risk of dementia and Alzheimer's. Is this finding ...

If a patient developed locoregional recurrence after initial chemoradiation, would resection of known disease followed by observation be preferred?

Do you use a PSA threshold, PSA doubling time, or only evidence of metastatic disease to trigger ADT? For those without rapid doubling time, do you ev...

And how should we compare checkpoint inhibitors? Given the FDA approval of atezolizumab and nivolumab as second-line agents for metastatic urothe...

For instance with isolated progression at one metastatic site, with all other disease stable and clinically doing well. 

How would the new data presented at ASCO GI 2021 from from Alliance A021501 influence your answer?

How do the different assays compare when choosing a specific immunotherapy, and does this change for first vs second (or beyond) line of therapy?

Is there a select patient population that you use it for? Is it also being used in cancers other than breast cancer?

At what point is the neuropathy a contraindication to further bortezomib therapy?

Although bendamustine + rituximab is a standard option for advanced follicular lymphoma when treatment is required, does the regimen rituximab + lenal...

There are many options to choose from, including large gene panels with up to 80 genes at the same cost as BRCA 1/2 testing, while others offer j...

Would you use 5-FU and radiation alone? Would your management be different for loco-regional (curative) vs metastatic situations?

Is there a role for routine use of additional or alternative imaging modalities for these patients, such as tomosynthesis, MRI, or ultrasound?  I...

Is there data related to types of metastases (tumor histology, anatomic distribution, hemorrhagic, diffuse, size, edema etc.) and risk for seizure?&nb...

Would your recommendations change if it was a partial vs complete radiographic response?

Are there differences between palbociclib and ribociclib?  What would make you choose one over the other?

Specifically, can you rechallenge after the effusion has resolved (e.g. therapeutic thoracentesis)? If so, how long do you wait to rechallenge (especi...

Would you add chemotherapy if there was gross residual disease, pN+ and/or ECE?

How long do you typically wait before starting consolidation chemotherapy, and do you routinely perform re-staging scans prior to consolidation? 

Imatinib, or a second-generation TKI? Are there specific factors that make you choose one over the other?

When would you use surveillance versus repeat excision or adjuvant systemic or local therapy?

If so, do you use antivirals and/or antibiotics? Does it matter if the patient has mantle cell lymphoma, CLL, or Waldenstrom's macroglobulinemia?

Can the classic indications for post-hysterectomy radiation (eg. "Sedlis" and "Peter's" criteria) be applied? Does the histology change radiation dose...

The CABOSUN trial showed a benefit in PFS and ORR, with unchanged OS, over sunitinib. 

In the setting of recent craniotomy and a plan for SRS to the surgical cavity, which systemic therapy would you choose and when would you start it?

For example, if a post-menopausal patient is treated in the first line setting with docetaxel, herceptin, and perjeta, would you add an aromatase...

The immediate response by patients in this situation seems almost universally to be, "But I'll starve to death!" Referencing literature about lack of ...

For a patient with a history of non-muscle invasive disease in the bladder, presenting with a prostatic urethra only recurrence, do you approach this ...

What immunosuppressive agents are used and in what order?  Does your approach differ depending on the organ involved, e.g. colitis vs. pneumoniti...

In addition to addresing the brain met (surgery vs. SBRT), would you proceed with systemic "adjuvant" chemotherapy, or would you treat the patient as ...

 Is there any data to support this approach? If not, are there trials you are aware of looking at "rescuing" these patients with a different chec...

At what point do you send these test, and in what instances do the results influence your treatment recommendations?

If so, how do you counsel patients who are node positive with low or intermediate risk scores? How do you interpret the existing data? NCCN and ASCO g...

Does the extent/duration of systemic disease control (complete response vs. stable disease, for example) influence your decision?  What about whe...

When do you offer trimodality bladder-sparing approaches? Is there any role for starting standard neoadjuvant therapy in an attempt to convert to rese...

Or in patients with metastatic disease on ADT who have not had primary therapy? In what situations do you consider palliative prostatectomy?

In a patient who underwent lumpectomy for presumed DCIS and was found to have a focus of invasive triple negative disease, would you offer chemotherap...

After confirming castration levels of testosterone, is the next best step to add docetaxel (as in CHAARTED and STAMPEDE, although not explicitly for G...

Is a monthly schedule x 1 year, followed by q3 months, now the the standard of care, as per the recently published OPTIMIZE-2 trial? 

When are you concerned for a false positive? FDA guidelines include a suggestion to try another assay in case heterophile antibodies are causing a fal...

How do you weigh the recently presented/published data from the NETTER-1 and RADIANT-4 trials in your decision making?

Is salvage liver resection considered the next step in treatment for patients who may have resectable tumors after TACE?  If so, do specific tumo...

Radium-223 has an overall survival benefit and lower hematologic toxicity, but at a significantly increased cost.  Does the cost-effectiveness fa...

This is rarely done, but recently came up in a tumor board discussion.  Which chemotherapy would you consider using, and when?

Specifically, do you just wait for count recovery? Do you check for morphologic or molecular remission at all during this time?

If so, at what point? McDermott et al. demonstrated some lasting responses after discontinuation of therapy (JCO 2015), but these responses are s...

How might a recent (within 6 months) myocardial infarction affect your recommendations?

In particular, would you offer memantine to those with WHO II or III gliomas and a good performance status but larger treatment volume?

Does the risk of severe inflammation of the liver lead you to choose other therapies in in this population?  What about in patients with mild liv...

Does the site of progression or response matter?  What if there is progression in the lungs but response in lymphadenopathy, for example?  

Is MRI being considered the primary mode of imaging in multidisciplinary tumor boards, especially in light of the results of the MERCURY trial (JCO 20...

Specifically, is there still a role for dd RCHOP followed by ICE, or do you recommend DA-R-EPOCH for all patients?

If these are presumed to be immune-mediated (e.g. immune neutropenia or immune thrombocytopenia), do you treat with steroids?

For patients who developed oligometastases while off systemic treatment, do you start systemic therapy following local therapy or return to active sur...

Do you typically use 5-FU/cisplatin/cetuximab, or do you prefer other options?

Does the site of palliative radiation therapy matter (i.e. femur, abdomen, pelvis vs base of skull)? How long should you wait to give palliative ...

The Phase III J-ALEX study and two phase II studies seem to suggest favorable intracranial response rates for alectinib. 

Are there circumstances when you would choose IL-2 over checkpoint inhibitor trials or TKIs for fit patients? How should IL-2 be sequenced with these ...

Would you send the patient to a surgeon for consideration of a mastectomy?  Would you then consider post mastectomy radiation when the risk of re...

NCCN guidelines suggest XRT as standard of care for this stage of disease. However, occasionally patients have their tumors completely excised when un...

The CALOR study showed a benefit of adjuvant chemotherapy for local recurrence but the regimens given were "physicians choice".

If PET/CT is unrevealing for a primary source, would you treat such a patient with platinum-etoposide or monitor closely until further disease progres...

In your practice, has tumor molecular profiling in pancreatic cancer led to the identification of any actionable targets for which a patient was put o...

Does the location of the pancreatic mass respective to the major vessels alter initial management (surgery, chemotherapy, radiation,  or some com...

Do you have a preference for Regorafenib or Lonsurf or do you refer to clinical trials immediately given the known low response rates to these drugs?&...

Would you consider HER-2 directed therapy (lapatinib-trastuzumab)? Does being KRAS-mutated affect your decision? 

Would taking the drug at a specific time point prior to their radiation appointment time to maximize blood levels of the drug be clinically beneficial...

How do you counsel them on risk in the curative setting?  Do you approach treatment in the metastatic setting any different than patients with &g...

What do you consider when making this decision (concurrent chemotherapy, amount of bone marrow in field, whether patient is already on antibiotics, et...

Does recent data from the OAK study showing a survival benefit for atezolizumab over docetaxel even in non-smokers affect your decision making?  

Does switching AIs help?  If so, is there a role for switching from a steroidal AI to a non-steroidal AI or vice versa?  Are there other adj...

In which circumstances should high-dose chemotherapy with autologous stem cell transplant be considered, versus second-line chemotherapy regimens or c...

Based on the abstract from IMvigor 210 presented at ASCO this year, are you offering atezo to patients who otherwise may not tolerate platinum-based c...

Based on results from PALOMA1 and recently reported MONALEESA2, do you use a CDK4/6 inhibitor as initial therapy?  In what circumstances would yo...

Based on a recent single-arm phase II trial, is there a role for paclitaxel, ifosfamide, and cisplatin (TIP) as a first-line regimen instead of BEP?

The results of the 70 gene panel Mammaprint in combination with Adjuvant! Online were published in NEJM recently. How will you incorporate this data i...

Do you ever consider de-escalating or stopping therapy in this situation? What is your approach to this conversation?

The MA17R trial only included "postmenopausal women" so how do you make a decision for men and pre-menopausal women.

If so, when? Although anemia is associated with worse local control in HN cancer, I don't know of any data that shows that blood transfusions can help...

Given recent advancements in the understanding of biological differences in prostate cancer patients of African vs. other ancestry, does your manageme...

Do you have a preference for specific steroids? Some practices may switch to prednisone during this time.   Patients with gliomas are often on d...

For patients who remain fit and interested in treatment, but for whom a clinical trial is not an option, what systemic therapy do you reach for in thi...

Do you use cytotoxic chemotherapy as first line or hormonally-targeted therapy such as letrozole + palbociclib?

Based on recently published data from CheckMate 032, do you now offer nivolumab to small cell patients who have progressed after first-line chemothera...

Do you treat with standard of care therapy for microsatellite stable (MSS) colorectal cancers or pursue further work-up? Does this differ between adju...

Based on the CALOR trial (http://www.ncbi.nlm.nih.gov/pubmed/24439313), adjuvant chemotherapy should be considered, but what regimen is preferred?&nbs...

If so, how do you sequence this with other therapies?  In addition, in the absence of an effect on radiographic PFS or serum PSA, how do you asse...

In situations where there is a significant risk of either local or nodal persistence/recurrence post prostatectomy with a rising PSA, or nodal involve...

4cm has historically been used as the cutpoint for determining benefit from adjuvant chemotherapy in this population (Strauss et al, JCO 2008; Bu...

In a patient who recently completed NAC, TM/LND and PMRT for a hormone positive locally advanced breast cancer and is then found to have a contralater...

In the IMvigor 210 trial, increased PD-L1 expression in patients’ tumors was associated with response to atezolizumab, but some patients whose t...

Since some prior subset analyses have suggested that oxaliplatin may not improve outcomes of older patients with colon cancer in the adjuvant settin...

The recently published MA.17R trial showed a DFS benefit for extending AI therapy to 10 years in post-menopausal women.

A recent publication of the TEXT and SOFT trials http://www.ncbi.nlm.nih.gov/pubmed/27044936 showed an improvement in breast cancer-fre...

Does the recent Hopkins trial of pembrolizumab change your management of these patients?

A recent systematic review suggested that disease progression owing to a testosterone "flare" may not be a real phenomenon: http://www.ncbi.nlm.nih.go...

Although PD-1 inhibitors are now standard of care for second-line therapy of advanced NSCLC, there remains the question of which therapy is best to us...

We have a great palliative care clinic and I like to refer many patients with metastatic disease, even if I feel that they will live a year or two lon...

Is there any consensus regarding the optimal RT dose, fractionation, and timing to the best abscopal response? What is the optimal metastatic site to ...

The role of adjuvant docetaxel with ADT following RT for high risk disease has been previously elucidated by RTOG 0521.  Following prostatectomy,...

If the systemic agent is going to be held, how many days prior to starting radiation therapy should the agent be held and when can it be restarted aft...

If a patient had a recurrence that was pathologically proven despite negative idodine scans, what imaging scans would you follow up with for surveilla...

At the ASCO 2016 annual meeting, results of the PRINCE trial were reported. A strategy of intermittent docetaxel was found to be non-inferior to conti...

What is the utility of repeating FISH studies to evaluate for clonal evolution if FISH studies were done at diagnosis?

Would you offer adjuvant TKI following ADAURA data?  Or proceed with durvalumab based on PACIFIC data?

 In a patient with node positive disease, treated definitively with radiation, should continuous or intermittent ADT be administered? If a patien...

Typically radium-223 is reserved for men with symptomatic bone disease after failure of multiple other therapies.  Is there a population of men w...

As it is suggested for larger tumors treated with surgery, based on post hoc CALGB analysis?

The NCCN guidelines discourage the use of PET/CT surveillance but the recent analysis of RTOG 0235 found post-CRT PET uptake to be associated with wor...

Based on the European data published in the Lancet (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2961085-0/abstract), are you s...

Should oxaliplatin/capecitabine alone be the standard of care?

I know that some would argue that healthy patients with an excellent performance status may not need an early palliative care referral, but wouldn't i...

Decrease the dose? Treatment break? Steroids?

For example, should nivolumab be considered standard second-line therapy for adenocarcinoma patients?   Can it be considered for first-line thera...

In a patient with an R0 resection, would you routinely recommend postop chemoradiation, since these patients were included in the MacDo...

Are there any clinical or pathologic factors that lean you towards or away from giving trastuzumab?

Our Radiation Safety officer reports a higher radiation dose to the patient from the two scans vs the PET.

Do you favor a short palliative regimen, or a full course definitive treatment to 64.8Gy? How does your management change if the patient has a good pe...

What factors should be considered with offering SBRT to oligometastatic bone disease in prostate cancer patients? Should this been done off of a proto...

I am aware that chemotherapy can obviate the need for RT in patients with SVC syndrome, but I'm not sure if this can be extrapolated to spinal cord co...

Assuming a patient who could tolerate either, which is preferred? Does this depend on the choice for concurrent chemotherapy (5FU+mitomycin vs ci...

Should mutations other then EGFR and ALK be routinely tested for? Should next generation sequencing be routinely done?

If a patient with stage I, low grade follicular lymphoma achieves a complete response after rituxan and treanda is there any role for consolidative ra...

With novel therapies quickly evolving, it's becoming more difficult to discern the proper sequence of therapies and the point at which a clinical tria...

Do you really feel the failure was because people crossed over to bev at progression, or is it simply that bev does not affect overall survival?

I've read about patients who were treated with concurrent bevacizumab-RT who developed lethal tracheoesophageal fistulas. How long would you have to w...

Even though we do not have the best data on the use of induction chemotherapy, what are current practices? Is your practice different between HPV+ an...


Papers discussed in this category


Gynecol Oncol, 2019 Aug 16

JAMA,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-03-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-01

The Lancet. Oncology, 2013-03

Cancer, 2004-03-15

Mayo Clinic proceedings, 2012-03

Oral oncology, 2016-09

N Engl J Med, 2006 Jul 6

The New England journal of medicine, 2001-09-06

BMC Cancer, 2015-07-21

International journal of radiation oncology, biology, physics, 2013-09-01

Proceedings of the National Academy of Sciences of the United States of America, 2011-03-15

JAMA Netw Open, 2021 Apr 01

Cancer, 2002-06-01

The New England journal of medicine, 2018-07-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10

Annals of oncology : official journal of the European Society for Medical Oncology, 2011-11

N Engl J Med, 2015 Jan 8

N Engl J Med, 2007 Aug 16

J Clin Oncol, 1999 Jul

Lancet, 2015 Jan 3

International journal of radiation oncology, biology, physics, 2011-11-01

Int. J. Radiat. Oncol. Biol. Phys., 2006-09-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-12

Lancet Oncol., 2017-05-01

The New England journal of medicine, 1999-08-12

BMC Cancer, 2015-08-15

Journal of cancer research and therapeutics, 2012

International journal of radiation oncology, biology, physics, 2012-05-01

Neurosurgery, 2013-10

Practical radiation oncology, 2015

J. Neurosurg., 2005-01-01

J Korean Neurosurg Soc, 2011-08-01

Radiat Oncol, 2014-07-08

BMC Cancer, 2015-03-04

Acta Neurochir (Wien), 2013-01-01

The Lancet. Oncology, 2009-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-04-01

J Clin Oncol, 2011 Jan 10

JAMA, 2016-07-26

Radiation oncology (London, England), 2014-09-30

Cancer, 2016-06-15

J. Clin. Oncol., 2018 May 22

Lung cancer (Amsterdam, Netherlands), 2018-06

The New England journal of medicine, 2018-08-23

The New England journal of medicine, 2018-12-06

International journal of radiation oncology, biology, physics, 2019-04-01

Lancet, 2019 Oct 04

JAMA oncology, 2019-06-01

International journal of radiation oncology, biology, physics, 2019-04-01

International journal of radiation oncology, biology, physics, 2019-04-01

Neurosurgery, 2019 Oct 10

JAMA Oncol, 2020 Jun 4

J Clin Oncol, 2020 Aug 10

Lung Cancer, 2014 Aug 02

N Engl J Med,

Lancet Oncol, 2020 Apr 03

Int J Radiat Oncol Biol Phys,

JAMA,

J Neurosurg,

Cancer,

International journal of radiation oncology, biology, physics, 2013-03-15

International journal of radiation oncology, biology, physics, 2011-05-01

International journal of radiation oncology, biology, physics, 2011-11-01

J. Clin. Oncol., 2014-04-10

J. Clin. Oncol., 2013-11-10

Lancet Oncol., 2012-01-01

The New England journal of medicine, 2015-02-19

The New England journal of medicine, 2010-08-19

The New England journal of medicine, 2013-03-28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-05-01

Oncology (Williston Park, N.Y.), 2012-12

N. Engl. J. Med., 2010-08-12

The New England journal of medicine, 2013-04-11

Lancet Oncol., 2012-04-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-10

Lancet, 2016 Mar 19

Eur. Urol.,

N Engl J Med, 2014 Sep 27

Cancer, 2007-11-15

Cancer, 2015-04-01

JAMA, 2012 Jul 11

JAMA, 2008-03-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

International journal of radiation oncology, biology, physics, 2011-09-01

American journal of clinical oncology, 2011-02

International journal of radiation oncology, biology, physics, 2013-12-01

JAMA, 2007 Jan 17

Cancer, 1987 Jun 15

Ann Surg, 2007 Nov

Radiother Oncol, 2006 Oct

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-07-01

International journal of radiation oncology, biology, physics, 2012-06-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

Lancet, 1998 Jul 25

Int. J. Radiat. Oncol. Biol. Phys., 1999-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-10

The Lancet. Oncology, 2010-01

Oral oncology, 2014-05

Head & neck, 2015-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-04-20

International journal of radiation oncology, biology, physics, 2018-03-15

International journal of radiation oncology, biology, physics, 2016-06-01

Int. J. Radiat. Oncol. Biol. Phys.,

Annals of surgical oncology, 2016-11

The Journal of thoracic and cardiovascular surgery, 2007 Aug

Lancet Oncol., 2017-09-01

J. Clin. Oncol., 2011 Mar 28

Cochrane Database Syst Rev, 2010 Mar 17

J Clin Oncol,

Curr Oncol, 2020 Dec 01

Lancet Oncol, 2020 Feb 26

J. Clin. Oncol.,

Lancet Gastroenterol Hepatol, 2019 Jul 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-01

Cancer, 2010-10-01

Head & neck, 2016-04

Cancer, 1990-11-01

Ann. Oncol., 2010 Apr 28

J Clin Oncol, 2017 Dec 8

Radiat Oncol, 2015 May 27

International journal of radiation oncology, biology, physics, 2016-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

The New England journal of medicine, 2016-11-10

The New England journal of medicine, 2018-01-11

N. Engl. J. Med.,

Journal of the National Comprehensive Cancer Network : JNCCN, 2018-10

JAMA Netw Open, 2019 Aug 2

Pract Radiat Oncol, 2020 May - Jun

J Thorac Oncol, 2021 Feb 02

J Clin Oncol, 2021 Jan 27

Int J Radiat Oncol Biol Phys, 2020 Nov 18

J Clin Oncol, 2021 Aug 11

J Clin Oncol, 2009 Oct 1

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019-09

N Engl J Med,

Pancreas, 2013-07

Eur J Radiol, 2006 Feb 21

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-09-01

Cancer, 2021 Oct 13

Eur J Cancer, 2022 Sep 19

Am J Transl Res, 2019 Sep 15

Eur Urol, 2015 Jul 16

BJU Int, 2009 Feb

European urology, 2014-06

Lancet Oncol., 2015-09-01

JAMA oncology, 2018-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-01

The New England journal of medicine, 2015-10-22

The New England journal of medicine, 2013-07-18

International journal of radiation oncology, biology, physics, 2015-11-01

The Lancet. Oncology, 2015-02

Eur. J. Nucl. Med. Mol. Imaging, 2014-06-01

Cancer, 2004-08-15

Br. J. Haematol., 2003-11-01

Br. J. Haematol., 1998-08-01

Cancer, 1990-11-15

Radiother Oncol, 1990-01-01

Oral oncology, 2018-03

J. Clin. Oncol., 2018 Mar 14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-11-01

Semin Radiat Oncol, 2015 Oct

N. Engl. J. Med.,

Lancet Oncol., 2015 Dec 16

Lancet,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

JAMA oncology, 2018-06-14

J. Clin. Oncol., 2019 Oct 08

The New England journal of medicine, 1985-06-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-11-01

J Can Assoc Radiol, 1981-09-01

J. Clin. Oncol., 1985-03-01

J. Natl. Cancer Inst., 1988-07-20

Ann. Oncol., 2008-09-01

Radiother Oncol, 2011-01-01

Acta Oncol, 2011-10-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-04-01

The Journal of urology, 1994-03

Lancet Oncol, 2021 Feb

Cancer, 2014-06-15

Cancer, 2010-07-01

European urology, 2014-09

European urology, 2012-07

J Urol, 2020 Apr

European urology, 2015 Sep 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Gastrointestinal cancer research : GCR, 2007-03

Practical radiation oncology, 2013

International journal of radiation oncology, biology, physics, 2017-02-01

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019-02

Technol Cancer Res Treat,

Am J Clin Oncol,

N. Engl. J. Med., 1999-01-28

Lancet Oncol., 2017 Jun 20

The oncologist, 2016-02

Clinical lung cancer, 2017-11

Anticancer Drugs, 2016-06-01

Practical radiation oncology, 2011

The New England journal of medicine, 2004-10-07

Lancet Oncol., 2014 May 13

The Lancet. Oncology, 2015-08

N Engl J Med, 2014 Mar 27

N Engl J Med, 2013 Jun 20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-01

The New England journal of medicine, 2016-07-21

The New England journal of medicine, 2010-06-17

Blood, 2014-01-23

The New England journal of medicine, 2010-06-17

N. Engl. J. Med., 2015-01-29

JAMA oncology, 2016-11-01

Breast cancer research : BCR, 2009

Cancer cell, 2012-10-16

Cancer cell, 2016-03-14

Cancer discovery, 2016-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-03-01

J. Nucl. Med., 2015 Jun 25

Nature reviews. Rheumatology, 2022 Oct 05

Oncoimmunology, 2023 Oct 30

Clinical breast cancer, 2010-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-01

Lancet Oncol., 2010-02-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-03-20

The Journal of urology, 2005-08

Mol Clin Oncol, 2015 May 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-10

The Journal of urology, 1999-07

Annals of oncology : official journal of the European Society for Medical Oncology, 2009-03

Mayo Clin Proc, 2004 Oct

JNCI Cancer Spectr, 2019 Oct 21

N Engl J Med, 1994 Aug 11

The New England journal of medicine, 2018-05-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-20

The Journal of urology, 2002-09

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-01-15

Nature, 2005-12-08

The New England journal of medicine, 2001-12-06

Lancet, 2001-09-22

Breast Cancer Res. Treat., 2010-02-01

The Journal of urology, 1982-06

Cancer research, 2000-04-15

J. Clin. Oncol., 2009-04-01

Oncol. Rep., 2015-12-01

Nat Commun, 2015-04-01

PLoS ONE, 2016-01-01

J. Urol., 2002-04-01

Lancet Oncol., 2015 Sep 09

European urology, 2018-02

Lancet, 2018 Oct 18

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-11-01

The Lancet. Oncology, 2016-07

Gynecologic oncology, 2010-03

The Lancet. Oncology, 2014-02

Int J Radiat Oncol Biol Phys,

Laryngoscope, 2016 Jun 12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-20

Lancet (London, England), 2009-08-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-07

Journal of the National Cancer Institute, 2007-03-21

The breast journal, 1999-01

Annals of surgical oncology, 2010-10

The Lancet. Oncology, 2015-07

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01

Br. J. Cancer, 2015 Jun 30

Head & neck, 2006-04

Journal of neuro-oncology, 2014-03

Brain : a journal of neurology, 2017-03-01

Radiat. Res.,

Lipids Health Dis, 2017 Jun 02

Annals of surgical oncology, 2014-10

The New England journal of medicine, 2016-08-25

Cancer, 2015-12-15

JCO Precision Oncology, 2017 Sep 29

Sci Rep, 2014 Sep 09

Medicine (Baltimore),

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-01

Blood, 2015-07-23

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Apr 19

Cancer, 2024 Jan 30

Haematologica, 2025 Feb 06

Hematology. American Society of Hematology. Education Program, 2024 Dec 06

The Lancet. Oncology, 2010-01

The New England journal of medicine, 2004-12-30

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Jun 03

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2021 May 11

The New England journal of medicine, 2014-02-20

The New England journal of medicine, 2014-02-20

Neuro-oncology, 2016-09

Onco Targets Ther, 2017 Jan 18

Indian J Urol,

The Lancet. Oncology, 2006-06

Lancet (London, England), 2016-05-07

Cancer Treat. Rev., 2016-04-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

Clin. Cancer Res., 2015-04-15

Lancet (London, England), 2016-04-09

N Engl J Med, 2015 Jun 25

Hepatology (Baltimore, Md.), 2015-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-20

JAMA oncology, 2016-04

JAMA oncology, 2017-01-01

Lancet Oncol., 2016-06-01

Lancet, 2015-10-03

JAMA, 2009-08-26

European urology, 2015-05

JAMA, 2008-01-23

The New England journal of medicine, 2015-12-17

Blood, 2022 Jul 14

Leukemia, 2021 Apr 27

J Am Coll Cardiol, 2019 Oct 01

J Cancer, 2016-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-15

N. Engl. J. Med., 2008-09-11

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-02-01

Journal for immunotherapy of cancer, 2015

Cancer immunology, immunotherapy : CII, 2016-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995-03

The cancer journal from Scientific American, 2000-02

Cancer immunology, immunotherapy : CII, 2016-12

Urologic oncology, 2015-11

Eur. J. Cancer, 2016-02-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

Lancet Oncol., 2011 Jun 05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-05-10

Lancet Oncol., 2014-10-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-06-10

International journal of radiation oncology, biology, physics, 2006-02-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15

Journal of the National Cancer Institute, 2001-12-05

International journal of radiation oncology, biology, physics, 2000-09-01

ESMO open, 2018

Cancer immunology research, 2015-11

Immunotherapy, 2020 Jun 22

Nature medicine, 2023 Mar 30

The Lancet. Oncology, 2023 Jul 14

Lancet Oncol., 2011-08-01

The New England journal of medicine, 2015-03-05

Lancet, 2007-05-19

Clin Lung Cancer, 2018 Nov

British journal of haematology, 2017-11

Medical and pediatric oncology, 1981

JAMA, 2013-04-03

Haematologica, 2016-12-01

Clin Pharmacokinet, 2012-12-01

Lancet (London, England), 2016-05-14

The New England journal of medicine, 2016-12-08

JAMA oncology, 2017-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-10

The New England journal of medicine, 2011-02-10

The New England journal of medicine, 2011-02-10

Lancet (London, England), 2016-03-05

The New England journal of medicine, 2017-01-12

Neuro-oncology, 2013-10

The Lancet. Oncology, 2016-12

Nat. Med.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-12-10

Lancet Oncol., 2013-05-01

Lancet (London, England), 2016-12-17

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-05-01

Medical and pediatric oncology, 1990

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986-01

N Engl J Med, 2017 Nov 16

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

Oncologist, 2016-12-01

JAMA otolaryngology-- head & neck surgery, 2016-11-01

Journal of the National Cancer Institute, 2008-10-01

Canadian Agency for Drugs and Technologies in Health, 2016-10-31

Medicine (Baltimore),

Future Oncol, 2015 Oct 05

The New England journal of medicine, 2019-06-13

Lancet Oncol., 2019 Jul 22

Gynecol Oncol, 2019 Sep

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01

Clinical breast cancer, 2006-12

Immunotherapy, 2016-10

Lancet (London, England), 2014-03-22

The New England journal of medicine, 2011-06-23

Journal of the National Cancer Institute, 2005-09-07

Annals of surgical oncology, 2013-11

N. Engl. J. Med.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-01-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-10

J. Clin. Oncol., 2020 Feb 14

Neuro Oncol,

J Clin Oncol, 2021 Aug 11

International journal of radiation oncology, biology, physics, 2011-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-01-01

Cancer, 2013-11-01

Journal of geriatric oncology, 2015-03

International journal of radiation oncology, biology, physics, 2013-07-15

Advances in radiation oncology, 2017

The Lancet. Oncology, 2009-05

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017-02

Cancer, 2010 Aug 27

J Clin Oncol, 2008 Dec 01

JCO Precision Oncology, 2017 May 31

The New England journal of medicine, 2016-08-04

NEJM Evidence, 2022 Jun 3

Dis. Colon Rectum, 2014-04-01

Clin Oncol (R Coll Radiol), 2017-04-01

Prostate cancer and prostatic diseases, 2014-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-10

J Thorac Oncol,

Clin. Cancer Res., 2015 May 27

Lancet (London, England), 2017-01-21

The New England journal of medicine, 2018-06-14

The Lancet. Respiratory medicine, 2019-05

Ann. Oncol.,

J. Clin. Oncol., 2018-07-01

Lancet (London, England), 2009-12-19

The Lancet. Oncology, 2014-06

The New England journal of medicine, 2012-11-08

J. Clin. Oncol.,

Lancet, 2017-03-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-20

Gynecologic oncology, 2004-04

American journal of obstetrics and gynecology, 2010-10

Obstetrics and gynecology, 1988-01

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2014-11

Gynecologic oncology, 2015-06

European radiology, 2022 May 07

The Cochrane database of systematic reviews, 2020 Dec 21

J Clin Oncol, 2010 Oct 10

J. Natl. Cancer Inst., 2011 Oct 21

The Lancet. Oncology, 2016-08

J. Clin. Oncol., 2010 May 03

Blood, 2016-10-13

Can Fam Physician,

Journal of the National Comprehensive Cancer Network : JNCCN, 2014-04

J Thorac Oncol, 2017-02-01

JAMA oncology, 2017-08-01

J. Clin. Oncol., 2018-06-10

Breast Cancer Res. Treat., 2013-01-01

J Clin Oncol, 2020 Feb 14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-07-15

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012-11

J Clin Oncol, 2008 Jan 10

The Lancet. Oncology, 2014-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-20

The New England journal of medicine, 2017-03-16

N Engl J Med, 2015 May 31

J. Hepatol., 2016-05-01

Eur. J. Cancer, 2011-09-01

Lancet Oncol., 2015-10-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20

National Cancer Institute (US),

Lancet, 2014-09-20

Pain practice : the official journal of World Institute of Pain, 2017-11

Med Phys, 2013-08-01

Int. J. Radiat. Oncol. Biol. Phys., 2009-01-01

ESMO Open, 2016-01-01

JAMA Oncol,

The New England journal of medicine, 2018-04-12

The New England journal of medicine, 2018-06-28

The British journal of surgery, 2002-11

European urology, 2012-04

European urology, 2014-07

N. Engl. J. Med., 2012-04-19

J. Urol., 2007-09-01

J. Clin. Oncol., 2006-05-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-07-10

The New England journal of medicine, 2015-08-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-01

Journal of the National Cancer Institute, 2024 Sep 30

The Lancet. Oncology, 2017-09

World journal of gastroenterology, 2010-06-28

The New England journal of medicine, 2012-01-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10

N Engl J Med,

N Engl J Med, 2019 Dec 11

N Engl J Med,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-09-01

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017 May 22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 19

J. Clin. Oncol., 2019 Oct 16

N. Engl. J. Med., 2017-07-13

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2015-04

Am J Case Rep, 2017-02-28

Lancet (London, England), 2017-01-07

J. Clin. Oncol., 2018-06-10

N. Engl. J. Med., 2012-05-03

N. Engl. J. Med., 2012-05-03

The New England journal of medicine, 2018-05-31

Lancet, 2017-09-09

Breast cancer research and treatment, 2014-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

Oncologist, 2007-09-01

Nat. Med., 2016-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01

The Lancet. Oncology, 2011-07

Lancet Oncol., 2015-10-01

Oncotarget, 2016-05-31

Journal of the National Cancer Institute, 2006-12-20

Medicine and science in sports and exercise, 2010-07

J Clin Oncol, 2016 Feb 20

Curr Breast Cancer Rep, 2016-01-01

Crit Rev Food Sci Nutr, 2018 Apr 19

JAMA, 2018-02-20

JAMA Oncol,

Cancer, 2010-05-01

The New England journal of medicine, 2016-11-17

N. Engl. J. Med., 2016-11-03

The Lancet. Oncology, 2016-04

N. Engl. J. Med., 2017-07-27

N. Engl. J. Med., 2004-06-03

JAMA, 2013-10-09

JAMA, 2011-02-09

Lancet Oncol., 2013-04-01

Lancet Oncol., 2014-11-01

Breast, 2017-02-01

J. Clin. Oncol., 2015-01-20

J. Clin. Oncol., 2009 Nov 02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-08-20

Lancet Oncol., 2019 Mar 25

J. Clin. Oncol., 2019 Feb 01

The New England journal of medicine, 2012-08-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

Breast cancer research and treatment, 2012-11

N Engl J Med,

British journal of clinical pharmacology, 2016-06

The New England journal of medicine, 2016-06-23

Cancer, 1987-10-15

Gynecologic oncology, 2015-09

The New England journal of medicine, 2014-07-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-01

Fertility and sterility, 2016-03

Breast Cancer, 2017-09-01

Pancreas, 2010-08

Cancer, 2020 May 01

JAMA Oncol, 2022 Oct 01

Dig Liver Dis, 2021 May 12

Journal of the National Cancer Institute, 2010-07-07

J Natl Cancer Inst, 2006 Jul 5

J. Natl. Cancer Inst., 2010-07-07

J. Clin. Oncol., 2003-10-01

International journal of radiation oncology, biology, physics, 2016-06-01

Br. J. Cancer, 2016-08-09

The New England journal of medicine, 2005-05-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01

Breast Cancer Res. Treat., 2014-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

Lancet Oncol., 2014-06-01

Blood, 2013-12-19

Oncology, 2013-01-01

PLoS ONE, 2015-01-01

Lancet Oncol., 2013-01-01

JAMA Oncol, 2021 Jul 01

Lancet Oncol, 2022 Apr 08

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2014-06

International journal of radiation oncology, biology, physics, 2013-07-01

Cancer, 2004-05-15

Lancet (London, England), 2013-03-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-04-20

Journal of the National Cancer Institute, 2013-07-17

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-09-01

The Lancet. Oncology, 2019-01

Ann. Oncol., 2018 Feb 26

Urologe A,

Blood, 2016-12-22

J Clin Oncol, 1998 Nov

J Clin Oncol, 2011 Jun 1

Breast Cancer Res. Treat., 2005-01-01

Breast, 2016-12-01

Zhonghua Zhong Liu Za Zhi, 2016-07-01

Breast, 2016-08-01

Nature medicine, 2017-06

Oncotarget, 2016-08-16

Eur J Cancer, 2012 Sep

Clin Cancer Res, 2020 Sep 1

Cancers (Basel), 2020 Jan 14

Clin Cancer Res, 2020 Jan 22

International journal of radiation oncology, biology, physics, 2015-04-01

Int. J. Radiat. Oncol. Biol. Phys., 2016-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-12-20

The New England journal of medicine, 2017-11-09

Journal of translational medicine, 2024 Feb 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-01

The Journal of molecular diagnostics : JMD, 2011-05

Cancer medicine, 2016-12

The New England journal of medicine, 2005-10-20

Springerplus, 2016-01-01

Lancet, 2017-03-25

N. Engl. J. Med., 2006-02-23

Lancet Oncol., 2013-07-01

Lancet Oncol., 2016-06-01

Lancet, 2020 Apr 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

JAMA Oncol,

J Urol,

Blood, 2014 Feb 05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-10

J. Clin. Oncol., 2015 Feb 17

The Lancet. Oncology, 2015-01

Urology, 1999-06

Biomed Res Int, 2014 Feb 06

JAMA oncology, 2016-11-01

JACC CardioOncol, 2019 Dec 17

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020 Dec 23

JAMA network open, 2024 Dec 02

JACC. CardioOncology, 2020 Mar 17

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2024 Oct 10

N. Engl. J. Med., 2015-04-23

Leuk. Lymphoma, 2007-09-01

N Engl J Med, 2011 Oct 6

Eur. J. Cancer, 2017 Dec 08

Lancet, 2011-09-17

Cancer, 2010-11-15

The breast journal, 2017-11

Lancet (London, England), 2016-02-27

JAMA Oncol, 2016 Mar

Clin Oncol (R Coll Radiol), 2016-12-01

The New England journal of medicine, 2009-05-14

Ann. Oncol., 2009-02-01

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-10-01

J. Clin. Oncol., 2011 Nov 21

N. Engl. J. Med., 2017-11-09

N. Engl. J. Med., 2012-05-31

J Hematol Oncol, 2015 May 17

Breast Cancer Res. Treat., 2015 Apr 08

J. Clin. Oncol., 2016-08-10

Lancet Oncol., 2014-07-01

Ann. Oncol., 2014-07-01

J. Clin. Oncol., 2015-10-01

The Annals of thoracic surgery, 2010-09

J. Clin. Oncol., 2009-10-20

Cancer journal (Sudbury, Mass.), 2017

Journal of gastrointestinal oncology, 2016-08

The Lancet. Oncology, 2014-10

Lancet, 2010 Aug 19

N Engl J Med, 2020 May 29

J Clin Oncol, 2020 Mar 24

The New England journal of medicine, 2015-08-13

Radiat Oncol, 2014 May 29

Br. J. Cancer, 2014 Aug 28

J Gastrointest Cancer,

Radiographics : a review publication of the Radiological Society of North America, Inc, 2014-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-01

J. Natl. Cancer Inst.,

J. Natl. Cancer Inst.,

Oncotarget,

Nature, 2017-04-26

Cancer discovery, 2017-12

Cancer discovery, 2016-10

Arthritis & rheumatology (Hoboken, N.J.), 2018-03

Practical radiation oncology, 2021 Sep 13

Asia-Pacific journal of clinical oncology, 2023 Apr 23

Advances in radiation oncology, 2018

Cancer, 2018-06-01

International journal of radiation oncology, biology, physics, 2015-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

J Clin Oncol, 2019 Aug 14

Lancet (London, England), 2019-01-05

J. Natl. Cancer Inst.,

Radiother Oncol, 2009 May 14

J Clin Oncol, 2021 Oct 26

J Clin Oncol, 2021 May 27

Radiother Oncol, 2020 Feb 07

Journal of the National Cancer Institute, 2014-01

Lancet Oncol., 2013 Jul 29

Ann. Oncol., 2010 May 21

Breast Cancer Res. Treat., 2010 Jul 15

J. Clin. Oncol., 2012 Feb 27

N. Engl. J. Med., 2018-01-25

Cancer investigation, 2011-11

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-12-01

Cancer Treat. Rev., 2011-10-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07

Ann. Oncol., 2013-12-01

Nat Rev Clin Oncol, 2016-08-01

Acta Oncol, 2011-04-01

Lancet Oncol., 2007-09-01

J. Clin. Oncol., 2011-06-01

J Clin Oncol, 2020 Oct 29

Semin Cell Dev Biol, 2011 Jul 28

Nat Med, 2019 Sep 30

British journal of haematology, 2004-04

Blood,

Blood,

Clin Colorectal Cancer, 2013 Jun 14

The Lancet. Oncology, 2016-11

Br. J. Haematol., 2017 Nov 21

N. Engl. J. Med.,

American journal of hematology, 2016-05

J Thorac Oncol, 2016 Oct 07

J. Natl. Cancer Inst.,

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2017-10

Blood, 2018-06-21

Nature, 2019-06

Leukemia, 2019-02

The Lancet. Oncology, 2018-02

J. Clin. Oncol.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-20

The Lancet. Oncology, 2009-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-05-15

Cancer, 2011-06-15

American journal of hematology, 2009-09

Cancer, 2010-08-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

Lancet (London, England), 2007-12-15

J. Clin. Oncol., 2009 May 18

The New England journal of medicine, 2017-06-22

Cancer, 2016-01-15

Annals of surgical oncology, 2017-09

Eur J Surg Oncol, 2017 Sep 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-15

Lancet, 2009 Sep 18

Eur. J. Nucl. Med. Mol. Imaging, 2016 Aug 18

Pancreas, 2016-11

N. Engl. J. Med., 2019 Jun 04

J Clin Oncol, 2023 May 16

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jun 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Dec 10

Lancet, 2021 Mar 06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Curr Oncol Rep,

Adv Anat Pathol,

Clinical genitourinary cancer, 2018-08

Cancer, 2018-04-15

Proc Natl Acad Sci U S A, 2015 Aug 3

Journal of the National Cancer Institute, 2018-01-01

Pediatrics, 2014-04

Vaccine, 2014 Dec 08

Blood, 2013-11-14

J. Clin. Oncol., 2016 Jan 25

Leukemia, 2016-02

The Lancet. Oncology, 2018-02

The Lancet. Oncology, 2010-01

The New England journal of medicine, 2014-09-04

The New England journal of medicine, 2019-05-30

Lancet (London, England), 2017-02-04

The New England journal of medicine, 2018-02-08

Blood, 2018-01-18

Ann. Oncol., 2018 Jan 19

Journal of global oncology, 2017-08

Breast cancer research and treatment, 2018-02

Journal of the National Cancer Institute, 2016-09

Cochrane Database Syst Rev, 2008 Apr 16

Eur. J. Cancer, 2013 May 22

Head & neck, 2014-01

Otolaryngol Head Neck Surg, 1994 Feb

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-09-01

J. Clin. Oncol.,

Thorac Cardiovasc Surg, 2015 Dec 15

Ann. Oncol.,

Gynecologic oncology, 2014-11

Clin. Cancer Res., 2018 Mar 26

Urology, 2013-06

Science translational medicine, 2013-12-18

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-02

Ann. Oncol.,

N. Engl. J. Med., 2017 Jun 04

Anticancer Res.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-20

Cancer,

Head Neck, 2019 Feb 01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-03-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-03-20

J Clin Oncol, 2007 Apr 1

J Clin Oncol, 2005 Apr 1

J. Clin. Oncol.,

The New England journal of medicine, 2018-05-31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-08-20

N. Engl. J. Med., 2019 Jun 02

Radiother Oncol, 2017 Sep 27

Lancet,

NEJM Evidence, 2022 Jun 1

Science translational medicine, 2016-07-06

The Lancet. Oncology, 2017-09

Breast Cancer, 2012 Apr 25

Annals of surgical oncology, 2018-10

J Clin Oncol, 2022 Jan 07

JAMA oncology, 2019-06-01

Lancet Oncol, 2021 Jun 11

The Lancet. Oncology, 2016-11

The New England journal of medicine, 2017-10-05

Lancet (London, England), 2017-10-21

Lancet,

Cancer, 2004-10-15

The New England journal of medicine, 2018-12-13

The New England journal of medicine, 2018-07-12

The New England journal of medicine, 2006-12-14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-06-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-01

The Lancet. Oncology, 2018-01

J Thorac Oncol,

N Engl J Med,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993-05

British journal of haematology, 2018-10

Blood Adv,

Pulmonary medicine, 2012

Lancet Oncol., 2016 Jun 23

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-02-10

Radiat Oncol, 2015 Apr 26

Nat Rev Urol, 2014 Apr

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-07-01

BMJ, 2016 Sep 30

International journal of radiation oncology, biology, physics, 2014-03-01

Breast cancer research and treatment, 2013-11

Annals of surgery, 2016-02

Breast cancer research and treatment, 2013-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-01

The Lancet. Oncology, 2016-09

Clinical breast cancer, 2018-02

Breast,

The New England journal of medicine, 2017-12-28

Journal of the National Cancer Institute, 2017-02

N. Engl. J. Med., 2018 Jun 03

The New England journal of medicine, 2018-11-22

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-06

Clin. Cancer Res., 2016 Feb 04

Cancer, 2012-06-01

Cancer, 2016-07-01

International journal of radiation oncology, biology, physics, 2016-03-15

Annals of internal medicine, 2018-01-16

The Lancet. Oncology, 2018-04

JAMA Oncol,

Neuroendocrinology,

J Gastrointest Cancer,

JAMA oncology, 2018-02-01

Blood,

Blood,

Blood, 1998-09-01

American journal of hematology, 2017-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-12-10

Cancer, 2022 Apr 05

Nature, 2013-07-11

The New England journal of medicine, 2015-10-29

N Engl J Med, 2016 Feb 25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-01

The New England journal of medicine, 2011-12-29

N Engl J Med, 2011 Dec 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-09-10

Eur. J. Obstet. Gynecol. Reprod. Biol.,

Br J Obstet Gynaecol,

Avicenna J Med, 2017 Jul-Sep

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10

Annals of surgical oncology, 2016-02

JAMA oncology, 2016-09-01

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013-04

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016-07

Clinical breast cancer, 2003-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-02-01

The Lancet. Oncology, 2017-12

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

N Engl J Med, 2021 Jun 03

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-04

Surgery,

The Annals of thoracic surgery, 2015-12

The Journal of thoracic and cardiovascular surgery, 2016-05

Lancet (London, England), 2014-08-23

Lancet Oncol, 2019 May 20

J Clin Oncol, 2022 Jun 03

Frontiers in immunology, 2023 Dec 11

The Lancet. Oncology, 2012-07

Annu. Rev. Med., 2015 Aug 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-06-20

Lancet,

Lancet Oncol, 2019 Feb 19

Lancet Oncol, 2019 Dec 02

Lancet Oncol, 2017 Oct 13

JNCI Cancer Spectr, 2021 May 28

Cancer research, 2008-10-01

N. Engl. J. Med.,

J. Clin. Oncol.,

NPJ breast cancer, 2016

The New England journal of medicine, 2016-11-24

The Lancet. Haematology, 2018-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-20

Br J Surg,

N Engl J Med, 2010 Jul 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-04-10

Cancer, 2006-09-15

Blood,

Cancer Discov,

Clin. Cancer Res.,

Breast Cancer,

Clin. Cancer Res.,

The Lancet. Oncology, 2009-11

Ann. Surg. Oncol., 2015 Feb 05

N. Engl. J. Med.,

N. Engl. J. Med.,

NPJ Breast Cancer, 2021 Nov 11

J Clin Oncol, 2020 Feb 25

Blood, 2014-05-22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10

Breast Cancer Res. Treat.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-20

NPJ breast cancer, 2016

NPJ Breast Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10

Breast cancer research and treatment, 2011-04

Breast (Edinburgh, Scotland), 2015-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-20

Lancet Oncol., 2018 Nov 06

Lancet (London, England), 2014-07-12

Practical radiation oncology, 2018

J. Clin. Oncol.,

N. Engl. J. Med.,

JAMA Oncol, 2021 Jan 21

Oncol Lett, 2019 Sep 10

J. Clin. Oncol.,

Br. J. Cancer,

J Clin Oncol, 2022 Apr 11

Lancet Oncol, 2018 May

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-09-01

JAMA Oncol, 2020 Aug 13

Oral Oncol., 2013 Nov 15

Cancer, 2009-07-15

Cancer, 2011-10-01

Hematol Oncol Clin North Am, 2019 Oct 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-06-10

Lancet Oncol, 2017 Jun

Lancet (London, England), 2017-10-28

The New England journal of medicine, 2016-12-01

The New England journal of medicine, 2012-04-12

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-03-15

The Lancet. Oncology, 2016-03

European urology, 2016-05

Clinical genitourinary cancer, 2017-12

American journal of clinical oncology, 1997-06

The Annals of thoracic surgery, 2015-02

Thorac Cardiovasc Surg,

Breast cancer research and treatment, 2017-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-07-20

Mol Oncol,

The Lancet. Oncology, 2016-10

J. Clin. Oncol.,

Lancet (London, England), 2018-02-17

J Clin Oncol, 2014 May 1

Int J Gynecol Cancer, 2018 Mar

Br. J. Cancer,

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015-02

The Lancet. Oncology, 2017-07

International journal of radiation oncology, biology, physics, 2017-06-01

JAMA oncology, 2018-01-11

Semin Oncol, 2006 Apr

Lancet,

The New England journal of medicine, 2018-02-22

The Lancet. Oncology, 2015-07

J. Clin. Oncol., 2019 Dec 11

Oncologist, 2015 Sep 09

J Thorac Oncol, 2016 Jul

Fertil. Steril., 2013 Sep 05

JAMA,

Eur. J. Cancer, 2017 Aug 04

The New England journal of medicine, 2010-06-03

Journal of the National Cancer Institute, 1997-11-19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Int. J. Radiat. Oncol. Biol. Phys., 2012 Jun 05

J Thorac Oncol, 2018 Feb

The New England journal of medicine, 2017-08-31

Ann Oncol, 2020 May 11

N Engl J Med,

J Clin Oncol, 2020 Aug 11

J Thorac Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 May 31

Prostate Int,

Ann Surg Oncol, 2018 Jul 9

JAMA, 2017-09-12

J. Clin. Oncol., 2018 Jun 15

The Lancet. Oncology, 2015-02

J. Clin. Oncol., 2017 Dec 14

Int. J. Radiat. Oncol. Biol. Phys.,

Cancer,

The Lancet. Oncology, 2013-10

Lancet Oncol., 2013 Oct 11

J Clin Oncol, 2015 Aug 20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-05-10

Nat Rev Urol, 2017 Dec 12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-01-01

NPJ breast cancer, 2017

N Engl J Med, 2018 Apr 15

Leukemia, 2018-08

The New England journal of medicine, 2015-10-29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-10

N Engl J Med, 2018 Oct 20

Lancet Oncol., 2013 Dec 19

The New England journal of medicine, 2018-12-27

The Lancet. Respiratory medicine, 2017-11

Curr Probl Cancer, 2016 Mar - Aug

Lancet Oncol, 2022 Oct 18

Lancet (London, England), 2017-01-07

JAMA Oncol,

Ann. Thorac. Surg.,

Int. J. Cancer, 2016 Jun 30

Annals of surgical oncology, 2009-06

Annals of surgical oncology, 2017-02

Breast Cancer Res. Treat., 2017 Sep 15

JAMA, 2011-11-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-02-20

The British journal of radiology, 2017-08

J. Clin. Oncol., 2013 Nov 25

Advances in radiation oncology, 2018

BMJ, 2006 Sep 19

J. Clin. Oncol., 2018 May 30

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-11-20

Target Oncol,

The Lancet. Oncology, 2017-06

Nature medicine, 2024 Jun 02

Lung Cancer,

Lancet Oncol., 2008 Jun 24

Eur. J. Cancer,

Breast cancer research : BCR, 2016-06-28

J. Clin. Oncol., 2018 Jul 05

J Natl Cancer Inst, 2018 Jun 1

Oncology reviews, 2017-03-03

J Surg Oncol, 2021 Aug 01

Am J Surg Pathol, 2016 Jan

Am Soc Clin Oncol Educ Book, 2021 Mar

Clin Colon Rectal Surg, 2015 Dec

Oncology (Williston Park), 2021 Jun 23

International journal of radiation oncology, biology, physics, 2009-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-12-10

BMC Cancer, 2018 Jan 11

Lancet, 2021 Dec 23

J Clin Oncol, 2011 Jan 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01

The New England journal of medicine, 2017-07-27

Ann. Oncol.,

Lancet, 2018 Nov 15

Lancet (London, England), 2019-01-19

The New England journal of medicine, 2019-02-14

Lancet Oncol., 2017 Oct 12

The Lancet. Oncology, 2016-03

JAMA Oncol,

Clinical cancer research : an official journal of the American Association for Cancer Research, 2016-09-15

J. Clin. Oncol., 2018 Mar 29

Lancet (London, England), 2009-03-28

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-09

N Engl J Med, 2020 Sep 19

Lancet, 2021 Sep 20

J Clin Oncol, 2020 Dec 17

Liver Int., 2011 Aug 31

Lancet Oncol., 2017 Feb 24

Eur. J. Cancer, 2017 May 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-10-01

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-02-01

British journal of cancer, 2012-08-21

Int J Radiat Oncol Biol Phys,

J Clin Oncol, 2016 Feb 29

J Clin Oncol, 2020 Sep 11

Blood, 2017-03-09

The Lancet. Oncology, 2013-08

Eur Urol, 2017 Oct 23

J Clin Oncol, 2017 Jul 28

JAMA Oncol,

Lancet Oncol., 2017 Mar 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

J. Clin. Oncol., 2009 Oct 05

Ann. Oncol.,

Cancer Res., 2010 Feb 02

Haematologica, 2019-04

J. Clin. Oncol., 2020 Feb 20

J Clin Oncol, 2019 Jun 02

JAMA network open, 2020 Nov 02

Dig Liver Dis, 2013 Jun 28

Am. J. Clin. Oncol.,

N. Engl. J. Med., 2019 May 31

J. Clin. Oncol., 2019 Jul 22

Lancet Oncol, 2019 Apr 12

The New England journal of medicine, 2017-04-06

Haematologica, 2011 Nov 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-03-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-10

JAMA, 2013-10-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04

The journals of gerontology. Series A, Biological sciences and medical sciences, 2001-03

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02

Medicine (Baltimore),

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-01-10

Journal for immunotherapy of cancer, 2018-01-29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-11-10

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01

Arch Surg,

Int. J. Radiat. Oncol. Biol. Phys., 2008-11-01

JAMA Oncol,

Lancet Oncol, 2021 Dec 15

Journal of oncology, 2018

Clin. Cancer Res., 2017 Oct 24

J. Clin. Oncol.,

Lancet, 2015 Apr 07

Int. J. Radiat. Oncol. Biol. Phys.,

Breast cancer research and treatment, 2019-05

Blood, 2018 Sep 04

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-04-15

JAMA, 2013 Oct 9

Lancet (London, England), 2018-03-24

JAMA oncology, 2017-05-01

Clin. Cancer Res., 2011 Feb 16

J. Clin. Oncol., 2013 Oct 21

Gynecologic oncology, 2018-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

Eur J Surg Oncol, 2017 Jan 16

Clin Colorectal Cancer, 2018 Oct 10

Blood Adv,

Cancer,

International journal of radiation oncology, biology, physics, 1994-06-15

International journal of radiation oncology, biology, physics, 2010-12-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010-06

Lung cancer (Amsterdam, Netherlands), 2021 Jan 30

JAMA oncology, 2019-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-11-01

International journal of radiation oncology, biology, physics, 2015-07-01

Tumori, 2018 May 08

The Lancet. Oncology, 2016-07

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15

JAMA oncology, 2017-07-01

Advances in radiation oncology, 2017

AJR. American journal of roentgenology, 2019-10

JAMA oncology, 2019-06-01

Clin Nucl Med,

The New England journal of medicine, 2018-04-05

Cancer medicine, 2019-01

Tumori,

Bone marrow transplantation, 2018-07

J. Clin. Oncol., 2017 Oct 02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-04-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-09-01

Ann. Oncol., 2013 Nov 04

Breast Cancer Res Treat, 2009 Jun

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019-02

Lancet (London, England), 2016-02-27

Journal of the National Cancer Institute, 2001-11-07

Int J Radiat Oncol Biol Phys,

Breast (Edinburgh, Scotland), 2019-04

Journal of clinical pathology, 2017-03

NPJ breast cancer, 2017

PLoS ONE, 2016 Oct 14

Sci Eng Ethics, 2017 Sep 15

Lancet, 2015 Mar 02

J. Clin. Oncol., 2015 Nov 02

Radiographics : a review publication of the Radiological Society of North America, Inc, 2004

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03

The New England journal of medicine, 2015-07-16

International journal of radiation oncology, biology, physics, 2015-09-01

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-01-01

J. Clin. Oncol., 2018 Dec 06

Journal of the National Comprehensive Cancer Network : JNCCN, 2017-04

Blood, 2017-02-02

Journal of neurosurgery, 2019-02-08

The Lancet. Haematology, 2016-05

The Lancet. Haematology, 2017-11

Eur. Urol., 2020 Jan 17

Radiation oncology (London, England), 2011-09-28

JAMA surgery, 2019-05-29

J. Clin. Oncol., 2020 Feb 27

Breast cancer research and treatment, 2018-06

Trials, 2013 Aug 19

Ann. Oncol., 2012 Jun 06

Cancer,

N. Engl. J. Med.,

Ann Surg Oncol, 2022 Apr 04

Future Oncol, 2019 Apr 25

Clin Transl Oncol, 2018 Mar 28

Thromb. Haemost.,

Eur J Haematol, 2023 Mar 27

BMC cancer, 2017-12-28

JAMA Oncol,

Lancet Oncol., 2016 Jan 26

ISRN Surg, 2013 Mar 20

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-04-15

Clinical cancer research : an official journal of the American Association for Cancer Research, 2015-12-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-10-20

N. Engl. J. Med., 2019 Sep 28

N Engl J Med, 2019 Dec 19

Science (New York, N.Y.), 2017-07-28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-20

Ann. Surg.,

Journal of Cancer, 2017

Onco Targets Ther, 2018

Cancer cell, 2018-09-10

Cancer Discov, 2017 Mar

Mol Oncol, 2017 Nov 17

Nat Commun, 2016 May 13

JAMA oncology, 2016-10-01

Nature reviews. Cancer, 2018-06

The New England journal of medicine, 2019-06-20

The New England journal of medicine, 2005-06-23

Lancet Oncol., 2006-09-01

N. Engl. J. Med.,

J Clin Oncol, 2023 Jan 31

Lancet (London, England), 2023 Jul 18

Lancet (London, England), 2023 Jul 18

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-01

Blood, 2016 Mar 21

Lancet Oncol, 2020 Aug 28

N. Engl. J. Med., 2019 May 31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20

J Thorac Oncol, 2019 Jan 18

Thrombosis research, 2019-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

The New England journal of medicine, 2018-02-15

N. Engl. J. Med.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-01

N. Engl. J. Med.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-01-20

The New England journal of medicine, 2005-03-10

The New England journal of medicine, 2016-04-07

J Clin Oncol, 2012 Oct 15

J Clin Oncol,

Neuro Oncol, 2016 Jul 01

Lancet Oncol., 2013 Jan 08

Cancer,

Eur J Surg Oncol,

Ann. Surg. Oncol., 2010 Sep 21

Clin Epidemiol, 2012 Nov 07

HPB : the official journal of the International Hepato Pancreato Biliary Association, 2016-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-09

Future Oncol, 2018 May 09

Breast Cancer Res Treat, 2019 Feb

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-12-01

J. Clin. Oncol., 2011 Jan 10

The New England journal of medicine, 2012-02-09

Cancer control : journal of the Moffitt Cancer Center, 2009-01

JAMA, 2015-07-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-11-10

Cochrane Database Syst Rev, 2013 Apr 30

Lancet Oncol., 2018 Apr 09

Lancet, 2019 Apr 11

Ann. Surg. Oncol., 2017 Mar 23

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019-08-01

Nat Commun, 2019 Mar 27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-09-01

The Lancet. Oncology, 2015-11

Ann Oncol,

Cancer, 2020 Sep 25

Clin Cancer Res, 2018 Oct 16

Annals of surgery, 2019-04-05

Journal for immunotherapy of cancer, 2019-06-06

J. Clin. Oncol., 2019 Feb 27

Nature, 2018-02-08

The Lancet. Oncology, 2019-04

The Lancet. Oncology, 2019-03

Lancet Oncol., 2017 Nov 02

Blood, 2018-03-15

Cancer, 2010-10-01

European journal of cancer (Oxford, England : 1990), 2013-03

American journal of clinical oncology, 2019-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-15

J. Natl. Cancer Inst.,

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017-10

J Thorac Oncol, 2020 Sep 08

Lung Cancer, 2017 Jun

N. Engl. J. Med.,

Lancet, 2012 Jan 07

World J. Gastroenterol.,

The New England journal of medicine, 2006-01-05

Lancet Oncol, 2013 Sep

J. Clin. Oncol., 2019 Apr 19

Cancer, 2015-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-01

JAMA oncology, 2018-02-01

Lancet, 2018 Jun 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-20

Neuro-oncology, 2009-04

Lancet Haematol, 2015 Jun 03

The New England journal of medicine, 2015-02-12

Breast Cancer Res. Treat., 2019 May 31

PLoS ONE, 2018 May 16

Cancer discovery, 2012-11

Clin Cancer Res, 2022 Apr 14

Breast cancer research : BCR, 2016-12-13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01-10

N. Engl. J. Med.,

Radiother Oncol, 2011 Jun 12

Annals of oncology : official journal of the European Society for Medical Oncology, 2011-02

Cochrane Database Syst Rev, 2019 Feb 18

JAMA oncology, 2019-01-01

Journal of gastrointestinal cancer, 2015-06

Eur. J. Cancer, 2017 May 11

Lancet Oncol., 2014 Feb 18

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Lancet, 2019 Apr 11

JAMA Oncol, 2019 Jul 11

JAMA Oncol, 2019 Jul 11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

Cancer Res., 2017 Feb 15

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-05

The Annals of thoracic surgery, 2019-08

Eur. Respir. J., 2017 Jun 01

International journal of radiation oncology, biology, physics, 2007-07-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-12-01

Lancet Oncol., 2015-03-01

Ann. Surg. Oncol., 2013 Nov 23

Haematologica, 2016 Jun 16

Blood, 2015-11-19

Blood, 2017 Apr 19

Blood, 2021 Jul 13

Ann. Surg.,

JAMA Oncol,

J Clin Oncol, 2012 Jan 20

J. Clin. Oncol., 2019 Sep 12

J Clin Oncol, 2022 Aug 15

Lancet Oncol, 2016 Oct 22

Ann Surg Oncol, 2014 Aug

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2018-05-23

Acta Oncol, 2017 Apr 21

Lancet Oncol., 2017 Sep 04

Lancet Oncol., 2012 Sep 04

Oral oncology, 2017-06

Clin. Cancer Res., 2018 Oct 08

European journal of cancer (Oxford, England : 1990), 2012-06

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019-02

The New England journal of medicine, 2017-08-03

J Thorac Oncol, 2019 Feb 16

Lancet, 2012 Apr 05

Haematologica, 2018 Aug 03

Sci Rep, 2018 Jun 06

JAMA Oncol,

The New England journal of medicine, 2020 Apr 22

The Lancet. Oncology, 2017-10

Cancer discovery, 2017-04

J. Clin. Oncol., 2019 Aug 28

Radiation oncology (London, England), 2014-09-19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-01

International journal of radiation oncology, biology, physics, 2018-08-01

Int. J. Radiat. Oncol. Biol. Phys., 2016 Jul 15

Eur. Respir. J., 2018 Jan 04

Practical radiation oncology, 2018

JAMA oncology, 2017-11-01

The New England journal of medicine, 2011-08-04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-20

Br. J. Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998-04

Neuroendocrinology, 2019 Aug 21

Ann. Surg., 2019 Aug 30

The New England journal of medicine, 2019-03-21

Oncotarget,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2016-08

J Thorac Dis,

J. Hepatol., 2017 Jan 23

The Journal of pathology, 2019-06

International journal of radiation oncology, biology, physics, 2017-05-01

The Lancet. Oncology, 2017-08

Neurology, 1989-06

Radiother Oncol, 2020 Jan

N. Engl. J. Med., 2019 Jun 02

Expert Opin Biol Ther, 2019 Mar 27

J. Clin. Oncol., 2019 Oct 14

Lancet Oncol., 2015 Aug 31

Lancet Oncol., 2020 Mar 09

Breast, 2013 Dec 22

Breast, 2015 Oct 09

Expert Opin Drug Saf,

Urology, 2007-02

Case Rep Urol, 2013 May 08

NPJ Breast Cancer, 2016 Nov 16

Cancer,

J. Clin. Oncol., 2013 Aug 26

Melanoma research, 2015-04

Nature, 2018-01-18

Cureus, 2019 Jun 18

PloS one, 2015

The Lancet. Oncology, 2016-07

Int. J. Radiat. Oncol. Biol. Phys., 2019 Aug 31

Lung Cancer, 2019 Jan 15

JAMA oncology, 2017-06-01

Neuro-oncology, 2019-02-23

Leukemia, 2014-03

The New England journal of medicine, 2015-11-05

The New England journal of medicine, 2015-11-05

European urology, 2018-08

N. Engl. J. Med., 2019 Sep 30

Lancet,

J. Clin. Oncol., 2012 Apr 02

Annals of surgery, 2019-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-12-20

Annals of oncology : official journal of the European Society for Medical Oncology, 2010-04

Cancer, 2011-09-01

Cancer treatment reviews, 2017-02

Strahlenther Onkol, 2019 Feb 08

Radiother Oncol, 2018 Jul 09

Oncologist, 2019 Aug 07

Lancet (London, England), 2012-02-04

Semin. Cancer Biol., 2019 Jul 19

J Natl Compr Canc Netw,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-01-10

Clinical lung cancer, 2017-07

Int. J. Radiat. Oncol. Biol. Phys., 2020 Feb 07

Cureus, 2019 Jun 22

Lung Cancer, 2009 Jan 24

Radiat Oncol, 2016 Dec 03

The Journal of molecular diagnostics : JMD, 2018-03

Ann Oncol, 2020 Feb 06

Acta Cytol, 2021 Jul 07

Cancer treatment reviews, 2017-02

N. Engl. J. Med.,

Radiother Oncol, 2015 Aug 04

J. Clin. Oncol., 2019 Aug 29

Eur. Urol., 2018 Jul 03

Ann. Oncol.,

The New England journal of medicine, 2023 Oct 20

Lancet Oncol, 2020 Mar 27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007 May 20

Annals of oncology : official journal of the European Society for Medical Oncology, 2021 Apr 20

Lung cancer (Amsterdam, Netherlands), 2022 Mar 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992 Aug

Clinical lung cancer, 2015 Apr 24

Lancet Oncol., 2012 May 22

Journal of immunotherapy (Hagerstown, Md. : 1997), 2013-09

J Immunother, 2010 Oct

J. Natl. Cancer Inst., 2017 Jan 28

JAMA Oncol,

The New England journal of medicine, 2003-08-28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-06-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-06-20

Lancet,

Cancer, 2012 Jan 03

JAMA Oncol, 2018 Nov 1

Cancer, 2014-12-01

Blood, 2019-04-04

JAMA, 2017-06-20

Annals of oncology : official journal of the European Society for Medical Oncology, 2017-08-01

Lancet Oncol, 2014 Jul 31

J Clin Oncol, 2022 Jun 06

J Clin Oncol, 2007 May 01

Science (New York, N.Y.), 2015-04-03

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-10

Annals of oncology : official journal of the European Society for Medical Oncology, 2018-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-06-10

J Immunother Cancer, 2019 Aug 22

Journal for immunotherapy of cancer, 2017-11-21

Cancer management and research, 2017

JAMA Oncol, 2019 Oct 03

J. Clin. Oncol., 2017 Dec 14

Eur. Urol., 2019 Jul 19

J. Clin. Oncol., 2003 Sep 08

N. Engl. J. Med., 2019 Sep 30

The Lancet. Oncology, 2017-11

Ann. Oncol.,

J. Clin. Oncol., 2011 Dec 12

J. Hepatol., 2019 Apr 06

The New England journal of medicine, 2018-12-20

Haematologica, 2017 Sep 21

Breast cancer research and treatment, 2008-01

British journal of haematology, 2015-12

Blood Adv,

Ann. Surg.,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-04-01

JAMA, 2014-05-21

Cancer, 1998-02-15

Cancer, 2010-04-15

Curr Treat Options Oncol, 2019 Aug 19

J Oncol, 2019 Feb 20

Endokrynol Pol, 2019 Mar 07

J Hepatol, 2021 Nov 19

N Engl J Med, 2020 May 14

J Hepatol, 2021 Dec 11

J. Clin. Oncol., 2019 Sep 25

Ann. Oncol., 2010 Jan 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-20

Curr Treat Options Oncol, 2019 Mar 14

European urology focus, 2019-11

Obstet Gynecol, 2009-09-01

Asian J Surg, 2019 Oct 26

SA J Radiol, 2018 Oct 29

Breast cancer research and treatment, 2016-04

J. Clin. Oncol., 2005 Feb 14

N. Engl. J. Med.,

Clinics in colon and rectal surgery, 2012-06

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-08-01

Cancer, 2005-04-15

Lung cancer (Amsterdam, Netherlands), 2015-12

Nature medicine, 2018-05

Cancer, 2017-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-08-20

Lancet (London, England), 2019-05-04

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-07

European journal of cancer (Oxford, England : 1990), 2019-03

Lung Cancer, 2012 Feb 10

N. Engl. J. Med., 2019 Sep 28

Breast cancer research and treatment, 2011-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-06-01

N Engl J Med, 2005 Jun 2

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-10-10

N Engl J Med,

J. Clin. Oncol., 2019 May 31

The Lancet. Oncology, 2014-03

The New England journal of medicine, 2012-05-10

Leukemia, 2019-01

Blood, 2017 Aug 3

Clin. Cancer Res., 2019 Aug 15

Ann. Oncol.,

Ann. Oncol., 2012 Feb 13

J. Clin. Oncol., 2019 Dec 27

Blood, 2018 Apr 19

J. Clin. Oncol., 2011 Sep 26

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10

Nature, 2017-08-10

Oncogene, 2018 Mar 15

Clin Cancer Res, 2019 Sep 12

JCO Precis Oncol, 2019 Aug 05

Cancer, 2016-04-15

Gastroenterology, 2018 May 17

Clin. Gastroenterol. Hepatol., 2018 Nov 28

Hepatology (Baltimore, Md.), 2019-10

Cancer, 2011-11-01

Case reports in oncology, 2017

BMC Cancer, 2015 Oct 15

JAMA oncology, 2018-05-10

Cancer,

Eur J Oncol Nurs, 2011 Jul 23

Support Care Cancer, 2013 Dec 22

Breast Cancer Res. Treat., 2017 May 09

J Pharm Sci,

J. Clin. Oncol.,

Eur. J. Cancer,

Sci Rep, 2017 Jul 04

J. Clin. Oncol.,

JAMA oncology, 2019-06-01

Lancet Oncol., 2017 Sep 25

Ann. Oncol.,

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2017-09

Springerplus, 2016 May 10

JAMA dermatology, 2018-06-01

Lancet Gastroenterol Hepatol, 2017 Jun 23

Br. J. Cancer, 2009 Feb 17

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011-05

Clin. Cancer Res., 2015 Oct 23

Invest New Drugs, 2015 Apr 12

J Hepatol, 2021 May 26

NEJM Evidence, 2022 June 6

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-04-10

Cancer, 2019-09-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-20

Int J Cancer, 2018 Apr 15

JAMA Oncol, 2019 Oct 31

Eur J Surg Oncol, 2014 Oct 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-11-01

N. Engl. J. Med.,

Br. J. Cancer,

Eur. J. Cancer, 2017-01-01

Lancet, 2008 Dec 16

Lancet, 2011-12-17

BMC Cancer, 2006 May 05

International journal of radiation oncology, biology, physics, 2001-05-01

International journal of radiation oncology, biology, physics, 1998-07-15

Eur. Urol., 2016 Mar 17

BJU Int, 2012 Aug 09

N. Engl. J. Med., 2020 Jan 29

The New England journal of medicine, 2016-07-07

J Clin Oncol. , 2019 Sep 1

Breast cancer research and treatment, 2012-11

Breast Cancer Res Treat, 2014 Apr 12

Breast cancer research and treatment, 2017-08

Blood cancer journal, 2018-06-12

Leukemia, 2013-08

J. Clin. Oncol., 2019 Oct 25

J Thorac Oncol. , 2019 Oct 17

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997-06

Eur Urol Oncol, 2019 Oct 08

Eur. Urol., 2019 Sep 26

Int. J. Cancer, 2017 Jun 08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-01-20

J. Clin. Oncol., 2012-06-01

Annals of surgery, 1999-07

Journal of the National Cancer Institute, 2000-03-01

Diseases of the colon and rectum, 2009-04

Radiother Oncol, 2012 Nov 28

J Gastrointest Oncol,

Radiat Oncol J, 2019 Jun 30

Radiat Oncol, 2019 Jan 16

Radiat Oncol, 2014 Jul 22

Radiat Oncol, 2016 Sep 05

International journal of radiation oncology, biology, physics, 2001 Aug 01

J Clin Oncol, 2019 Jul 22

British journal of cancer, 2011-02-01

Anticancer Res.,

Ann. Oncol.,

The Lancet. Oncology, 2018-02

The New England journal of medicine, 2014-11-13

Lancet Oncol., 2017 Sep 11

Cancer, 2020 Feb 19

The New England journal of medicine, 1994-08-25

N. Engl. J. Med.,

Sci Rep, 2016 May 20

N. Engl. J. Med., 2019 Dec 11

J. Clin. Oncol., 2019 Jan 17

The American journal of surgical pathology, 2017-11

Breast Cancer, 2016 Feb 13

Oncologist, 2020 Jul 03

The Lancet. Oncology, 2018-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-11-15

Annals of surgical oncology, 2018-08

British journal of haematology, 2017-08

Biotechnol. Prog., 2015 Mar 04

PLoS ONE, 2008 Jul 09

Public Health Rep,

Cochrane Database Syst Rev, 2011 Jul 06

J. Clin. Oncol., 2010 May 10

BMJ (Clinical research ed.), 2010-03-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-01-01

Br. J. Cancer, 2013 Feb 05

Int J Radiat Oncol Biol Phys, 2010 Aug 21

JAMA Netw Open, 2019 Jul 03

Urology, 1995-12

J Urol,

Int. J. Radiat. Oncol. Biol. Phys.,

Lancet Oncol., 2020 Mar 03

Lancet, 2020 Feb 07

JAMA Netw Open, 2020 Feb 05

Lancet Oncol., 2020 Feb 14

Ann. Oncol., 2020 Mar 26

Clinical lymphoma, myeloma & leukemia, 2016-09

J Endocr Soc, 2019 Oct 11

J Clin Oncol, 2020 Jan 1

J. Clin. Oncol., 2015 Nov 16

Lancet Oncol., 2018 Oct 19

Semin. Oncol., 2017 Feb 11

Lancet Oncol., 2018 Nov 23

Ann. Oncol., 2011 Apr 28

Lancet Oncol., 2020 Feb 17

JAMA Oncol, 2019 Sep 30

JAMA,

N Engl J Med, 2020 Mar 27

J. Clin. Oncol., 2019 Jul 24

Cell stem cell, 2017-09-07

Blood,

The Lancet. Oncology, 2010-10

Breast Cancer Res. Treat.,

Annals of surgical oncology, 2016-05

Oncology, 2020 Jan 09

Clinical cancer research : an official journal of the American Association for Cancer Research, 2007-06-15

Seminars in oncology, 2003-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2003-07

Crit Rev Oncol Hematol, 2017 Mar 29

Current treatment options in oncology, 2018-11-15

Gynecol. Oncol., 2019 Oct 17

J Oncol Pharm Pract, 2020 Jan 06

Clinical cancer research : an official journal of the American Association for Cancer Research, 2009-02-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01

The Lancet. Oncology, 2018-07

British journal of haematology, 2016-06

Chest, 1997-03

J. Clin. Oncol.,

Clin Genitourin Cancer, 2017 Sep 04

Eur. Urol., 2020 Jan 01

Anticancer Res.,

J. Clin. Oncol., 2020 Jan 24

Lancet Oncol., 2020 Mar 02

Clin. Cancer Res., 2018 Jun 27

N Engl J Med, 2021 Sep 18

Gynecologic oncology, 2007-05

Gynecol Oncol Rep, 2016 Dec 18

Gynecol Oncol,

BMC Cancer, 2019 Mar 11

Clin Cancer Res, 2017 Sep 27

Oncogene, 2020 Mar 02

Blood, 2019-01-03

Leukemia, 2019 Oct 18

J. Clin. Oncol., 2019 Sep 10

Biosci. Rep.,

J Natl Compr Canc Netw,

Sarcoma, 2020 Jan 30

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-06-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-09

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-01

Lancet, 2019 Nov 29

Lancet Oncol., 2014 Feb 28

Lancet,

International journal of radiation oncology, biology, physics, 2005-07-15

Lancet (London, England), 2017-06-24

The Lancet. Oncology, 2018-07

J. Clin. Oncol., 2019 Dec 02

International journal of radiation oncology, biology, physics, 2007-02-01

Annals of surgical oncology, 2015-12

International journal of radiation oncology, biology, physics, 1993-12-01

International journal of radiation oncology, biology, physics, 2017-12-01

Clin Oncol (R Coll Radiol), 2017 Dec 07

J Contemp Brachytherapy, 2019 Feb 28

Blood, 2019-05-16

Blood,

Journal of the National Cancer Institute, 2005-09-21

Eur. J. Cancer,

Br. J. Cancer, 2007 Jan 30

Leuk. Lymphoma, 2011 Feb 08

Cancer,

Leukemia, 2009-10

Eur J Gastroenterol Hepatol,

The Lancet. Oncology, 2015-08

Radiother Oncol, 2020 Mar 30

Ann. Surg., 2020 Mar 20

Lancet Oncol., 2017-03-01

Adv Radiat Oncol, 2020 Apr 22

J Clin Oncol, 2020 Feb 10

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005-01

J. Nucl. Med.,

Neuroendocrinology, 2017 Apr 13

N Engl J Med, 2021 Dec 11

Lancet,

Gynecologic oncology, 2009-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-01

Lancet Oncol.,

Br. J. Cancer, 2018 Oct 24

Lancet (London, England), 2004-05-22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-01-01

J. Clin. Oncol., 2019 Sep 25

Clin Oncol (R Coll Radiol),

Lancet Oncol., 2018 Mar 27

Cochrane Database Syst Rev, 2012 Apr 18

Cancer, 2016 Jun 10

International journal of radiation oncology, biology, physics, 2017-11-15

International journal of radiation oncology, biology, physics, 1997-03-01

Neurosurgery, 2020 Apr 21

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-04-10

Cancer journal (Sudbury, Mass.), 2007

The journal of supportive oncology, 2003

J Clin Oncol,

Breast Cancer (Dove Med Press), 2017 Jan 23

American journal of hematology, 2018-08

Am. J. Hematol., 2019 Nov 19

J. Neurosurg., 2017 Mar 03

Acta Neurochir (Wien), 2019 Jan 29

J. Neurooncol., 2018 Apr 06

J. Clin. Oncol., 2011 Mar 28

BMC Cancer, 2017 Apr 28

J Natl Compr Canc Netw,

Endocr. Relat. Cancer, 2017 Oct 24

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-04-20

Anticancer Res.,

JAMA Oncol, 2020 Dec 10

Cancer discovery, 2015-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2018-10-01

Nature, 2014-07-31

Cancer discovery, 2015-08

Clin Genitourin Cancer, 2019 Mar 13

Ann. Allergy Asthma Immunol., 2019 Aug 07

Clin Lymphoma Myeloma Leuk,

Clinical cancer research : an official journal of the American Association for Cancer Research, 2018-02-15

N Engl J Med, 2019 Dec 19

J Clin Oncol, 2020 Apr 10

J Clin Oncol, 2020 May 10

J Thorac Oncol, 2021 Oct 12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-02-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-11-01

J. Clin. Oncol., 2020 May 20

The New England journal of medicine, 2012-11-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-04-10

Cancer, 2018-06-01

Journal of the National Cancer Institute, 2018-11-01

Invest New Drugs, 2012 Oct 09

J. Clin. Oncol., 2019 Dec 05

J. Clin. Oncol., 2019 Oct 16

N. Engl. J. Med., 2020 May 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-12-01

J Clin Oncol, 2020 Dec 04

N. Engl. J. Med.,

Blood, 2012-01-05

Lancet (London, England), 2019-01-19

The Lancet. Oncology, 2019-01

Lancet Haematol, 2020 Apr 30

Leukemia, 2017 Jul 04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-07-10

JAMA oncology, 2019-05-09

JAMA oncology, 2019-05-09

J. Clin. Oncol., 2012 Aug 20

Gut, 2018 Feb 02

Journal of the National Cancer Institute, 1998-09-16

Lancet (London, England), 2002-09-14

Journal of the National Cancer Institute, 2007-05-02

Lancet,

Breast Cancer Res. Treat., 2006 May 11

Ann. Oncol., 2019 Jun 13

The New England journal of medicine, 2018-08-23

Lancet Oncol., 2020 Mar 12

Nature, 2013-05-02

Gynecologic oncology, 2019-09

F1000Res, 2019 Jun 12

J Clin Oncol, 2020 May 29

J Clin Oncol, 2021 Jan 13

Lancet Oncol, 2020 Dec 04

International journal of radiation oncology, biology, physics, 2012-11-01

Lancet Oncol., 2008 Jan 15

Lancet Oncol., 2009 Nov 10

J Clin Oncol, 2020 Apr 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-04-01

Oncol Lett, 2015 Aug 11

International journal of radiation oncology, biology, physics, 2016-03-15

Cancer medicine, 2019-05

American journal of clinical oncology, 2019-03

Nature medicine, 2015-02

Proceedings of the National Academy of Sciences of the United States of America, 2015-11-03

Oncologist, 2020 Mar 10

Semin Diagn Pathol, 2016 Dec 23

Lancet Gastroenterol Hepatol, 2017-07-01

Breast cancer research and treatment, 2014-11

J. Clin. Oncol., 2020 Jun 12

J Surg Oncol, 2019 Jan 12

Ann. Surg. Oncol., 2015 Aug 05

Oncotarget, 2014-11-30

Curr Oncol Rep,

Clin Lymphoma Myeloma Leuk, 2017 Jun 21

Pancreas,

The New England journal of medicine, 2007-01-25

Lancet, 2019 Nov 01

British journal of cancer, 2005-03-14

Case Rep Oncol, 2020 Jan 21

Mol Clin Oncol, 2019 Nov 29

Clin. Cancer Res., 2019 Oct 24

The American journal of surgical pathology, 2006-06

J Clin Oncol, 2019 Apr 11

The oncologist, 2013

J Thorac Dis,

Ann. Oncol., 2015 Apr 28

J Clin Oncol, 2020 Sep 10

Lung cancer (Amsterdam, Netherlands), 2017-10

Curr Oncol, 2020 May 01

Mol Cancer, 2020 Sep 11

PLoS One, 2018 Aug 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-11-10

Cancer Treat. Rev., 2012 Nov 28

Lancet, 2020 Mar 05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-08-01

Lancet Oncol., 2014 Dec 11

BJU international, 2011-09

Advances in radiation oncology, 2019

Cancer, 2016-12-01

Cancer Sci., 2016 Aug 09

European urology, 2013-08

Cancer,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

Lancet Oncol, 2020 Dec 07

Ann Oncol,

Lancet Oncol, 2021 Apr 13

Translational gastroenterology and hepatology, 2017

Surg Oncol, 2016 May 10

Haematologica, 2020

Nature, 2019-03

Blood, 2018 May 02

Leuk Lymphoma, 2019 Dec 26

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-05-20

J. Clin. Oncol., 2018 Dec 04

J. Thorac. Cardiovasc. Surg.,

Cancer, 2015 Jan 06

Eur J Cardiothorac Surg,

Cancer Treat Rev, 2022 Mar 12

Chest,

Interact Cardiovasc Thorac Surg, 2014 Aug 20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-01

The Lancet. Oncology, 2017-09

J Natl Compr Canc Netw,

Future Oncol, 2016 Aug 23

The New England journal of medicine, 2006-02-09

Breast Cancer Res. Treat., 2017 Mar 21

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-07-20

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2011-08

Am. J. Surg., 2013 Jul 01

J Surg Oncol, 2015 Oct 13

Nature, 2013 Aug 14

Journal of the National Cancer Institute, 2013-08-21

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010-02

Nature genetics, 2016-04

J. Urol., 2012 Nov 15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-07-20

Lancet Oncol., 2018 Feb 12

Blood, 2016-07-28

Blood advances, 2016-12-27

Cancer, 2016-10

Blood, 2017-08-31

Biol. Blood Marrow Transplant., 2019 Aug 22

Cancer, 2008-10-15

The Lancet. Oncology, 2018-02

Chinese clinical oncology, 2015-03

JAMA surgery, 2018-01-17

J Clin Oncol, 2020 May 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-07-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-10-01

Journal of the National Cancer Institute, 2012-02-08

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-04

Cancers (Basel), 2021 Jan 15

ESMO Open,

J. Clin. Oncol., 2009 Sep 28

Lancet Oncol, 2020 Apr 27

Journal of cutaneous pathology, 2014-11

Journal of the National Cancer Institute, 2005-11-16

Front Endocrinol (Lausanne), 2020 Apr 29

Case Rep Pathol, 2016 Oct 20

Breast Care (Basel),

Lancet Oncol, 2020 Mar 20

Leukemia & lymphoma, 2017-12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-01-01

Int. J. Radiat. Oncol. Biol. Phys., 2012 Jul 24

The Lancet. Oncology, 2017-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-03-10

N Engl J Med,

Lancet Oncol., 2017 May 09

Lancet Oncol., 2014-04-01

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2016-04

Blood, 2018 Jul 12

Ann. Intern. Med., 2019 Oct 15

N Engl J Med, 2019 Oct 31

Ann. Rheum. Dis., 2019 Sep 20

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012-12-15

,

J. Clin. Oncol., 2016 Jan 19

JCO precision oncology, 2019

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2016-07

Clin Lung Cancer, 2020 Feb 10

JTO Clin Res Rep, 2020 May 13

Lancet Oncol.,

Blood Transfus, 2018 Oct 24

J Thromb Haemost, 2018 May 08

Clin Lymphoma Myeloma Leuk, 2020 Mar 06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-01-20

J Clin Oncol,

Liver Cancer, 2019 Sep 18

AJR Am J Roentgenol,

N Engl J Med,

British journal of cancer, 2011-06-07

N Engl J Med, 2021-04-01

J Hematol Oncol, 2018 Jan 16

Blood, 2017-07-06

The Lancet. Oncology, 2019-06

Cancer, 2020 Jun 10

Journal of surgical oncology, 2017-06

Leukemia, 2016-04

Leukemia & lymphoma, 2018-07

Blood,

Blood, 2016 Dec 27

Blood, 2008-05-15

The New England journal of medicine, 2019-02-21

J Thromb Haemost, 2019 Jul 28

N Engl J Med, 2018 Dec 04

Lancet, 2020 Sep 20

Blood, 2015-10-29

JAMA oncology, 2018-09-01

Human pathology, 2019-06

Oncoimmunology, 2018

Lancet, 2019 Jun 03

Blood,

BJR Case Rep, 2018 Sep 08

Blood, 2018 Apr 5

N Engl J Med,

The New England journal of medicine, 2017-02-02

Blood, 2009 Nov 10

Breast cancer research and treatment, 2015-11

Breast Cancer Res Treat, 2020 May 20

Pathol Oncol Res, 2017 Sep 11

J Clin Oncol, 2020 Jan 13

Chest, 1975-12

Clin Nephrol,

Blood, 2019-01-24

J Thorac Oncol, 2019 Nov 18

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-10-10

N Engl J Med,

Annals of oncology : official journal of the European Society for Medical Oncology, 2000-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-03-15

Clin Nutr, 2015 Aug 28

JAMA ophthalmology, 2016-08-01

Clinical nuclear medicine, 2015-11

Surgery, 2016-01

J Nucl Med, 2012 Sep 17

Cardiovasc Intervent Radiol, 2019 Oct 23

Eur J Nucl Med Mol Imaging, 2018 Sep 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-10

JAMA network open, 2018-11-02

Obstet Gynecol,

JAMA,

Cancer Prev Res (Phila), 2019 Aug 16

The New England journal of medicine, 2018-03-22

Lancet Oncol, 2016 May 20

Lancet Oncol,

BMC Cancer, 2014 Sep 15

JAMA Oncol,

Eur Urol, 2019 Feb 28

Medicine (Baltimore),

Mod Pathol, 2017 Jan 06

Clin Lymphoma Myeloma Leuk, 2017 Mar 07

Seminars in oncology, 2018-08

Endocrine-related cancer, 2016-09

Pancreas, 2017-07

JAMA Oncol, 2020 Apr 16

Pancreas, 2020 Jan

Surg Oncol Clin N Am, 2020 Oct 20

Scand J Gastroenterol, 2019 Aug 01

J Am Coll Surg, 2017 Jan 11

J Clin Oncol, 2018 Jun 07

Leuk Lymphoma, 2011 Dec 13

Breast cancer research : BCR, 2004

ESMO Open,

Journal of the National Cancer Institute, 2011-10-05

BMC Cancer, 2018 Oct 12

Blood, 2018 Jun 18

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005-02-01

Urology, 2001-08

American journal of hematology, 2011-10

The American journal of medicine, 2017-12

American journal of hematology, 2018-05

Am J Hematol, 2020 Jun 29

Am J Hematol, 2019 Sep

Am J Hematol, 2019 Sep

Am J Hematol, 2018 Jun

JAMA,

Br J Cancer,

The New England journal of medicine, 2016-03-03

Cancer immunology, immunotherapy : CII, 2017-01

Cancer, 2017-06-01

Journal of the American Academy of Dermatology, 2019-07-11

J Immunother,

Oncologist, 2020 Feb 11

Eur J Intern Med, 2008 Jun 10

Clinical genitourinary cancer, 2017-02

Journal of immunotherapy (Hagerstown, Md. : 1997), 2014-04

Journal for immunotherapy of cancer, 2019-02-18

N Engl J Med,

JAMA Oncol,

J Vasc Interv Radiol, 2020 Sep 09

Breast cancer research and treatment, 2018-09

Blood, 2015 Dec 22

Contraception, 2016 May 03

Cancer, 2017-10-01

Pancreas, 2010-08

Annals of surgical oncology, 2006-03

Neuroendocrinology, 2012 Feb 15

Neuroendocrinology, 2015 Sep 10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-09

J Thorac Dis,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-07

Gastroenterology clinics of North America, 2018-06

Eur J Cancer, 2015 Jun 08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10

Blood, 2017 Jan 19

Int. J. Radiat. Oncol. Biol. Phys., 2019 May 11

The American surgeon, 2001-06

J Clin Oncol, 2014 Mar 24

J Natl Cancer Inst,

Ann Surg Oncol,

Clin Oncol (R Coll Radiol), 2017 Nov 16

Blood Cancer J, 2018 Feb 09

Blood, 2017 May 08

The journal of allergy and clinical immunology. In practice, 2017

J. Clin. Oncol., 2020 Sep 20

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-08

Lancet, 2010-03-06

Lancet,

Gynecol Oncol Rep, 2020 Jan 30

World J Surg Oncol, 2017 Jan 10

Archives of surgery (Chicago, Ill. : 1960), 2008-07

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018-01

Ann Surg,

Therapeutic advances in hematology, 2012-04

J Clin Oncol, 2021 Jan 13

N Engl J Med, 2022 Sep 12

Front Oncol, 2023 Jan 04

Br J Dermatol, 2015 Aug 08

Breast J, 2019 Jul 04

Journal of the American College of Surgeons, 2016-04

Urol Oncol, 2021 Jul 20

N Engl J Med,

Cancers (Basel), 2020 Sep 14

Am J Surg, 2020 Nov 04

Leukemia, 2020 May 07

Blood, 2018 Sep 6

J Clin Oncol, 2017 Mar 14

The New England journal of medicine, 2017-02-02

Lancet Oncol., 2016-06-01

JAMA Oncol, 2020 Mar 26

Lancet, 2020 Sep 28

Lancet Oncol,

Lancet Oncol,

Breast cancer research and treatment, 2011-10

Cancer Treat Rev, 2013 Jun 10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014-06

Radiother Oncol, 2020 Jul 31

N Engl J Med, 2020 Apr 28

Mod Pathol, 2021 Jan 18

Cancer discovery, 2015-07

J Immunother Cancer,

J Clin Oncol, 2019 Sep 18

Leukemia, 2009-05

Haematologica, 2019 Oct 03

Clin Cancer Res, 2019 Sep 12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998-01

Annals of surgery, 1982-09

J Clin Oncol, 2020 Dec 23

Lancet Oncol,

Advances in radiation oncology, 2018

Journal of clinical pharmacology, 2010-04

BJU Int, 2011 Oct

Anticancer Drugs,

Cancer, 2010-11-15

Ann Oncol, 2010 Feb 12

European journal of cancer (Oxford, England : 1990), 2019-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-06-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-20

J. Clin. Oncol., 2020 Jun 02

N Engl J Med, 2021 Mar 4

Cancer, 2000-03-15

Front Oncol, 2020 Dec 03

Lancet Oncol, 2021 Mar 18

Lancet Oncol, 2015 Jun 23

Ann Hematol, 2020 Apr 19

Annals of surgical oncology, 2018-07

Clinical genitourinary cancer, 2018-12

Ann Oncol, 2020 Sep 29

J Clin Oncol, 2021 Apr 26

Eur J Cancer, 2019 Feb 13

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-11-20

Oncologist, 2020 Dec 01

Blood, 2020 Sep 23

Lancet Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-08

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999-02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-01

Cancer Cell, 2018 May 03

Expert Opin Emerg Drugs, 2020 Aug 04

Lung Cancer, 2020 Sep 10

J Clin Oncol, 2018 Aug 14

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2011-03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-02-01

Cancer Epidemiol Biomarkers Prev, 2012 Apr 26

Blood, 2020 Sep 10

Blood Adv,

The Lancet. Oncology, 2018-03

The Lancet. Oncology, 2019-06

J Hematol Oncol, 2016 Jun 03

The Lancet. Oncology, 2017-11

Laryngoscope, 2014 Jul

The New England journal of medicine, 2018-07-05

J Gastroenterol, 2019 Nov 12

Am Heart J, 2010 Sep 18

N Engl J Med,

The Lancet. Oncology, 2019-02

Hepatology, 2019 Oct 14

Blood, 2015 Sep 17

Cancer cell, 2018-05-14

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-07-01

Lancet Oncol, 2020 Sep 10

JAMA Oncol,

Cancer Discov, 2020 Nov 02

J Gastrointest Oncol,

Hum Mutat,

Ann. Surg. Oncol., 2017 May 30

Gut,

Clin Imaging, 2021 Feb 10

N Engl J Med,

Lancet Oncol, 2021 Mar 12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Oct 11

The New England journal of medicine, 2024 Sep 15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-20

British journal of cancer, 2016-03-29

Blood, 2013-12-05

Blood Adv,

Blood,

Pediatric blood & cancer, 2017-04

N Engl J Med,

Cancer, 2010-05-15

JAMA Oncol, 2021 Feb 18

Pancreatology, 2020 Oct 18

Lancet (London, England), 2016-02-06

European journal of cancer (Oxford, England : 1990), 2019-02

Clinical breast cancer, 2008-06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-06-20

Endocr Relat Cancer,

J Nucl Med, 2018 Aug 16

Eur J Nucl Med Mol Imaging, 2017 Sep 12

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2016-12

Head Neck,

Clinical genitourinary cancer, 2017-06

The Journal of urology, 2014-02

Blood, 2013 Sep 19

The Lancet. Haematology, 2015-09

Haematologica, 2017-07

Thrombosis, 2013

Thrombosis journal, 2023 Oct 26

Annals of oncology : official journal of the European Society for Medical Oncology, 2014-12

International journal of radiation oncology, biology, physics, 2018-09-01

Cancer Med, 2021 Jan 19

JAMA oncology, 2018-02-01

J Immunother Cancer,

Cancer discovery, 2015-08

Lancet Oncol, 2021 Dec 15

Nature, 2019 Oct 30

N Engl J Med, 2021 Jun 04

The New England journal of medicine, 2018-11-22

Lancet, 2017 Jan 24

Journal of the National Cancer Institute, 2007-05-02

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2018-02

Support Care Cancer, 2020 May 06

J Oncol Pract,

Hematol Oncol, 2017 Oct 30

Circulation, 2020 Feb 17

The New England journal of medicine, 2012-09-06

The New England journal of medicine, 2023 Oct 19

European urology oncology, 2023 Oct 09

European journal of cancer (Oxford, England : 1990), 2018-01

J Clin Oncol, 2020 Jun 18

Clin Lung Cancer, 2021 Jan 27

Case Rep Oncol, 2019 Oct 09

J Clin Oncol, 2019 Dec 06

Lancet Oncol, 2020 Mar 11

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2019 Mar 20

American journal of hematology, 2019-04

Seminars in radiation oncology, 1993-01

Radiother Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-05-15

J Clin Oncol, 2016 Dec 28

The Lancet. Oncology, 2014-09

Cancer Sci,

Radiother Oncol, 2020 Apr 01

The Lancet. Oncology, 2012-02

International journal of radiation oncology, biology, physics, 2016-11-01

Cancer, 2018-07-15

J Clin Oncol, 2012 Feb 13

Ann Oncol, 2013 Apr 04

Cancer, 2018 Sep 14

Journal of the National Cancer Institute, 1988-07-06

Annals of oncology : official journal of the European Society for Medical Oncology, 2015-02

Anticancer Drugs,

J Adolesc Young Adult Oncol, 2019 Nov 08

CPT Pharmacometrics Syst Pharmacol, 2019 Nov 20

Lancet,

Lancet Oncol, 2019 Dec 16

N Engl J Med,

Lancet,

ESMO Open, 2021 Oct 01

J Clin Oncol, 2021 Apr 19

Lancet Oncol, 2021 Jan 18

PLoS One, 2021 Apr 08

Lancet Haematol, 2020 Oct 01

Lung cancer (Amsterdam, Netherlands), 2012-12

N Engl J Med,

Blood,

Cancers (Basel), 2019 Dec 25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-02-01

J Clin Oncol, 2013 Nov 12

Blood Adv,

Future Oncol, 2021 Feb 03

Ann Rheum Dis,

European urology, 2017-07

Bone Marrow Transplant, 2019 Oct 01

Front Immunol, 2020 Apr 03

Breast Cancer Res, 2020 Nov 04

Breast Cancer Res Treat, 2011 Jul 27

Clin Breast Cancer, 2019 May 24

Lancet,

J Thorac Oncol, 2021 Jul 08

N Engl J Med,

J Clin Oncol, 2020 Sep 16

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-12-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-07-10

Blood, 2007-01-15

Blood,

Blood, 2017 Jan 27

J Clin Oncol, 2021 Jan 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-10

Breast, 2011 Sep 08

Sci Rep, 2019 Dec 02

Gastric Cancer, 2013 Feb 28

J Clin Oncol, 2012 May 1

Oncologist, 2020 Dec 03

International journal of radiation oncology, biology, physics, 2018-10-01

Blood, 2021 Mar 08

Annals of surgery, 2014-05

J. Clin. Oncol., 2006-03-01

The New England journal of medicine, 1992-12-03

Ann Oncol,

JAMA Oncol,

N. Engl. J. Med.,

Lancet (London, England), 2017-10-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-10

J Clin Oncol, 2019 Nov 04

Lancet Oncol, 2021 Apr 09

Gynecologic oncology, 2016-01

Gynecol Oncol, 2020 Jul 9

Gynecol Oncol, 2020 Jul 25

J Clin Oncol, 2021 Mar 08

International journal of radiation oncology, biology, physics, 2011-01-01

Lancet (London, England), 2009-03-07

International journal of radiation oncology, biology, physics, 1989-02

Int J Radiat Oncol Biol Phys,

The New England journal of medicine, 2016-07-14

Practical radiation oncology, 2021 Sep-Oct

Palliative medicine, 2022 Mar 31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Mar 28

Am J Kidney Dis, 2019 Aug 05

J BUON,

Br J Cancer, 2019 Sep 30

J. Clin. Oncol., 2008-07-20

The Lancet. Oncology, 2017-12

Pract Radiat Oncol, 2022 Oct 22

N Engl J Med, 2019 Sep 28

Blood, 2013-10-24

The Lancet. Oncology, 2011-08

The Lancet. Oncology, 2018-03

J Clin Oncol, 2021 Apr 07

The New England journal of medicine, 2007-10-25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998-04

N Engl J Med,

Urology, 2000-11-01

Abdom Radiol (NY), 2019 Aug 29

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000-04

British journal of haematology, 2018-07

J Geriatr Oncol, 2021 Mar 06

Leukemia, 2018 Apr 25

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 27

JAMA oncology, 2018-12-01

Cancer discovery, 2017-03

Annals of oncology : official journal of the European Society for Medical Oncology, 2005-08

J Clin Oncol, 2020 Oct 27

Annals of Oncology, 2021 Sep 29

Gynecologic oncology, 1998-08

Ann Oncol, 2007 Nov 15

Cancer Manag Res, 2012 Jun 13

Ann Oncol, 2007 Feb 13

Int. J. Radiat. Oncol. Biol. Phys., 2011 Jun 15

Cancer, 2004-12-01

J Clin Oncol, 2021 Feb 04

Clin Cancer Res, 2020 Jul 21

NPJ breast cancer, 2023 Oct 23

Neuro-oncology, 2023 Jan 05

Leuk Lymphoma, 2019 Nov 04

Blood, 2011-05-05

Haematologica, 2016 Dec 01

Blood Cancer J, 2021 May 12

Leuk Lymphoma, 2019 Nov 18

Blood, 2013-10-03

Leukemia, 2019-09

Ann Oncol, 2019 Oct 1

Int J Cancer, 2020 Dec 21

Adv Ther, 2020 Oct 29

Annals of surgical oncology, 2010-10

Br J Cancer, 2014 Jun 10

Cochrane Database Syst Rev, 2010 Nov 10

Blood, 2016-01-21

Seminars in hematology, 2013-07

EMBO Mol Med, 2020 Apr 29

J Oncol, 2020 Jun 24

Oncologist, 2018 Dec 12

J Clin Oncol, 2020 Jul 13

J Thorac Oncol, 2016 Apr 16

J Thorac Oncol, 2018 Jun 05

J Clin Oncol, 2021 Mar 01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-11

Ann Oncol, 2020 Nov 20

J Immunother Cancer, 2021 Feb

J Natl Compr Canc Netw,

Ann Oncol,

J Immunother Cancer,

J Immunother Cancer,

J Clin Oncol, 2021 Dec 20

J Natl Compr Canc Netw,

JAMA Oncol,

JAMA, 2010-03-17

International journal of radiation oncology, biology, physics, 2015-06-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-20

Chest, 2003-11

J Immunother Cancer,

Oncotarget, 2018 Feb 22

J Thorac Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-12-10

Pediatr Blood Cancer, 2019 Jul 24

Thromb Haemost,

J Clin Oncol, 2012 Jul 16

N Engl J Med, 2018 Mar 29

Lancet, 2021 May 07

N. Engl. J. Med., 2016-10-13

J Urol, 2020 Apr 13

Eur J Nucl Med Mol Imaging, 2020 Aug 12

J Urol,

N Engl J Med, 2021 Apr 14

Gynecologic oncology, 2019-06

Gynecol Oncol, 2021 Mar 05

The Lancet. Oncology, 2017-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-20

JAMA Oncol,

J Clin Oncol, 2020 Jun 17

Ann Surg Oncol, 2019 Jul 24

J Clin Oncol, 2020 Mar 03

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-02-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-20

Cancer, 2021 Mar 15

J Clin Oncol, 2015 Nov 1

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Jan 04

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-04-01

BMC Cancer, 2018 Mar 07

N Engl J Med,

JCO Oncol Pract, 2022 Jan 07

Lancet Oncol, 2020 Aug 27

Hepatology (Baltimore, Md.), 2018-08

Radiology, 2018-06

Hepatology, 2021 Mar 19

JAMA Oncol,

BMC Cancer, 2016 Jul 19

J Clin Oncol, 2021 Jun 02

The lancet. Gastroenterology & hepatology, 2023 Sep 18

The New England journal of medicine, 2024 Sep 14

Annals of oncology : official journal of the European Society for Medical Oncology, 2013-11

Int J Radiat Oncol Biol Phys, 2015 Jan 30

J Nucl Med, 2011 Jul 15

BMC Cancer, 2016 May 18

Eur J Cancer, 2021 Apr 29

Lancet Oncol, 2020 Jan

N Engl J Med, 2021 Feb 13

Am J Transplant, 2016 Jun 09

Transplantation, 2021 Apr 27

Surgery, 2017 Jun 16

N. Engl. J. Med., 2009-06-11

Lancet Oncol, 2010 Oct 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-04-10

Prostate Cancer Prostatic Dis, 2020 May 13

The Lancet. Oncology, 2018-11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-07-10

The New England journal of medicine, 1980-11-13

The Prostate, 2019-09

J Urol, 2020 Dec 28

Clin Sarcoma Res, 2013 Dec 18

Int J Radiat Oncol Biol Phys, 2020 Apr 11

Br J Cancer, 2020 Jun 26

Clinical genitourinary cancer, 2018-06

Cancer treatment and research communications, 2019

Prostate Cancer Prostatic Dis, 2020 Feb 28

Cancer, 2019 Dec 1

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-09-20

Practical radiation oncology, 2015

J Clin Oncol, 2021 Feb 02

J Natl Cancer Inst,

Lancet Oncol, 2021 May 04

The New England journal of medicine, 2009-01-08

Am J Surg, 2020 Aug 16

Eur J Endocrinol, 2013 Apr 15

Jpn J Clin Oncol, 2013 Dec 22

Pancreas,

J Clin Endocrinol Metab,

J Endocrinol Invest, 2018 Jun 09

Cancer, 2020 May 19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-02-01

Cancer, 2020 Mar 15

J Clin Oncol, 2021 Apr 06

Bladder Cancer, 2020 Mar 28

Human pathology, 2013-04

Urol Oncol, 2014 Jul 30

Br J Cancer, 2021 Jan 21

Lancet (London, England), 2016-04-09

The Lancet. Oncology, 2019-06

Lancet Oncol,

European journal of haematology, 2017-04

J Allergy Clin Immunol Pract, 2021 Feb 03

Eur J Haematol, 2020 May 18

Br J Haematol, 2019 Nov 13

Br J Haematol, 2021 Jun 08

N Engl J Med,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-09-01

Lancet Oncol, 2021 May 14

Strahlenther Onkol,

Eur J Cancer, 2021 Apr 01

Lancet Oncol, 2019 Oct 25

Nat Rev Urol, 2021 Apr 06

Eur Urol, 2020 Dec 03

Ann Oncol,

J Clin Oncol, 2021 Jun 06

Br J Radiol, 2018 Mar 20

Eur J Nucl Med Mol Imaging, 2013 Sep 13

BMC Cancer, 2019 Aug 08

Scand J Gastroenterol, 2021 Jan 20

Int J Endocrinol, 2021 Jan 23

Cancer Treat Rev, 2020 Dec 22

JAMA Oncol,

Lancet, 2021 Jun 05

Human pathology, 2016-03

Lancet Oncol, 2020 Aug 06

Immunotherapy, 2019 Jun 12

Nat Rev Clin Oncol, 2020 Aug 05

Curr Health Sci J, 2018 Jan 05

Clin Cancer Res, 2020 Mar 6

American journal of clinical and experimental urology, 2014

The Prostate. Supplement, 1998

The Prostate, 2001 May 15

Clinical nuclear medicine, 2017 Jan

Medicine (Baltimore),

Clin Cancer Res,

Ann Oncol, 2021 Mar 18

The New England journal of medicine, 2019-03-28

Clin Cancer Res, 2019 Sep 11

J Clin Oncol, 2021 Jul 26

Strahlenther Onkol, 2017 Jun 01

Lancet Oncol, 2019 Oct 16

JAMA Oncol,

Nature communications, 2019-04-23

Blood, 2012 Aug 13

J Clin Oncol, 2020 Apr 16

Blood,

Blood,

Biochemistry, 2015 Jul 06

N Engl J Med, 2019 Nov 21

Lancet Oncol, 2016 Apr 12

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013-01

Future Oncol, 2018 Nov 08

World J Clin Cases,

Br J Cancer, 2016 Nov 22

Melanoma research, 2017-06

JAMA Dermatol,

Pathology, 2018 Nov 26

Semin Cancer Biol, 2019 Oct 23

J Natl Cancer Inst, 2011 Jul 09

Br J Clin Pharmacol, 2020 Jun 02

Clin Transl Oncol, 2020 Sep 17

J Assist Reprod Genet, 2020 Jun 02

Lancet Oncol, 2018 Sep 13

Int J Radiat Oncol Biol Phys, 2019 Dec 1

Pract Radiat Oncol, 2020 Oct 21

International journal of radiation oncology, biology, physics, 1988-02

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2017-08-01

Eur J Cardiothorac Surg, 2014 Nov 18

J Thorac Cardiovasc Surg, 2019 Sep 30

Nephron,

ESMO Open, 2017 Jul 19

Ann Oncol,

Am J Surg Pathol, 2021 Jun 10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-02-20

Lancet (London, England), 2010-12-11

Blood, 2012 Apr 04

Clin Lymphoma Myeloma Leuk, 2019 Sep 30

Bone Marrow Transplant, 2018 Jun 08

Eur J Cancer, 2020 Jun 27

The Journal of urology, 1997-11

The Journal of urology, 2004-07

BJU Int,

Am J Surg Pathol,

Journal of the National Cancer Institute, 2006-01-18

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2008-03

BMC Cancer, 2020 Jan 29

International journal of radiation oncology, biology, physics, 2019-12-01

The Lancet. Oncology, 2019-01

Molecular therapy : the journal of the American Society of Gene Therapy, 2018-11-07

Cancer immunology research, 2019-07

Br J Haematol, 2020 Mar 5

Lancet, 2020 Sep 01

Blood Adv,

Int J Radiat Oncol Biol Phys, 2020 May 22

Radiother Oncol, 2021 Dec 7

Int J Radiat Oncol Biol Phys, 2021 Dec 1

Int J Radiat Oncol Biol Phys, 2022 Dec 20

Transplant Cell Ther, 2022 Dec 30

Blood advances, 2020 Jul 28

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2022 Oct 26

Blood advances, 2020 Nov 24

Haematologica, 2023 Jun 15

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011-10-01

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2015-01

Lung Cancer, 2020 Nov 13

Neuropathology, 2019 Mar 13

Respir Investig, 2014 Nov 13

BJU international, 2014-12

Bladder cancer (Amsterdam, Netherlands), 2017-07-27

Am J Hematol, 2021 Jun 29

European urology, 2014-07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001-02-01

Nature, 2021 Jun 16

European urology, 2005 Apr 25

Leukemia, 2023 May 05

PLoS One, 2013 Oct 09

European urology focus, 2018-12

Int J Radiat Oncol Biol Phys, 2015 Jul 15

Clin Genitourin Cancer, 2019 Mar 28

Int J Radiat Oncol Biol Phys, 2021 Feb 06

Circulation, 1995-08-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-01

Endocrine-related cancer, 2018-03

N Engl J Med,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-07-01

International journal of radiation oncology, biology, physics, 1990-05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-01-01

Ann Oncol,

Lancet, 2021 Jan 21

Ann Oncol,

The New England journal of medicine, 2018-11-08

Eur J Haematol, 2021 Aug 11

Lancet Oncol, 2020 Oct 29

Blood Adv, 2021 Sep 01

Cell,

Am J Hematol, 2021 Jul 05

The Lancet. Oncology, 2017-09

J Clin Oncol, 2020 Apr 10

Lancet Oncol, 2021 May 26

N Engl J Med, 2020 Sep 18

The Lancet. Oncology, 2018-07

Blood Cancer J, 2020 Mar 09

JAMA Oncol,

JAMA, 2016-11-15

N Engl J Med,

J Clin Oncol, 2019 Apr 10

J Clin Oncol, 2020 Feb 21

J Clin Oncol, 2020 Oct 06

Cancers (Basel), 2019 Jul 31

N Engl J Med, 2021 Apr 22

J. Clin. Oncol., 2021 Aug 10

N Engl J Med,

Thromb Res, 2021 Jun 25

Blood, 2016-07-14

Blood, 2016 Sep 26

The Lancet. Oncology, 2021 Oct 13

The Lancet. Haematology, 2023 Sep 11

Clin Breast Cancer, 2020 Oct 06

Mol Cell Endocrinol, 2021 Jan 26

Lancet (London, England), 2004-02-07

European journal of cancer (Oxford, England : 1990), 2012 Aug 11

J Am Coll Surg, 2020 Jul 19

JCO Oncol Pract, 2020 Aug 21

J Clin Oncol, 2020 Jul 14

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-06-20

J Clin Oncol, 2019 Dec 19

Ann Oncol,

Cancer, 2018-02-15

Clin Colorectal Cancer, 2020 Dec 17

Cancer, 2016-09-01

JAMA Oncol,

Ann Surg, 2021 Jul 16

Mayo Clin Proc,

Neurol Sci, 2021 Sep 16

Cancer Discov, 2021 Aug 17

Ann Oncol, 2021 Mar 16

Annals of oncology : official journal of the European Society for Medical Oncology, 2001-09

Cochrane Database Syst Rev, 2021 May 26

Clin Cancer Res, 2020 Jan 1

JAMA Oncol, 2019 Sep 29

J Clin Oncol, 2021 Mar 26

Cancer, 1987 Aug 15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-06-01

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2004

Cochrane Database Syst Rev, 2011 Jun 15

Arch Gynecol Obstet, 2009 Mar 21

Strahlenther Onkol, 2011 Nov 17

Gynecol Oncol Res Pract, 2016 Jun 17

Indian J Med Paediatr Oncol,

J Clin Oncol, 2020 Sep 29

N Engl J Med, 2022 Jun 05

J Clin Oncol, 2022 May 18

The New England journal of medicine, 2023 Jun 01

Lancet (London, England), 2023 Aug 23

Seminars in oncology, 2018-08

Pancreas, 2020 Aug

Neuroendocrinology, 2021 Feb 02

The American journal of surgical pathology, 2008-01

Int J Part Ther, 2021 Jun 25

J Thromb Thrombolysis,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-10-10

JAMA Oncol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-12-01

BJS open, 2021 Nov 09

Journal of clinical pathology, 2017-09

Leukemia, 2018-06

Journal of the National Comprehensive Cancer Network : JNCCN, 2017-10

N Engl J Med,

Lancet Haematol, 2020 Jan 31

Int J Cancer, 2018 May 10

Annals of surgery, 2009-05

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-06-01

J Thorac Oncol, 2019 Nov 19

Future Oncol, 2021 Feb 11

Haematologica, 2021 Jun 01

Transfusion, 2020 Sep 24

Lancet Haematol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011-05-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-01-10

J Urol, 2021 Feb 26

Eur Urol, 2021 Apr 16

The Lancet. Oncology, 2023 Jul 11

European urology, 2019-06

Cancer, 2020 Nov 20

Gynecologic oncology, 2011-07

BMC Cancer, 2018 May 04

Gynecol Oncol, 2017 Sep 24

J Thorac Oncol, 2020 Jan 13

J Immunother Cancer, 2019 Jan 21

ESMO Open, 2021 Aug 31

Annals of surgical oncology, 2019-04

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017-05

Transplant Proc,

Clin Cancer Res, 2017 Mar 07

Lancet Oncol, 2019 Dec 11

Ann Oncol,

The New England journal of medicine, 2015-11-05

Haematologica, 2018 May 24

Blood,

Leukemia, 2011 Jul 01

Haematologica, 2019 Sep 19

Blood, 2017 Aug 17

Blood, 2015 May 28

Cancer,

BMC Cancer, 2020 Aug 12

Eur J Cancer, 2012 Nov 19

BJU international, 2011-09

Cancer, 2009-09-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-04-01

Clinical genitourinary cancer, 2016-02

Cancer, 2019-05-01

Int Urol Nephrol, 2007 Mar 02

Clin Genitourin Cancer, 2017 Jul 22

Clin Genitourin Cancer, 2020 Feb 08

Eur Urol, 2019 Nov 08

J Clin Oncol,

Ann Oncol, 2007 Mar 09

Ann Oncol, 2022 Mar 23

Journal of the National Cancer Institute, 2011-11-16

Archives of pathology & laboratory medicine, 2016-01

Lancet Oncol,

J Clin Oncol, 2009 Apr 20

Clin Cancer Res,

JAMA oncology, 2019-03-01

Clin Lymphoma Myeloma Leuk, 2020 Mar 07

Clin Lymphoma Myeloma Leuk, 2021 Jul 18

Biomark Insights, 2016 Apr 21

Br J Haematol,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996-04

Andrology, 2014 Oct 01

Blood Cancer J, 2021 Jan 11

JAMA Oncol,

J Urol, 2020 Jul

Cancer, 2021 Apr 21

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993-03

Biomark Med, 2018 Dec 19

Biomark Med, 2019 Jun 25

British journal of haematology, 2014-06

International journal of radiation oncology, biology, physics, 2019-06-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2007-04

Blood, 2018-07-05

Blood,

Blood,

J Clin Oncol, 2021 Jun 25

The New England journal of medicine, 2004-09-02

J Rheumatol, 2019 Apr 01

RMD Open,

Clin Genitourin Cancer, 2021 Apr 19

Lancet Oncol, 2021 Oct 27

Eur Urol, 2020 Sep 13

Eur Urol Oncol, 2019 Sep 19

N Engl J Med,

N Engl J Med,

Annals of oncology : official journal of the European Society for Medical Oncology, 2012-06

Br J Cancer, 2019 Jan 17

American journal of clinical oncology, 2016-10

Journal of the American College of Surgeons, 2008-04

Annals of surgical oncology, 2013-05

Clinical breast cancer, 2016-04

International journal of radiation oncology, biology, physics, 2017-06-01

Oncology (Williston Park), 2021 Aug 13

Eur J Cancer, 2016 Dec 08

Oncologist,

Ann Oncol, 2021 Apr 22

J Thorac Oncol, 2020 Apr 30

Blood Cancer J, 2020 May 11

J Clin Oncol, 2021 Aug 03

Journal of the National Comprehensive Cancer Network : JNCCN, 2014-05

Haematologica, 2010-07

Exp Hematol, 2008 Nov

J Natl Compr Canc Netw, 2021 Mar 24

Annals of oncology : official journal of the European Society for Medical Oncology, 2020 Nov 25

The Lancet. Oncology, 2022 Sep 29

Acta Radiol Open, 2021 Apr 30

Breast Cancer Res Treat, 2018 Jul 04

Eur J Haematol, 2021 Feb 18

Journal of the National Cancer Institute, 2010-08-18

Lancet Oncol, 2021 Apr 20

Blood, 2019-06-06

Eur J Haematol, 2021 Feb 17

Proceedings of the National Academy of Sciences of the United States of America, 2011-06-07

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2017-01

European journal of nuclear medicine and molecular imaging, 2018-11

European urology oncology, 2018-05

J Nucl Med, 2021 Dec 16

J Nucl Med, 2018 Dec 14

Eur J Nucl Med Mol Imaging, 2019 Nov 15

Eur J Nucl Med Mol Imaging, 2019 Dec 26

JAMA Oncol,

J Urol, 2021 Feb 03

J Nucl Med, 2020 Jan 10

Clin Cancer Res, 2021 Feb 23

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-10

The Lancet. Oncology, 2016-07

N Engl J Med, 2016 Oct 08

The New England journal of medicine, 2019-06-06

Leukemia, 2022 Jan 01

Blood Adv,

Breast cancer research and treatment, 2010-08

Blood, 2018 Dec 13

J Clin Oncol, 2021 Jun 02

PLoS One, 2021 Mar 26

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2018-04

J Thorac Oncol, 2021 May 05

Breast cancer research and treatment, 2017-11

Front Genet, 2018 Dec 17

J Clin Oncol, 2021 Nov 02

Blood, 2008-07-15

N Engl J Med, 2017 Jun 1

Ann Intern Med,

Leukemia, 2021 Apr 28

Annals of surgery, 2004-10

Pediatric blood & cancer, 2007-02

Blood, 2021 Nov 15

Lancet Haematol, 2019 Sep 16

J Am Heart Assoc, 2020 Nov 23

Am J Hematol,

N Engl J Med, 2021 Sep 18

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2011-10

Journal of oncology practice, 2019-01

Support Care Cancer, 2021 Aug 16

Int J Radiat Oncol Biol Phys, 2021 Nov 20

Invest New Drugs, 2017 Oct 25

Arthritis Rheumatol, 2021 Apr 01

Lancet Oncol, 2019 Oct 23

The New England journal of medicine, 2024 Sep 15

Blood, 2011-09-15

Haematologica, 2011 Dec 01

Cancer Chemother Pharmacol, 2016 Jun 10

Clin Cancer Res, 2020 Aug 17

The New England journal of medicine, 2013-08-22

JAMA oncology, 2016-02

Annals of oncology : official journal of the European Society for Medical Oncology, 2017-02-01

Ann Oncol,

Immunology,

J Immunother Cancer, 2019 Jan 06

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2019-05

J Mol Diagn, 2017 Oct 19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008-07-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-06-01

Head & neck, 2014-05

J Thorac Oncol, 2021 Mar 04

JTO Clin Res Rep, 2021 Mar 09

J Transl Med, 2019 Feb 21

Lung Cancer, 2020 Jun 06

J Clin Oncol, 2016 Feb 29

Lancet Haematol, 2016 Dec 05

Lancet Oncol, 2022 Jan 21

N Engl J Med,

Lancet Oncol., 2011 May 17

J Clin Oncol, 2015 Sep 28

The New England journal of medicine, 1981-09-24

Ann Intern Med,

Cancer, 2011 Feb 01

Eur J Surg Oncol, 2021 Jul 31

BMJ Open, 2021 Sep 24

The Lancet. Oncology, 2013-04

Ann Surg,

Int J Radiat Oncol Biol Phys, 2021 Aug 01

J Clin Oncol, 2022 Jan 27

American journal of hematology, 2019-11

J Clin Oncol, 2011 Jan 31

J Natl Compr Canc Netw,

J Clin Oncol, 2022 Mar 17

Int J Gynecol Cancer, 2020 Dec 18

Transpl Int, 2010 May 20

Eur J Surg Oncol,

World J Surg, 2019 Apr

J Surg Oncol, 2020 Sep 24

World J Gastrointest Surg, 2019 Jun 27

JAMA, 2017-12-19

Neuro Oncol,

Cureus, 2022 Feb 01

Prostate cancer and prostatic diseases, 2018-04

JCO Precis Oncol, 2020

Lancet Oncol, 2019 Sep 09

Clinical cancer research : an official journal of the American Association for Cancer Research, 2013-03-01

J Clin Oncol, 2022 Sep 27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Sep 01

Nature medicine, 2023 Aug 17

Journal for immunotherapy of cancer, 2023 Mar

N Engl J Med, 2021 Jun 23

N Engl J Med, 2021 Dec 01

Clin Cancer Res, 2019 Nov 20

J Clin Oncol, 2021 Dec 03

Lancet Oncol, 2022 Jan 11

Lancet,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-11-01

BJU international, 2014-12

The Journal of urology, 2002-09

The New England journal of medicine, 2020 Jan 09

Lancet (London, England), 2023 Jun 10

Blood advances, 2023 Jul 25

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Feb 19

Pharmacotherapy, 2010-02

Obes Surg,

BMC Cancer, 2020 Feb 20

Cancer, 2019 Jul 18

J Clin Oncol, 2021 Dec 10

Front Oncol, 2018 Apr 17

Lancet, 2020 Sep 28

BMC cancer, 2019-06-13

Adv Radiat Oncol, 2020 Sep-Oct

Lancet Oncol, 2020 Aug 03

Nature, 2021 Dec 15

Br J Cancer, 2021 Feb 03

Hepatogastroenterology, 2013 Jan 16

Medicine (Baltimore),

Cancer Sci,

Oncotarget, 2017 May 10

Breast Cancer Res Treat, 2020 Sep 10

Lancet Oncol, 2022 Dec 06

J Clin Oncol, 2011 Oct 31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-02-20

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-03-10

J Clin Oncol, 2022 Jan 18

Hematology (Amsterdam, Netherlands), 2019-12

Expert review of anticancer therapy, 2009-01

Annals of the New York Academy of Sciences, 2001-12

J Clin Oncol, 2021 Aug 13

Head Neck, 2021 Jun 07

N Engl J Med, 2022 Feb 17

Brachytherapy, 2018

The New England journal of medicine, 2022 Feb 03

Blood advances, 2018-11-27

Blood advances, 2018-11-27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-05-10

Lancet, 2019 Dec 12

N Engl J Med, 2022 Jan 19

Gynecol Oncol, 2020 Nov 05

Blood, 2015-03-26

Clin Lymphoma Myeloma Leuk, 2019 Oct 09

JCO Oncol Pract, 2019 Nov 25

J Clin Oncol, 2018 Aug 28

Leukemia, 2021 Mar 02

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-03-01

J Clin Oncol, 2021 Aug 18

Lancet Oncol, 2010 Dec 07

J Immunother Cancer,

Lancet Reg Health West Pac, 2021 May 13

J Clin Oncol, 2021 Jan 28

J Clin Oncol, 2017 Jun 29

Lancet Haematol,

Leukemia, 2020 Jul 21

Pharmacotherapy, 2017 Jun 28

N Engl J Med, 2022 Apr 11

Haematologica, 2015-01

Blood advances, 2019-01-22

Am J Hematol, 2019 Apr 04

N Engl J Med,

Cancer Cell, 2020 Oct 08

J Gen Intern Med, 2021 Feb 02

JAMA Netw Open, 2020 Jun 01

Practical radiation oncology, 2019-03

J Urol,

J Clin Oncol, 2022 Mar 15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Feb 13

Oncologist, 2019 Apr

Eur J Cancer, 2022 Feb 21

Br J Cancer, 2021 Jan 21

Clin Cancer Res, 2022 Jan 19

JCO Precis Oncol, 2019 Nov 15

Lancet, 2022 Dec 06

Lancet Gastroenterol Hepatol, 2022 Feb 01

Cancer chemotherapy and pharmacology, 2003-07

J Oncol Pharm Pract, 2009 Sep 16

Cancer Treat Rep,

Ann Pharmacother, 2012 Jan 31

Am Soc Clin Oncol Educ Book,

Annals of surgical oncology, 2019-10

Sci Rep, 2022 Jan 20

Ann Oncol, 2006 Jun 01

NPJ Breast Cancer, 2022 Jan 13

Cancer, 2008 Oct 01

Breast Cancer Res Treat, 2017 Jun 24

The New England journal of medicine, 2013-10-31

ESMO Open, 2021 Nov 24

Clin Cancer Res, 2017 Dec 29

J Clin Oncol, 2022 Jan 19

Int J Cancer, 2021 Mar 18

The Lancet. Oncology, 2019-06

J Clin Oncol, 2020 Feb 14

JCO oncology practice, 2023 May 19

Ann Pharmacother, 2021 Jul 20

Ann Transl Med,

Can Fam Physician,

Clin Lymphoma Myeloma Leuk, 2020 Jul 29

World J Gastroenterol,

Prostate, 2022 Jun 08

Cancer Commun (Lond), 2019 Oct 21

Lancet Oncol, 2014 Oct 26

Blood cancer journal, 2016-07-29

Leukemia, 2022 Apr 11

Breast Cancer Res Treat, 2016 Feb 18

Mol Cancer Ther, 2018 Mar 28

Eur J Cancer, 2014 Aug 12

Clin Infect Dis,

The Lancet. Oncology, 2019-05

Nat Commun, 2021 May 03

Ann Surg, 2021 Aug 13

Lancet, 2021 Jun 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-03-01

Annals of oncology : official journal of the European Society for Medical Oncology, 2014-05

Annals of oncology : official journal of the European Society for Medical Oncology, 2017-10-01

N Engl J Med,

Front Oncol, 2020 Sep 25

Blood Adv, 2017 Jun 22

Cancer medicine, 2018-06

Gynecologic oncology, 2015-03

Gynecologic oncology, 1999-02

Gynecol Oncol, 2017 May 19

N Engl J Med, 2009 Jun 10

Cancer Res, 2020 Jul 08

Ann Oncol, 2013 Mar 01

N Engl J Med,

JAMA Netw Open, 2022 Feb 01

J Clin Oncol, 2021 May 03

The Lancet. Oncology, 2018-03

Nature medicine, 2019-01

J Immunother Cancer,

Cancer Discov, 2021 Sep 21

Blood, 2008-02-15

The Lancet. Haematology, 2018-12

Lancet Oncol, 2020 Jun 05

J Clin Oncol, 2019 Nov 06

Br J Cancer, 2008 Feb 12

Lancet,

Eur Urol, 2015 Dec 17

BJU Int, 2016 Nov 12

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-05-20

J Neurosurg, 2009 Aug

J Clin Oncol, 2020 Jul 24

Ann Surg,

J Clin Oncol, 2020 Mar 02

N Engl J Med, 2022 Dec 11

J Clin Oncol, 2022 Dec 22

Blood Adv, 2022 May 10

Blood, 2022 Dec 15

Translational oncology, 2019-02

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015-04

Pediatr Blood Cancer, 2019 Jul 31

Nat Med, 2020 Apr 06

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013-10-10

JAMA oncology, 2018-03-01

J Clin Oncol, 2015 Nov 02

J Natl Cancer Inst, 2016 Feb 01

International journal of radiation oncology, biology, physics, 2006-07-15

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012-04

Oncotarget,

Virchows Archiv : an international journal of pathology, 2012-10

Eur Respir J, 2017 Oct 12

American journal of hematology, 2020 Dec 08

Blood cancer journal, 2023 Oct 11

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-10-10

Lancet, 2019 Feb 08

J Immunother Cancer,

N Engl J Med, 2022 Jun 05

N Engl J Med, 2022 Jun 04

Lancet, 2021 Feb 11

Clin Cancer Res, 2020 Oct 27

Future Oncol, 2021 Jan 11

N Engl J Med, 2022 Jun 03

J Clin Oncol, 2021 Mar 19

N Engl J Med, 2022 Jun 05

N Engl J Med, 2022 Jun 05

International journal of radiation oncology, biology, physics, 2014-03-01

BMC Cancer, 2021 May 27

N Engl J Med, 2022 Jun 03

Ann Oncol, 2021 Jul 01

BMC Cancer, 2010 Aug 09

N Engl J Med,

Oncologist,

J Clin Oncol, 2022 Jan 14

Eur J Cancer, 2021 Nov 17

J Immunother Cancer, 2020 Dec

Virchows Arch, 2022 Aug 16

J Thorac Oncol, 2017 Oct 31

J Nucl Med, 2021 Jun 24

Oncotarget, 2017 Feb 25

BMC Cancer, 2020 Mar 18

Int J Surg Pathol, 2021 Jun 28

Int J Mol Sci, 2020 Sep 03

The New England journal of medicine, 2024 Sep 15

The New England journal of medicine, 1987-12-10

Korean J Intern Med, 2020 Feb 28

Clin Cancer Res, 2010 May 11

Cancer Chemother Pharmacol, 2014 Jun 17

Breast Cancer Res Treat, 2020 Jul

JCO Oncol Pract, 2021 Aug

Eur. J. Cancer, 2015-03-01

The American journal of medicine, 1997-01

Blood, 2019 Jul 25

Haematologica, 2019 Aug 14

Blood,

J Clin Oncol, 2022 Jun 06

Journal of hospital medicine, 2018-08-01

Front Oncol, 2022 Mar 09

BMJ Support Palliat Care, 2022 Jul 08

Nutr Cancer, 2019 Oct 12

Annals of oncology : official journal of the European Society for Medical Oncology, 2024 Jul 08

N Engl J Med,

Int J Radiat Oncol Biol Phys, 2022 Jul 04

Gynecologic oncology, 2017-02

Lancet Oncol, 2014 Sep 28

Lancet Oncol, 2012 Nov 16

Lancet Oncol,

International journal of radiation oncology, biology, physics, 2015-06-01

Lancet Oncol,

Eur Urol, 2020 Jun 09

Nat Rev Clin Oncol,

N Engl J Med,

Eur J Cancer, 2021 Sep 15

Thorac Cancer, 2020 Feb 11

J Immunother Cancer,

JAMA Oncol,

BJU Int, 2022 Apr 03

Int J Radiat Oncol Biol Phys, 2020 Sep 11

Lancet Oncol, 2022 Jan 17

Prostate Int, 2019 Feb 22

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-10-01

Arthritis care & research, 2018-10

J Natl Compr Canc Netw, 2021 Aug 24

J Neuroendocrinol, 2022 Apr 05

Neuroendocrinology, 2019 Sep 17

Pancreas,

J Clin Oncol, 2021 Jan 26

J Urol, 2019 Sep 06

Lancet,

J Clin Oncol, 2020 Dec 11

Lancet Oncol,

Ann Oncol, 2021 Feb 19

JCO precision oncology, 2022 Jul

J Clin Oncol, 2022 Mar 22

Clinical cancer research : an official journal of the American Association for Cancer Research, 2017-01-15

American journal of hematology, 2019-05

Oncology, 2020 May 28

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-03-01

Sci Rep, 2020 Jul 01

Neuro Oncol,

Ann Surg,

International journal of radiation oncology, biology, physics, 2012-04-01

Cancers (Basel), 2022 Mar 28

AJR Am J Roentgenol, 2022 Jun 29

Eur Radiol, 2022 Aug 08

Urology,

Clin Nucl Med,

Skeletal Radiol, 2014 May 20

Eur J Nucl Med Mol Imaging,

Amyloid, 2017 Apr 23

Leukemia, 2015 Oct 07

British journal of haematology, 2017-10

Blood Adv,

Blood Cancer J, 2018 May 24

Amyloid, 2019 Jan 20

Ann Surg Oncol, 2021 Jul 01

Gynecologic oncology, 1994-04

J Clin Oncol, 2022 Mar 20

Crit Rev Oncol Hematol, 2018 Dec 24

PLoS One, 2017 Jan 26

Gynecol Oncol Res Pract, 2018 Aug 18

Mod Pathol, 2020 Feb 17

Front Oncol, 2021 Apr 29

J Clin Oncol, 2022 Aug 12

Future Oncol, 2022 May 24

Clin Genitourin Cancer, 2020 Oct

Endocrine-related cancer, 2015-06

Eur J Cancer, 2013 Jan 23

Ann Oncol, 2012 Sep 11

Endocr Relat Cancer, 2012 Nov 06

J Cancer, 2014 Aug 01

Clin Cancer Res, 2019 Oct 31

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-01

Annals of oncology : official journal of the European Society for Medical Oncology, 1993-11

J Clin Oncol, 2020 Mar 13

N Engl J Med, 2015 Apr 19

Gynecol Oncol, 2021 May 03

Breast cancer research and treatment, 2019-06

Gynecologic oncology, 2019-04

Gynecol Oncol, 2019 Oct

Gynecol Oncol, 2020 Aug 15

Int J Gynecol Cancer, 2021 Mar 26

International journal of radiation oncology, biology, physics, 2019-06-01

Eur Urol, 2021 Apr 03

Pathol Res Pract, 2020 Apr 11

Oncologist, 2021 Aug 21

Endocr Connect,

ESMO Open, 2021 Apr 23

Oncologist, 2020 Sep 17

Future Sci OA, 2020 Aug 03

Cancer Treat Res Commun, 2022 Jul 01

Trends Immunol, 2021 Mar 10

Gastroenterology, 1993-06

Gastroenterology, 1991 Jul

Z Naturforsch C J Biosci, 2002 Mar-Apr

Immunopharmacol Immunotoxicol, 2003 Nov

Exp Toxicol Pathol, 2002 Feb

Biochem Biophys Res Commun, 1999 Sep 24

Ital J Gastroenterol Hepatol, 1998 Dec

Chem Biol Interact, 2001 Dec 21

J Urol, 2019 Jun 12

Eur J Heart Fail, 2020 Aug 06

Eur Heart J Cardiovasc Imaging, 2022 Sep 10

Metal-based drugs, 2010

J Allergy Clin Immunol Pract, 2019 Feb 15

Lancet Oncol, 2013 Jan 04

J Clin Oncol, 2022 Aug 30

Proc Natl Acad Sci U S A, 2019 Apr 15

N Engl J Med,

International journal of radiation oncology, biology, physics, 2018-04-01

N Engl J Med, 2021 Jun 24

Annals of oncology : official journal of the European Society for Medical Oncology, 2023 Aug 18

Journal of the National Cancer Institute, 2003-01-15

Breast (Edinburgh, Scotland), 2022 Sep 28

Oncotarget, 2016 Apr 05

Journal of breast cancer, 2018 Nov 23

Archives of pathology & laboratory medicine, 2021 Jun 01

Br J Cancer, 2020 Mar 10

Melanoma research, 2017-10

Cancer, 2011-04-15

Blood Cancer J, 2022 Sep 14

Blood, 2018-01-11

N Engl J Med,

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-12-10

J Immunother Cancer,

The Lancet. Oncology, 2018-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-07-01

Blood,

World J Clin Oncol,

BMC Cancer, 2020 Jul 16

Ann Oncol, 2022 Feb 14

Nat Med, 2022 Aug 08

Melanoma research, 2017-04

Lung Cancer, 2021 Aug 03

SAGE Open Med Case Rep, 2020 Nov 06

Blood,

FEBS J, 2009 Nov 18

Clin Lung Cancer, 2018 May 01

J Thorac Oncol, 2021 Feb 01

,

Lupus Sci Med, 2018 Sep 25

Int. J. Radiat. Oncol. Biol. Phys., 2017-06-01

Radiother Oncol, 2012 Feb 16

Arthritis & rheumatology (Hoboken, N.J.), 2018-03

International journal of radiation oncology, biology, physics, 1999-02-01

J Clin Oncol,

NEJM evidence, 2022 Jun 01

Prostate Cancer Prostatic Dis, 2021 Feb 10

Prostate Cancer Prostatic Dis, 2022 Mar 15

N Engl J Med,

Urol Oncol, 2022 Mar 27

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-08-10

Ann Oncol, 2009 Jul 01

Blood, 2010 Jul 21

Pediatr Blood Cancer, 2021 Apr 12

The Lancet. Haematology, 2019-03

J Clin Oncol, 2021 Dec 02

World journal of urology, 2014-04

Urol Oncol, 2020 Dec 08

BJU Int, 2019 Aug 07

J Urol, 2019 Oct 09

Clinical cancer research : an official journal of the American Association for Cancer Research, 2020 Sep 09

Breast Cancer Res, 2021 Aug 23

Medicine (Baltimore), 2019 Dec

J Clin Invest, 2013 Nov 15

Eur Urol, 2021 Jul 08

Eur Urol Focus, 2021 Mar

Adv Radiat Oncol, 2022 Jul 28

Clin Oncol (R Coll Radiol), 2016-09-01

European urology, 2024 Mar 14

BMJ open, 2024 Dec 26

European urology, 2014-09

Journal of immunotherapy (Hagerstown, Md. : 1997), 2018-05

Neurology, 2019 Mar 08

Front Immunol, 2022 Aug 22

J Urol, 2019 01

J Natl Compr Canc Netw, 2019 Jul 1

Lancet Oncol, 2022 Oct 10

Chest, 2020 Aug 14

Chest, 2020 Jul

ERJ Open Res, 2020 Oct

Journal of neuro-oncology, 2012-01

Lancet (London, England), 2019-06-15

Cochrane Database Syst Rev, 2016 Jun 09

BMC Cancer, 2021 Oct 18

J Clin Oncol, 2005 Nov 01

EClinicalMedicine, 2022 Aug 11

Clin Cancer Res, 2022 Mar 01

Annals of oncology : official journal of the European Society for Medical Oncology, 2022 Oct 10

Future Oncol, 2020 Nov 10

Journal of the National Cancer Institute, 2000-04-05

Breast cancer research : BCR, 2018-10-19

Breast Care (Basel), 2019 Nov 26

Cancer Chemother Pharmacol, 2019 May 11

Lupus, 2019 Jun 19

Ann Rheum Dis, 2011 Nov 09

J Clin Oncol, 2022 Nov 15

Targeted oncology, 2023 Apr 15

Urology, 2021 Oct 06

Front Oncol, 2020 May 29

Cancer Cell Int, 2021 May 17

Nat Commun, 2022 Nov 16

Blood Adv, 2022 Sep 13

Urology, 1982-09

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2009-03

Clin Infect Dis, 2005 Jan 21

Pediatr Transplant, 2014 Sep 08

J Clin Oncol, 2021 Apr 30

Pediatr Infect Dis J, 2014 Nov

Bone Marrow Transplant, 2006 Mar

Clinical cancer research : an official journal of the American Association for Cancer Research, 2008-01-15

Eur J Clin Pharmacol, 2001 Aug

JAMA Netw Open, 2021 Aug 02

Blood, 2006-05-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-02-01

The Lancet. Oncology, 2015-10

N Engl J Med, 2013 Jul 11

Blood, 2012 Jun 19

Lancet Oncol, 2019 Jan

J Clin Oncol, 2022 Apr 28

N Engl J Med, 2022 Nov 03

Genetic epidemiology, 2016-09

American journal of hematology, 2019-03

Blood, 2021 Jan 07

NPJ Breast Cancer, 2022 Mar 21

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007-06-01

Cancer, 2007-08-01

Journal of gastrointestinal oncology, 2017-12

Cardiooncology, 2019

Cardiol Clin, 2019 Aug 26

JACC CardioOncol, 2021 Mar 16

J Immunother Cancer, 2021 Jun

Ann Oncol, 2022 Oct 18

Blood, 2017-09-28

, 2022 Dec

Sports medicine (Auckland, N.Z.), 2021 Dec 29

JAMA internal medicine, 2024 Sep 01

Eur Urol Oncol, 2020 Aug 15

Ann Gastroenterol, 2020 Jan-Feb

BMC Cancer, 2019 Oct 21

JAMA Oncol, 2021 Sep 01

JAMA Netw Open, 2021 Jul 01

Blood, 2019-04-11

Clin Cancer Res, 2021 Feb 19

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Mar 14

J Clin Oncol, 2021 Jul 20

Br J Haematol, 2021 Aug 15

Blood, 2022 Dec 08

European journal of cancer (Oxford, England : 1990), 2017-04

Lancet (London, England), 2024 May 16

Clin Cancer Res, 2022 Feb 15

JAMA Otolaryngol Head Neck Surg, 2022 Dec 22

PET Clin, 2020 Feb 11

Rheumatology (Oxford), 2022 Jul 22

Clin Cancer Res, 2020 Aug 20

American journal of clinical oncology, 2005-12

Head & neck, 2016-01

The Laryngoscope, 1994-02

Oral and maxillofacial surgery, 2023 Apr 05

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006-02-01

Obstet Gynecol, 1998 Oct

Acta Oncol, 2019 Apr 08

Breast cancer research and treatment, 2013 Oct 11

Arthritis Care Res (Hoboken), 2017 Dec

JAMA, 1999 Dec 08

Reumatologia, 2020 Feb 28

J Thorac Oncol, 2013 Nov

Cancer, 2019-01-01

HPB : the official journal of the International Hepato Pancreato Biliary Association, 2017-07

JAMA Oncol, 2021 Dec 01

Transpl Infect Dis, 2015 Sep 26

Clin Lymphoma Myeloma Leuk, 2021 Feb 07

Lancet, 1994 Apr 30

Journal of neurosurgery, 2013-04

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-05-01

Cochrane Database Syst Rev, 2020 Apr 28

N Engl J Med, 2020 Mar 29

N Engl J Med, 2003 Jul 10

Clin Cancer Res, 2020 Nov 18

Int J Cancer, 2021 Oct 07

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004-08-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002-09-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-02-20

Journal of the National Cancer Institute. Monographs, 2001

J Clin Oncol, 2003 Dec 02

Oncotarget, 2016-04-26